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ABSTRACT 
 
ANGELA PROCTOR: Development of Peptidase-Resistant Peptide Substrates for  
Measurement of Protein Kinase B and Bcr-Abl Kinase Activity 
(Under the direction of Nancy L. Allbritton) 
 
 Synthetic peptides are widely used by the biomedical research community as kinase 
substrates for purified kinases, in cell lysates, and sometimes in intact single cells.  Peptides 
are relatively straightforward to construct, they have a long shelf-life, and they are easily 
derivatized with labels to facilitate detection.  However, despite the benefits of peptides, they 
suffer from susceptibility to degradation by intracellular peptidases.  Peptidolysis is often 
extremely rapid, yielding peptide fragmentation within minutes of introduction into a cell 
lysate or single cell.  While protease inhibitors can be used to slow degradation, they do not 
entirely eliminate protease activity and they are difficult to use with intact cells.  In order to 
render peptides more suitable as substrates in in vivo settings, proteolytic degradation needs 
to be dramatically slowed or halted. 
 The work described in this dissertation develops an iterative strategy to screen 
rationally designed peptides for their suitability as kinase substrates in cell lysates and single 
cells.  Peptide bonds susceptible to peptidolysis were identified and stabilized by replacement 
of native residues with non-native residues, which are poor substrates for peptidases.  
Modified peptides were screened for substrate suitability as well as for resistance to 
degradation by peptidases.  Substrates were designed for two kinases, protein kinase B and 
Bcr-Abl kinase, because of their roles in cancer.  Protein kinase B is involved in regulation of 
 iv 
multiple cellular functions, including stress response and programmed cell death, and is 
upregulated in many cancers, including pancreatic, breast, and prostate tumors.  Bcr-Abl is 
the primary driver of chronic myelogenous leukemia.  This dissertation outlines the 
development of peptidase-resistant substrate reporters for these two kinases.  Initial 
characterization and design was performed in cytosolic lysates.  Once suitably designed 
peptide substrates were synthesized, they were incubated in single cells to characterize 
substrate metabolism and phosphorylation in the intracellular environment.  Finally, protein 
kinase B activity was measured in single primary cells from a human pancreatic cancer 
xenograft.  The design strategy presented in this dissertation should be applicable for future 
design of peptidase-resistant peptide substrates for alternative kinases. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Kinase Pathways and Implications in Cancer 
1.1.1 Kinases and Kinase Functions 
 Nearly all proteins undergo post-translational modification after synthesis.  These 
modifications can be irreversible, such as proteolysis of peptide bonds in the degradation and 
reprocessing of substrates, or reversible, such as acylation or glycosylation used to modify 
protein properties.1  One common form of reversible modification is phosphorylation by a 
kinase.  A protein kinase catalyzes the transfer of the terminal phosphoryl group from 
adenosine triphosphate (ATP) to a serine, threonine, or tyrosine residue on a substrate.  This 
reversible modification is often used as a switching mechanism to activate and deactivate 
proteins.  Phosphorylation of a target protein alters its properties by addition of the 
negatively charged phosphoryl group.  Addition of this phosphoryl group changes the local 
charge properties of the protein and can also induce a conformational change in the protein.  
Either of these properties alone or together can cause a protein to alter its activity and 
function.  For example, phosphorylation of proteins can control a protein’s location within 
the cell, its enzymatic activity, and any interactions with other proteins.1  Removal of the 
phosphoryl group is catalyzed by a phosphatase, which reverts the protein back to its non-
phosphorylated form.  The balance of kinase and phosphatase activity within a cell regulates 
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many of the signal transduction pathways leading to growth, metabolism, transcription 
differentiation, behavior, and apoptosis.1, 2  Kinases themselves are often regulated by 
phosphorylation and dephosphorylation. 
 There are over 500 known kinases in the human genome which have been grouped 
into eight different families based on their structure and function.2  For example, the tyrosine 
kinase (TK) family of the human genome contains all of the receptor tyrosine kinases (RTKs) 
responsible for signal transduction from the extracellular environment to the cytoplasm of 
cells.3  RTKs on the surface of cell membranes bind to ligands, resulting in propagation of 
signal transduction within the cell.  Included in tasks accomplished by RTKs are roles in 
regulation of cell proliferation or differentiation, vital processes for organism growth and 
function.3  The TK family also contains multiple non-receptor tyrosine kinases (NRTKs), 
critical members of signaling cascades within a cell.  Among other tasks, the NRTKs are 
involved in glucose uptake and metabolism, as well as in regulation of the immune system.  
Another family in the human kinome is the AGC family (related to protein kinases A, G, and 
C), which contains approximately 60 kinases responsible for a variety of functions including, 
but not limited to, proliferation, metabolism, protein synthesis, cell shape, and motility.4  As 
kinases are involved in modulation of multiple signal transduction pathways, dysregulation 
of TK, AGC or other family kinase activity is implicated in many diseases, including 
multiple cancers.2-5  It is for this reason that kinases are prime targets for therapeutic 
modification, notably as chemotherapeutic targets leading toward individualized treatment.5, 6  
While multiple kinases are implicated in many different types of cancers, the work presented 
in this dissertation focuses on two kinases, protein kinase B and Abl kinase, each discussed 
in detail in the following sections. 
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1.1.2 Protein Kinase B 
 Protein kinase B (PKB, also known as Akt) has been implicated in many cellular 
functions such as insulin signaling, glucose metabolism, transcription, proliferation, stress 
response, and apoptosis.7  PKB was first described in 1977 by Staal et al. in their work with a 
murine leukemia virus found to be linked to lymphoma formation.8  It was not until 1991 that 
the genes encoding PKB were found, when three independent research groups published 
results regarding PKB.9-11  Interest in PKB has steadily increased as it has been implicated in 
assisting cellular survival during stressful events, such as prevention of apoptosis in cells 
programmed for cell death.12  Increased PKB activity has been found to enhance tumor 
progression and is present in multiple cancers, including pancreatic, breast and prostate 
tumors.13, 14  Many reasons exist for high PKB activity and any of these can lead to tumor 
survival and progression: i) PKB can be constitutively activated;15  ii) normal PKB can be 
over-expressed;12, 16  or iii) regulatory feedback control of PKB can be impaired.8, 17  While 
increased PKB activity may not be directly responsible for producing tumors, there is 
abundant evidence that increased PKB activity does enable tumors to survive and proliferate, 
making PKB an attractive candidate for targeted therapy.13, 18, 19 
 PKB is a serine/threonine kinase and a member of the AGC family of kinases.2  There 
are three isoforms of PKB, termed PKBα, PKBβ, and PKBγ, each responsible for different 
functions within cells.  All three isoforms are approximately 80% homologous and share 
similarities in three highly conserved functional domains (Figure 1.1).  These domains are: i) 
a pleckstrin homology (PH) domain found on the N-terminus which is a region of 
approximately 100 amino acids that interacts with lipids, including the plasma membrane; ii) 
a central kinase domain, containing the catalytic active site where substrates are 
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phosphorylated; and iii) a C-terminal regulatory domain containing one of the 
phosphorylation sites for PKB regulation.7, 14, 15, 17, 20 
 PKB activity is controlled by phosphorylation on two residues, Thr308, located in the 
kinase domain, and Ser473, found in the regulatory domain.  Phosphorylation of both 
residues leads to maximum PKB activity, while phosphorylation solely at Thr308 has been 
shown to decrease PKB activity to approximately 10% of maximum.14, 17  When a cell is 
stimulated, PKB is recruited to the plasma membrane by PIP3 (phosphatidylinositol-3,4,5-
trisphosphate).  The PH domain acts to localize PKB to the membrane, where Thr308 is 
phosphorylated by the membrane protein PDK-1.  At this stage, uncertainty exists as to how 
the Ser473 residue is phosphorylated, with some evidence suggesting phosphorylation by 
mTORC2 and others implicating autophosphorylation by PKB itself or attributing it to 
members of the PI3-K kinase family.16, 17  After dual phosphorylation, PKB detaches from 
the membrane and moves to the cytosol or the nucleus to phosphorylate its substrates (Figure 
1.2).  PKB is no longer actively phosphorylated by PDK-1 when PTEN (phosphatase and 
tensin homolog) dephosphorylates the lipid messenger PIP3, leading to a decrease in the 
association of PKB to the membrane and a decrease in additional PKB activation8, 17, 21 and 
PKB activity is effectively halted when the Ser473 residue is dephosphorylated by PHLPP1 
or 2 (PH-domain leucine-rich repeat protein phosphatase).13, 17, 21  Aberrant activity at any of 
these regulatory steps can be responsible for abnormal PKB signaling and can lead to tumor 
survival and proliferation, reiterating the possibility of targeting PKB for therapeutic drug 
design.  Chapters 4 and 5 of this dissertation focus on measurements of PKB activity in 
single tissue cultured cell lines and in single cells obtained from mouse xenograft models. 
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1.1.3 Abelson Tyrosine Kinase 
 Abelson tyrosine kinase (Abl) is a member of the TK family of kinases as a non-
receptor kinase and is normally encoded by a gene found on chromosome 9.  Abl can be 
found in many locations within the cell and is known to be involved in many cellular 
processes such as cell migration, DNA damage responses, and even regulation of growth and 
survival.22  Abl contains the same three core domains as other Src-family kinases—an SH3, 
SH2 and kinase domain (Figure 1.3).22, 23  Normal chromosomal Abl (c-Abl) contains a 
region upstream of the SH3 domain that is myristoylated and is responsible for regulation of 
the kinase.  c-Abl is tightly regulated both temporally and spatially by auto-inhibition 
involving this myristate tail, the SH2-SH3 connector and the SH2-kinase domain linker.22-24 
 In the early 1960s, it was discovered that many chronic myelogenous leukemia 
(CML) patients had a shortened version of chromosome 22 (termed the Philadelphia 
chromosome), but it was not until the 1970s that it was discovered that this was the result of 
a reciprocal translocation between chromosomes 9 and 22.25, 26  Chromosome 9 is disrupted 
within the abl gene and chromosome 22 below the breakpoint cluster region (bcr) gene 
during the translocation event.  This fuses the bcr gene to abl and encodes for synthesis of a 
fusion protein known as Bcr-Abl (Figure 1.4).26, 27  Bcr-Abl does not have the autoinhibition 
of c-Abl and has been discovered to be the primary driver of formation of leukemic cells in 
greater than 90% of all CML patients.26, 27  Because of its primary role in the formation of 
leukemic cells, Bcr-Abl was targeted for specific inhibitor design and became the first kinase 
for which targeted therapy was approved for patient use.  Gleevec, marketed by Novartis, is 
also known as imatinib mesylate or STI-571.  Gleevec was developed in the mid-1990s and 
approved for use in CML therapy in the early 2000s.28  Gleevec is a small molecule inhibitor 
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that competes with ATP for the binding pocket in the catalytic domain of Bcr-Abl29, 30 and 
prevents Bcr-Abl from phosphorylating its substrates.  Treatment with Gleevec has proven 
useful for many CML patients, notably those still in the chronic phase of the disease.31  The 
success of Gleevec has led to the development of 2nd and 3rd generation inhibitors of Bcr-Abl 
as well as investigation and development of alternative drug therapies aimed specifically at 
targeting aberrant kinase activity.   
 As successful as Gleevec treatment has been for treatment of chronic phase CML, it 
has not worked for all patients, especially those in advanced or blast-stage CML.32-34  There 
is also a sub-population of CML patients that do not have the Philadelphia chromosome, so 
drugs targeting Bcr-Abl are useless as these patients do not express Bcr-Abl.26  Direct 
measurement of Bcr-Abl kinase activity would allow for quantification of Bcr-Abl activity 
and investigation of the likely response and sensitivity to Gleevec or to its 2nd and 3rd 
generation relatives.  Chapters 3 and 6 of this dissertation discuss development of a peptide 
substrate reporter for Bcr-Abl kinase activity. 
 
1.2 Use of Peptides in Biomedical Research 
 Synthetic peptides are widely used in the biomedical research community as 
substrates for kinase activity.  Peptides are easily synthesized via solid phase peptide 
synthesis (SPPS) and large libraries of peptides composed of native and non-native amino 
acids are straightforward to construct, allowing for relatively simple synthesis of a wide 
variety of substrates.35  Peptides possess a long shelf-life and are easily derivatized with 
labels (such as fluorophores) or targeting elements (such as biotin).  Based on these traits, 
peptides are often preferred over proteins in a variety of assays such as determining enzyme 
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activity in vitro, in cell lysates, or in vivo.  In addition, peptides can be constructed to contain 
only the select kinase’s consensus sequence, the short region of a handful of amino acids 
around the phosphoryl-accepting residue recognized by a specific kinase or kinase family.  
Sometimes, these short peptide regions can mimic a full-length substrate protein and large 
libraries of consensus sequences have been determined for many kinases and the preferred 
sequences are readily available for nearly all known kinases.20, 36-38  For these reasons many 
peptides are available commercially for use as substrates to measure kinase activity. 
1.2.1 Peptides as Substrates 
1.2.1.1 Techniques for Measuring Peptide Phosphorylation 
 Peptides are frequently utilized by commercial companies and research laboratories to 
quantify kinase activity of purified kinases.  These formats are relatively inexpensive ways to 
quickly assess kinase activity and specificity.  Select methods frequently utilized to measure 
phosphorylation of a peptide substrate by a kinase are discussed below.  Transfer of a 
radioactive phosphoryl group from [32P]-γ-ATP to the substrate can be quantitatively 
determined by capturing the radioactive substrates on a negatively charged phosphocellulose 
membrane and measuring radioactivity.35, 39  An alternative radioactive technique is a 
homogenous scintillation proximity assay (SPA) that measures incorporation of the 
radioactive phosphoryl group on a substrate.  When the radiolabeled substrate binds to the 
SPA bead, the emitted radiation activates the scintillant, which produces light that can be 
measured with a scintillation counter.40, 41  However, due to the cost of disposal of 
radioactive materials and concern over radioactive exposure in the laboratory, use of these 
methods have decreased as more non-radiometric techniques are developed.39, 42  One non-
radiometric assay utilized to monitor phosphorylation is Förster resonance energy transfer 
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(FRET).42  For example, a substrate constructed with a donor and acceptor fluorophore emits 
no fluorescence when the target amino acid is not phosphorylated as the conformation of the 
substrate separates the two fluorophores from one another.  A conformational change is 
induced upon phosphorylation, usually when a phosphoryl-recognition sequence binds to the 
phosphoryl-group, arranging the fluorophores in close proximity to one another.  When the 
proper wavelength of light illuminates the substrate, FRET occurs as the donor fluorophore 
emits in the acceptor fluorophore excitation region.  The emission of the acceptor 
fluorophore is measured over time and utilized to quantify phosphorylation.  Additional 
techniques to measure phosphorylation include immobilization of biotin-labeled substrate 
peptides on a streptavidin-coated surface, where phosphorylation is detected via 
radioactivity, colorimetric changes, or fluorescence of a labeled antiphosphoserine,  
-threonine, or -tyrosine antibody.43-45  Enzyme activity is inferred based on the amount of 
phosphorylated substrate relative to non-phosphorylated substrate.  An alternative technique 
to monitor substrate phosphorylation measures fluorescence polarization in the presence of 
an appropriate antiphospho antibody or a metal nanoparticle.46, 47  Fluorescence polarization 
is high when the phosphorylated substrate is bound by the relatively large antibody or 
nanoparticle because the bulky addition prevents free rotation of the molecule, resulting in 
highly polarized emitted light.  This fluorescence polarization change upon substrate 
phosphorylation permits quantification of enzyme activity.  Additionally, capillary 
electrophoresis can be used to monitor substrate phosphorylation over time, as the addition of 
the double negatively-charged phosphoryl group results in altered electrophoretic mobility 
between the substrate and its phosphorylated counterpart, allowing for separation and 
quantification of reactant and product.48-51  This method can use UV or absorbance detection, 
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but most often utilizes fluorescence detection of fluorescently-labeled substrates because of 
the exquisite sensitivity offered by laser-induced fluorescence detection.  These techniques, 
as well as others not mentioned, can all be used to measure kinase activity of purified 
kinases, for example, to determine substrate suitability or as validation of new technology to 
measure enzyme activity.50, 52, 53 
1.2.1.2 Peptide Substrates in Cell Lysates 
 In addition to their usefulness in monitoring activity of purified kinases, peptides are 
also utilized in vitro to monitor kinase activity in a cytosolic lysate.  Cytosolic lysates 
provide an environment in which many of the cofactors and regulatory elements are present, 
though minimally regulated, allowing for a simulation of kinase behavior in these 
environments.  Cytosolic lysates are also attractive because they are less expensive to use 
than intact cells for many reasons.  Lysates are generated via a freeze-thaw cycle or by 
adding a lysis buffer, neither of which require specialized or costly materials.  Many different 
measurement techniques can be utilized to accommodate assays performed in a cytosolic 
lysate, eliminating the need for purchase or construction of specialized detection instruments.  
Cytosolic lysates are easy to prepare in large volumes and can be modified to match nearly 
any detection strategy.  Lysates are easily amenable to addition of co-factors or inhibitors to 
monitor enzyme reaction to changes and the substrate can be directly mixed with the lysate in 
vitro.  A search of the literature yields multiple examples of peptides utilized as substrates of 
kinases in cell lysates.54-64 
1.2.1.3 Peptide Substrates in Intact Cells 
 While cell lysates are a straightforward and cost-effective way to measure kinase 
activity in a simulated cellular environment, they do not entirely mimic the environment 
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within an intact cell.  Intracellular compartments exist within intact cells, which keeps cell 
components isolated from other components and localized to certain areas.  When a lysate is 
generated, these subcellular compartments are ruptured, eliminating this separation and 
localization.  Additionally, intracellular compartments also facilitate formation of local 
regions of high concentration of a specific analyte, also eliminated when the lysate is 
generated and diluted into a homogenous mixture.  
 However, despite the cost advantages of lysates over single cells, lysates cannot 
recapitulate the native environment of an intact cell and lysates eliminate the ability to detect 
heterogeneity within a cell population.  To gain an understanding into protein behavior 
within a population of cells, peptides are also being increasingly used in single cells as 
substrates to measure protein activity at the single cell level, such as that of kinases, acyl 
transferases, and proteases.49, 51, 65-67  In these examples, peptide substrates were introduced 
into tissue-cultured cell lines via endocytosis,66 electroporation,65 or microinjection49, 51, 67 
and measurements were made utilizing laser-induced fluorescence detection after capillary 
electrophoresis on custom-designed systems mounted on a microscope stage.  These 
substrate loading and measurement strategies are also amenable for use with primary cells, an 
exciting new frontier for studying protein activity in a population of diseased and healthy 
cells. 
1.2.2 Peptide Susceptibility to Degradation 
 Despite all of the advantages listed above and the widespread use of peptides as 
substrates both in vitro and in vivo, peptides suffer from a susceptibility to degradation by 
intracellular proteases and peptidases.  Cleavage of peptide bonds by endo- and exo-
peptidases can be extremely rapid as they are integral in the protein-recycling machinery of 
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cells, responsible for breaking proteins and peptides into their constituent amino acids.68  
While not a problem for use with purified kinases, this is a major concern when peptides are 
utilized in cell lysates or intact cells because of the prevalence of peptidases.  Peptidolysis 
can be extremely rapid, yielding peptide fragmentation within minutes of introduction into a 
lysate or single cell.51, 69, 70  This is true for peptide substrates and inhibitors and low 
bioavailability due to peptide hydrolysis is a major disadvantage for peptide-based 
therapeutics.71-75  
 While protease inhibitors can be used to slow degradation, several drawbacks exist to 
using these inhibitors.  Protease inhibitors do not entirely eliminate protease activity, they are 
often poorly soluble in aqueous solutions, rendering them available only in organic solvents 
not compatible with enzymes.  Most inhibitors cannot be used with intact cells since they are 
not membrane permeable.  Once a peptide is cleaved, it is generally no longer an effective 
substrate for the desired kinase as it does not possess all of the elements required for kinase 
recognition.  In order for peptides to become more useful in biomedical research, proteolytic 
degradation needs to be dramatically slowed or eliminated.  Strategies for achieving 
proteolytic stability are discussed in the following sections. 
1.2.3 Strategies to Stabilize Peptides Against Degradation 
1.2.3.1 Cyclization 
 Two strategies that exist for cyclizing peptides are head-to-tail cyclization or 
cyclization via the amide backbone.76  Cyclization affords excellent resistance to degradation 
by creating a fixed secondary structure that prevents protease access to the peptide bonds.76-79  
However, it simultaneously prevents access to the substrate binding region of the protein and 
diminishes substrate efficacy.78  Peptide cyclization can be somewhat varied in the size of the 
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rings used and in the methods utilized for cyclization, offering a range of useful strategies for 
prolonging peptide lifetime.  However, cyclization methods are very challenging 
synthetically, requiring excessive amounts of time and resources for a very low yield of 
substrate.  While cyclization is a valid strategy for stabilization of peptides, it does not lend 
itself to rapid synthesis and screening of possible substrates because of its synthetic 
challenges, expense, and reduction of substrate efficacy. 
1.2.3.2 PEGylation 
 Addition of a poly-ethylene glyocol moiety (PEGylation) has also been demonstrated 
to reduce proteolytic activity on peptides.80-82  PEGylation is relatively straightforward to 
accomplish and is easily incorporated into regular SPPS methods.  PEG groups of various 
sizes (with molecular weights ranging from 1 – 30 kDa) can be added to peptides, thus 
altering their properties depending on the PEG group added.  Lower molecular weight 
PEGylated substrate peptides tend to have better substrate activity than higher molecular 
weight substrates, yet also demonstrate a diminished resistance to degradation when 
compared to their higher-molecular weight counterparts.81  While PEGylation of peptides 
allows them to resist degradation, problems exist due to the size and polydispersity of PEG 
groups.  The molecular weights of most PEG groups are dramatically larger than the 
substrate peptides, rendering the mass difference between substrate and its phosphorylated 
counterpart much less and making electrophoretic separations difficult to achieve.  
Additionally, PEG moieties exist in a polydispersity unacceptable for most capillary 
electrophoretic applications as the band broadening significantly diminishes the peak 
capacity generally afforded by capillary electrophoresis. 
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1.2.3.3 Terminal Modifications 
 Modifications to either or both the C- and N-terminus have also been shown to impart 
some stability to peptides.80, 83, 84  These modifications are varied and include lipid 
conjugations, acetylation of the N-terminus and amidation of the C-terminus.  All of these 
modifications are easily accomplished via standard SPPS techniques.  Lipid conjugation of 
peptides serves the added benefit of making the reporter more lipophilic, allowing it to 
become more cell permeable while also increasing loading efficiency into cells.  Terminal 
modifications provide added protection against carboxy- and amino-peptidases, but do not 
stabilize the peptide against endo-peptidase degradation.  For this reason, terminal 
modifications are often used in combination with one or more alternative stabilization 
strategies. 
1.2.3.4 Non-Native Amino Acids 
 A strategy frequently utilized in peptide substrate and inhibitor design for promotion 
of peptide stability is utilization of non-native amino acids within the peptide.  These can 
include D-amino acids, where the stereochemistry of the α-carbon is mirror image to the 
natural L-amino acids;85 N-methylated amino acids, where a methyl group is added to the 
backbone nitrogen;86 β- or γ-amino acids, where the backbone nitrogen is on the β- or γ-
carbon as opposed to the α-carbon;87 or a modification of any sort to the side chain.35  Many 
non-native amino acids are available and ready for synthesis using standard SPPS techniques, 
making their incorporation into a peptide straightforward.  There are multiple examples of 
use of peptides constructed with non-native amino acids in the literature.35, 51, 77, 85, 86, 88, 89  An 
added benefit is that these peptides can be degradation resistant while simultaneously 
retaining efficacy as kinase substrates.  Based on this property and their ease in incorporation 
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in peptide synthesis, this is the strategy utilized to stabilize reporters chosen for the work 
described in this dissertation.  A more thorough discussion of how this was accomplished is 
presented in Chapters 3 through 6 of this work. 
 
1.3 Capillary Electrophoresis 
 Capillary electrophoresis (CE) was first described in the early 1980s by Jorgenson 
and Lukacs.90  CE is a separation method utilizing small inner-diameter fused silica 
capillaries (on the order of 50 µm) filled with and immersed in a current-carrying buffer 
solution.  Sample is introduced at the inlet and a high voltage (typically up to 30 kV) is 
applied across the capillary.  A detector near the capillary outlet monitors the species as they 
move toward the column exit (Figure 1.5).  The velocity and direction of electrophoretic 
migration is a property of the size, shape, and charge of the species.  Overall migration is 
determined by a combination of the electrophoretic mobility of the analytes and the 
electroosmotic flow of the buffer.  For a rigid sphere, electrophoretic mobility can be 
approximated as shown in equations 1.1 and 1.2 and velocity of a species in CE is defined in 
equation 1.3.90, 91  
Equation 1.1: 
 
        µ = electrophoretic mobility 
        q = particle charge 
        η = buffer viscosity 
        r = Stoke’s radius (Eq 1.2) 
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Equation 1.2: 
 
        M = mass 
        r = Stoke’s radius 
        V = partial specific volume 
 
Equation 1.3: 
 
        v = velocity 
        µep = electrophoretic mobility 
        µeo = electroosmotic mobility 
        E = applied electric field 
 
 Electroosmotic flow within a narrow bore capillary arises when an electric field is 
applied across the ends of a capillary with a charged inner surface.  The amount of charge on 
the inner surface of the fused silica capillary varies depending on the capillary surface 
properties and the buffer utilized.  For example, a neutral or basic buffer results in a higher 
negative charge on the capillary surface, causing a large proportion of the positively-charged 
ions in the buffer to remain at the capillary surface.  This causes an electric double layer to 
form at the interface of the capillary surface with the buffer.  When a voltage is applied 
across the capillary, the charged ions in the electric double layer migrate toward the opposite 
pole.  These ions are associated with other buffer components via hydrogen bonds and 
electrostatic interactions.  These interactions are strong enough within the narrow bore 
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capillary that bulk migration of all buffer contents occurs in one direction, as the double layer 
ions migrating in the electric field pull their associated components with them.  This results 
in a nearly flat fluid profile as all capillary components migrate to one end of the capillary.90, 
92  This flow, termed electroosmotic flow (EO flow) can be quite significant and it is utilized 
in CE to sweep all species toward the detector (Figure 1.6).  Electrophoresis separates the 
analytes into discrete bands based on electrophoretic mobility and EO flow sweeps all bands 
toward the detector, allowing for detection of all species, including those of opposite charges 
as well as neutral species. 
 In this dissertation, CE was used for the separation of phosphorylated and non-
phosphorylated peptides as well as peptide fragments.  Phosphorylation of a peptide 
sequence yields an addition of a relatively small amount of mass and two negative charges, 
altering the electrophoretic mobility of the peptide and causing it to migrate differently than 
its non-phosphorylated counterpart.  A comparison of the integrated peak areas under the 
peaks corresponding to non-phosphorylated substrate and its phosphorylated counterpart can 
be used to measure phosphorylation over time and allow for an inference of kinase activity.49, 
67, 93, 94  Also, when a peptide undergoes proteolysis, the differences in electrophoretic 
mobility of each fragment can be exploited, allowing for separation of all possible fragments.  
The high resolving power of CE permits separation and quantification of peptide fragments 
differing by a single amino acid, with the area under each fragment peak correlating to the 
concentration of the peptide fragment in solution.51  Coupling of CE with ultrasensitive laser-
induced fluorescence detection (LIF) allows for work at extremely low peptide 
concentrations, as mass detection limits are routinely in the range of 10-20 moles.95, 96  Other 
benefits of CE include the high resolution due to minimal band broadening, fast separations, 
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small sample volumes (less than 10 nL) and ease of automation, all amenable to work with 
single cells.  Chapter 2 provides a more thorough description of the custom made CE system 
utilized in this work. 
 
1.4 Chemical Cytometry 
 Classic cytometry refers to instrumental methods utilized in the characterization of 
individual cells, such as image and flow cytometry.97  These techniques are often 
nondestructive and can process large numbers of cells in relatively short periods of time to 
provide a wealth of information about cell populations.  Both image and flow cytometry rely 
on fluorescence detection and can simultaneously monitor multiple parameters.  However, 
spectral overlap of fluorescence markers is an important limitation of classic cytometry 
techniques, as it limits the number of parameters that can be monitored simultaneously.  As 
opposed to classical cytometry, the use of highly sensitive analytical tools to characterize 
single cells has been given the name “chemical cytometry.”  The infancy of chemical 
cytometry was initiated with a 1953 study that used a copper silk thread to isolate and 
quantify RNA levels in single cells.   More modern chemical cytometry techniques emerged 
from the Jorgenson, Ewing, and Yeung labs in the 1980s.98, 99  Some current chemical 
cytometry measurement techniques include capillary electrophoresis, mass spectrometry and 
electrochemistry.99-101  Chemical cytometry techniques are usually low throughput and 
destructive, as the cell is often lysed prior to analysis.  However, an abundance of 
information on the cell contents can be obtained for each cell analyzed.  Chemical cytometry 
provides the analytical techniques sensitive enough to measure heterogeneity within cellular 
populations, including differences that arise from mutations at the nucleic acid level all the 
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way to those originating from post-translational modifications of proteins in a signaling 
pathway.97, 99, 101-104 
 Population averages measured when thousands or millions of cells are pooled masks 
the heterogeneity that no doubt exists and can give a skewed version of the events.  For 
example, cell signaling within a population was often thought of as being a graded response, 
in that all cells partially responded to a stimulus.  However, it was determined that cells 
actually can respond in an all-or-none fashion, such that only part of the population responds 
fully to the signal while other cells do not respond at all.105, 106  This is also true when seeking 
to identify rare subsets within a population, such as what is found in a tumor.  Tumors are 
heterogenous, with only a small portion of cells that may be abnormal.104, 107, 108  A 
population average would not reveal the aberrant cells, whereas interrogation of each cell 
would indicate how many cells were functioning as expected and how many were not.  
Single cell analysis is the ultimate goal for the work developed in this dissertation as a means 
for identification of abnormal kinase signaling in single cells, with the future intent of 
probing primary cells from a patient to determine kinase activity. 
 
1.5 Scope of the Dissertation 
 The work described in this dissertation focuses on designing peptidase-resistant 
peptide substrate reporters for probing kinase activity in single cells.  Chapter 2 presents a 
detailed description of the design and construction of a CE instrument capable of analyzing 
single cells.  In addition to hardware construction, the software program was written 
specifically for this new system design and is also outlined in Chapter 2.  Chapters 3 and 4 
focus on the first cycle of rational design and development of peptide substrate reporters 
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resistant to degradation by intracellular peptidases.  Both chapters outline the strategy of 
identifying specific locations in the reporter most susceptible to degradation, the iterative 
redesign and testing of successive substrates, and the analysis of the reporters in single cells.  
Chapter 3 describes the first cycle in development of a reporter for Bcr-Abl kinase and has 
been published in the Analyst.51  Chapter 4 details the strategy for design and construction of 
a reporter for PKB and a manuscript has been submitted to Analytical Chemistry on this 
work.  Chapter 5 extends upon the work presented in Chapter 4 by utilizing the designed 
substrate to measure PKB activity in pancreatic cancer cell lines with and without kinase 
inhibitor and to measure PKB activity in single cells obtained from human pancreatic tumor 
xenografts grown in mice.  This work is being prepared for manuscript submission in the 
near future.  Chapter 6 presents preliminary work accomplished on further development of a 
Bcr-Abl kinase substrate based on the work presented in Chapter 3. 
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1.6 Figures 
 
 
 
Figure 1.1: The domains of the three isoforms of PKB.  Phosphorylation of the Thr and Ser 
residues leads to maximum activity of PKB.14, 16  
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Figure 1.2:  A simplified schematic of PKB activation.  A stimulus (such as growth factor or 
insulin) activates a transmembrane receptor which activates PI3-K.  PI3-K phosphorylates 
PIP2 to PIP3, which recruits inactive PKB to the membrane.  At the membrane, Thr308 is 
phosphorylated by PDK-1, followed by phosphorylation of Ser473 (shown here by 
mTORC2).  Once both residues are phosphorylated, active PKB moves to the cytosol or 
nucleus to regulate downstream effectors.16, 17, 19, 21, 109, 110 
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Figure 1.3: The domains of Abl and Bcr-Abl.  Bcr-Abl does not include the myristate group, 
necessary for autoinhibition and tight regulation of Abl kinase activity.22, 23 
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Figure 1.4: Formation of the Philadelphia chromosome.  (A) The abl gene is on chromosome 
9 and the bcr gene is on chromosome 22.  (B) Chromosome 9 breaks just upstream of the 
SH3 domain in the abl gene and chromosome 22 breaks in the breakpoint cluster region.  (C) 
Reciprocal translocation occurs when the bottom of chromosome 22 fuses to chromosome 9 
and the bottom of chromosome 9 fuses to chromosome 22.  Altered chromosome 22 is 
known as the Philadelphia chromosome.  Translation of the Philadelphia chromosome leads 
to formation of Bcr-Abl fusion protein.25-27 
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Figure 1.5: Diagram of a generic CE-LIF instrument.  A high voltage power supply drives 
separation through a narrow-bore fused silica capillary.  Detection via laser-induced 
fluorescence occurs through a window burned through the polyimide capillary coating.  Data 
is collected and displayed on a computer.90-92 
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Figure 1.6:  Movement of analytes through a capillary during CE.  (A) A sample plug 
composed of ions and neutral species is injected into the capillary inlet.  (B) When a voltage 
is applied across the capillary, the analytes separate into discrete bands based on 
electrophoretic mobility.  In appropriate conditions, electroosmosis flows in one direction 
with a magnitude larger than electrophoresis and acts to sweep all species past the detection 
window at the capillary outlet.90, 92 
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CHAPTER 2 
 
DESIGN, CONSTRUCTION AND VALIDATION OF A 
SINGLE-CELL CE-LIF INSTRUMENT 
 
2.1 Introduction 
2.1.1 Capillary Electrophoresis for Single-Cell Analysis 
 A discussion of the benefits of single-cell analysis is presented in Chapter 1.  
Capillary electrophoresis was chosen as the analytical tool for this work for many reasons, 
outlined below.  CE is fast, efficient, and quantitative, with sensitive detection of very small 
sample sizes, a requirement when assaying single cells that are approximately 1 pL in 
volume.1-8  In addition, CE has very high resolution with a large peak capacity, giving the 
option of simultaneous measurements of multiple analytes.  The relative speed of CE affords 
high temporal resolution, and can be coupled with rapid lysis techniques to allow for fast 
analysis of enzymatic activity in single cells.9-11  CE coupled with laser-induced fluorescence 
detection has very low detection limits, on the order of 10-20 moles, which is excellent for 
analysis of extremely low amounts of analyte, precisely that found in single cells.12, 13  These 
benefits taken together with the amenability to incorporating higher throughput designs10, 11, 
14 are the reason CE was selected as the analytical measurement technique utilized in this 
work. 
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2.1.2 Single-Cell CE Instrument Designs 
 Multiple types of instruments for utilizing CE to analyze singe cells have already 
been described in the literature with many detection strategies.4, 15  Several of these different 
designs are described below.  The earliest work on single-cell CE appears in the late 1980s 
and early 1990s.  An early design utilized micromanipulation to remove single neurons from 
land snails to a nanoliter-sized “test tube” generated by sealing one end of a glass capillary.16  
The contents of the single cell were homogenized and a finely pulled tip from a glass 
micropipette was attached to a pressure source and utilized to microinject the single cell 
homogenate directly into the capillary used for electrophoresis.  Utilization of this sample 
injection method provided enough material for multiple samplings from the same cellular 
homogenate, giving the option of replicate studies with identical electrophoretic conditions or 
additional studies utilizing different conditions to probe alternate queries from the same cell.  
An LIF detection method was utilized to monitor naphthalene-2,3-dicarboxyaldehyde-labeled 
phenylalanine with a detection limit of 2 x 10-9 M.  Benefits of this setup include the LIF 
detection for fluorescent compounds because of the increase in detection limits and the 
ability to sample the cellular homogenate multiple times.  Difficulties of this design include 
the early lysis of the single cell and the tedious manipulation required to inject the contents 
into the capillary.  The lysis of the single cell causes a loss of intracellular 
compartmentalization and could potentially damage analytes by making them more 
susceptible to proteolysis and could change signaling as requisite components are no longer 
in proper locations after lysis. 
 An alternate system also sampled the cytoplasm of a large neuronal cell, this time 
isolated from pond snails.17  However, it differed from the previously described system in 
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both sample injection into the capillary and method of detection.  The 5-µm inner diameter 
capillary used for electrophoresis was etched on the inlet side with hydrofluoric acid (HF) to 
create a very fine point.  This tip was directly inserted into the neuron and a voltage applied 
across the capillary to electrokinetically load the compounds.  This setup utilized a carbon 
fiber electrode for sub-attomole detection limits of electroactive compounds.  This system 
was the first to describe sub-cellular sampling and detection, with the HF-etched capillary 
allowing for very small spatial resolution within the neuron.  The main drawback of this 
design lies with the electrochemical detection setup, limiting the detectable analytes to 
electroactive compounds.  However, this particular setup was designed for analysis of 
neurotransmitters in single cells, many of which are electroactive, so it remains a drawback 
only when the designated analyte is not compatible with this detection scheme. 
 Another early single cell CE system design was used to analyze contents in single 
human erythrocytes, a much smaller cell than the snail neurons previously described.18-21  
Single erythrocytes were loaded when the electrophoretic capillary was positioned over a 
single cell in a small drop of a dilute cell suspension.  Vacuum was applied to the outlet to 
aspirate the cell and was halted when the cell was visually observed to enter the capillary 
lumen.  The cell was lysed with a small plug of detergent loaded immediately after cell 
injection or via contact with the electrophoretic buffer.  LIF was utilized for direct detection 
of native fluorescent compounds, on-column derivatized compounds or for indirect detection 
by monitoring the formation of a non-target analyte proportional to analyte concentration.  
This system was the earliest system described to sample the much smaller mammalian blood 
cells and opened the door for single cell analysis of alternative cells much smaller in size.  A 
main drawback of the loading method is the uncontrollable and variable size of the sample 
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plug.  Time required, and therefore amount injected, almost certainly varied from cell to cell.  
This could lead to different lengths of time to achieve cell lysis as the diffusion of the lysis 
solution through a larger plug would be slower than through a shorter plug.  Additionally, 
injection plug volume can alter the separation if the background solution is different from the 
electrophoretic buffer.  Band broadening can occur if destacking results from these 
differences or a localized region of elevated heat can occur if Joule heating in the higher 
ionic strength, cell-compatible buffer is not dissipated rapidly enough, also leading to band 
broadening. 
 As the technology progressed into the later 1990s and 2000s, other system designs 
began to emerge, combining the older strategies with new methods for cell lysis, sample 
loading and detection designs.  The Dovichi group first introduced an off-column quartz 
sheath flow detector that utilized a helium/neon (HeNe) laser focused just beyond the 
capillary outlet.22  The sheath flow detector is beneficial in that it provides a flat surface for 
the excitation laser to be focused and emission to be collected, as opposed to the curved 
surface of on-capillary detection windows.  The flat surfaces result in less optical scatter, 
allowing for more sensitive detection techniques.  A drawback of the sheath flow design is 
the complexity that arises from balancing the sheath flow rate and capillary flow rate while 
simultaneously ensuring appropriate seals to prevent fluid leakage.  This sheath flow detector 
has been combined with many different sample injection and lysis strategies, discussed 
below.  A chemically etched capillary tip was positioned just above the cell and suction 
applied to the outlet until the cell was aspirated into the capillary, where the cell was lysed 
when it came into contact with the non-physiologic electrophoretic buffer or when a strong 
electric field was applied with a Tesla coil.5, 23-27  This injection and detection strategy has 
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also been combined for two-dimensional (2D) CE analysis of single cells when the eluent 
from one capillary is transferred to a second capillary using orthogonal electrophoretic 
separation strategy.  For example, when capillary sieving electrophoresis in the first 
dimension is followed by micellar electrokinetic chromatography.28-30  
 More recent work from the Dovichi lab attempts parallel CE analysis of single cells 
using microfabricated microwell arrays to trap formalin-fixed cells in known positions so an 
array of capillaries can be lowered over the individual cells.  These cells are then loaded 
when a vacuum is applied to the outlet.14, 31  The design of the 5-capillary array14 affords the 
potential to analyze single cells in parallel, but it is difficult to execute.  Often, no cells or 
multiple cells settle into the wells over which the capillary was aligned, limiting the 
effectiveness of the parallel capillaries.  In addition, the cells were fixed with formalin prior 
to experimental analysis.  Formalin cross-links with itself and with amine groups while also 
making the membrane permeable.32  Anything not cross-linked will leak out of the cell, so 
small molecule reporters such as peptides will not be present.  Additionally, cross-linking of 
proteins generally renders them inactive, as they no longer have the dynamic range of motion 
available prior to fixation, so protein activity cannot be measured after formalin fixation. 
 More recent single cell CE on neurons has come from the Sweedler lab.  The design 
of the systems in this lab combine many setups already described above.  Cells or sub-
cellular regions are loaded into the capillary tip electrokinetically when a voltage is 
applied.33-35  Detection strategies have varied, with use of the same sheath flow detector as 
described above,34 online absorbance detection utilizing an ultraviolet (UV) light source33 
and online LIF detection of fluorescent compounds.35 The benefits and drawbacks of these 
injection and detection strategies are discussed in the above paragraphs, with the exception of 
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the absorbance detector.  Absorbance depends on the detection pathlength through the 
sample, which is inherently small inside the fused silica capillaries, and leads to poor 
detection limits. 
 Finally, the Allbritton lab has utilized single cell CE-LIF instruments for various 
analyses of single cells.  Early work focused on Xenopus laevis oocytes, where a piezo-
driven, HF-etched capillary was used to obtain a plug of cytoplasm before the inlet was 
transferred to electrophoretic buffer for CE.36-40  LIF detection was utilized to detect 
fluorescent analytes.  An alternative design was introduced by Sims et al. in the late 1990s 
that utilized a focused pulse from an Nd:YAG laser to lyse an individual cell, halting cellular 
reactions within milliseconds.41  The contents were then electrokinetically loaded into the 
capillary when a voltage was applied across the capillary.  Many uses of this system have 
been described in the literature,9, 42-45 mostly in the analysis of kinase activity in single cells.  
Additional usage of this system design has recently been described by the Audet lab.3, 46, 47  
An alternative lysis strategy has also been used by the Allbritton lab, where electroactive 
coverslips were used to apply an electrical pulse to cells, lysing them prior to loading into the 
capillary for separation.10, 11, 48  Recent improvements to these system designs include 
replacement of the open beam excitation pathway by fiber optics49 and similar conversion of 
the open emission pathway to fiber optics.50, 51  The fiber optic design reduces the overall 
footprint of the instrument by moving the excitation and emission components to the 
microscope stage.  This more compact design permits for shorter capillaries, yielding faster 
separations as the electrophoretic voltage can be increased and the distance traveled by 
samples is shorter.  The main drawback to these systems is the cost of the pulsed laser 
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utilized for cell lysis, making this system more expensive than other designs lacking the 
Nd:YAG laser. 
2.1.3 Instrument Design Rationale 
 Design of the instrument described in this chapter was based on previous designs of 
systems utilized in the Allbritton lab.  Laser-based cell lysis was chosen because it lyses cells 
on sub-millisecond time scales, causing turbulent mixing of the contents, rapidly terminating 
cellular reactions.  Laser-based lysis gives excellent temporal resolution of enzymatic 
reactions as the cell remains unperturbed until the moment of lysis.  This is in contrast to the 
seconds or minutes required to lyse cells with detergents or buffers, times too long to allow 
for accurate assessment of enzymatic activity.  As an example, PKB can be activated in 
response to cellular stress and has been found to be activated within one minute of cell 
stimulation.52  Addition of a stressful stimulus such as detergent in a lysis buffer might 
activate PKB, causing substrate phosphorylation during the lysis step.  Measurement of 
substrate phosphorylation after lysis with detergent could yield higher values than were 
present before the detergent was added and could lead to false assessment of PKB activity.  
The short timescales of lysis by the Nd:YAG laser greatly reduces this time lag, resulting in a 
measurement of kinase activity with little or no artifacts related to lysis-induced enzymatic 
stimulation.  Finally, laser-based lysis is easily coupled to electrokinetic injection of the 
cellular contents and both functions are easily programmed and controlled with the chosen 
software. 
 Laser-induced fluorescence detection was chosen because of its exquisite sensitivity, 
on the order of atto- and zeptomoles,13 and the peptide substrates utilized in these studies are 
easily synthesized to contain a fluorescent tag such as carboxyfluorescein.  The conversion to 
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the fiber optics in this design versus earlier systems made the system more compact with a 
smaller footprint so both the excitation and emission optics were placed on the microscope 
stage.  This instrument was also designed and constructed to facilitate incorporation of a 
commercial microinjection system that could be used to microinject cells with the reporter of 
choice prior to cell lysis and CE.  While similar to previous designs of single cell CE-LIF 
systems constructed in this lab, the instrument described in this chapter consists of upgrades 
in the software and instrumentation to fit with the work described in this dissertation and in 
future work anticipated by the Allbritton lab. 
 
2.2 Experimental Design 
2.2.1 Instrument Parts 
 Appendix A contains the blueprints for the custom parts described below.  The parts 
were machined by the UNC Physics Machine Shop (Chapel Hill, NC).  The following 
components were machined from aluminum: two (2) microscope stage adapters and the CE-
LIF base bottom, front and top.  The remaining components were constructed of black delrin: 
photomultiplier tube (PMT) shutter, PMT shutter plate, PMT filter drawer, PMT housing, 
CE-LIF detector housing and the collection lens holder.  Two (2) plate adapters (07 RPC521, 
Melles Griot, Albuquerque, NM) were adapted by the Physics Machine Shop by 
counterboring 2 screw locations and removing the lip in the slots on either side, indicated in 
Appendix A. 
 The following optical components were purchased from OZ Optics (Ontario, 
Canada): excitation fiber optic cable for 473 nm light with focusing optic, spot size of 40 µm 
at a distance of 3.9 cm (LPF-04-473-3.5/125-S-9.5-39-3.9AS-40-3AF3-2); fiber collimator 
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and collection lens (HPUCO-23-400/700-M-50AC-30OD); fiber patchcord for emission 
pathway (QMMJ-33-IRVIS-200/300-3-1); and a fiber collimator (HPUCO-23-400/700-M-
3.5AC-SP).  The following optical filters were purchased from Semrock (Rochester, NY): 
single band bandpass filter centered around 525 nm, 50 nm bandwidth (FF01-525/50-25); 
ultrasteep long-pass edge filter at 488 nm (LP02-488RS-25); and a single notch filter at 532 
nm, 17 nm bandwidth (NF01-532U-25).  Both the photomultiplier tube (H7732-10) and the 
PMT power supply (Mode C7169) were purchased from Hamamatsu (Bridgewater, NJ).  The 
following data acquisition components were purchased from National Instruments (Austin, 
TX): connector block (SCB-68 shielded connector block); shielded cable (SHC68-68-EPM 
shielded cable); and the data acquisition (DAQ) card and board (NI-PCI-6229, M-Series 
DAQ, 32 analog inputs, 48 digital I/O, 4 analog outputs.) 
 Additional parts were purchased from the following companies, as listed below: 
computer (Optiplex 980, Dell, Round Rock, TX); 473 nm excitation laser (BML-473-10F0-
A1-FC9) and power supply (DPSSL, Lasermate Group Inc., Pomona, CA); pre-amplifier 
(PMT-5 amplifier) and power supply (F-100PS, Advanced Research Instruments 
Corporation, Golden, CO); two (2) x, y translational stages (07-TMS512) and two (2) z 
translational stages (07-TEZ701, Melles Griot, Albuquerque, NM); capillary x, y, z 
translational stage (custom order, World Precision Instruments, Sarasota, FL); objective for 
gathering emission (PlanFluor. 40X/numerical aperture of 0.75); microscope (Axiovert 135, 
Zeiss, Thornwood, NY); high voltage power supply (CZE 1000R) and cable (105719-034, 
Spellman High Voltage Corporation, Hauppauge, NY); Nd:YAG pulsed laser and power 
supply (Minilite, Continuum, Santa Clara, CA); CMOS camera (MCN-B013-U, Mightex 
Systems, Pleasanton, CA); beam expander (Model 15900), two (2) high-energy mirrors 
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(10QM20HDM.15) and optical breadboard (LW3048B-OPT, Newport Corporation, Irvine, 
CA); dry bath incubator (Isotemp, Fisher Scientific, Waltham, MA); and microinjector 
(Transjector 5246, Eppendorf, Hamburg, Germany).  Other mounting components and 
brackets were purchased from Newport or Melles Griot.  Tubing used in the buffer flow 
system was purchased from Fisher Scientific (Waltham, MA).  Data was collected with 
custom software (Appendix B) made with LabVIEW (Version 9.0.1, National Instruments, 
Austin, TX) and analyzed using Origin Software (Version 7.5, OriginLab Corporation, 
Northampton, MA). 
2.2.2 Instrument Validation 
2.2.2.1 Chemicals and Materials 
 Chemicals used in the validation of the instrument were purchased from the following 
companies: Fluorescein Reference Standard was procured from Invitrogen (Carlsbad, CA); 
trizma base and tricine were obtained from Sigma (St. Louis, MO); sodium hydroxide 
(NaOH) and hydrochloric acid (HCl) were bought from Fisher Scientific (Waltham, MA).  
Fused silica capillaries [50 µm inner diameter, 360 µm outer diameter (Polymicro 
Technologies, Phoenix, AZ)] had a total length of 38 cm and an effective length of 21.5 cm.  
Capillaries were conditioned prior to use with 0.1 M NaOH for 12 h, H2O for 1 h, 0.1 M HCl 
for 6 h, and H2O again for 12 h.  After each sample, the capillary was sequentially washed 
with 1 M NaOH, H2O and buffer for 10 min (approximately 10 column volumes) by applying 
pressure with nitrogen to the capillary outlet.  A sample plug was injected by elevating the 
capillary inlet 3 cm relative to the outlet for 10 s.  The volume injected was estimated with 
Poiseuille’s equation (Eq 2.1) and was determined to be 0.13 nL s-1. 
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Equation 2.1:53 
 
       
      V = volume 
      t = time sample is applied 
      ρ = density (assumed 1 g mL-1) 
      g = acceleration due to gravity (9.8 m s-2) 
      h = height difference between inlet and outlet 
      d = inner diameter of capillary 
      η = viscosity (assumed 8.9 x 10-3 g cm-1 s-1) 
      L = total capillary length 
 
2.2.2.2 Optimum Electrophoretic Voltage 
 To determine the optimal electrophoretic voltage, an Ohm’s Plot was generated by 
filling the capillary with and immersing both ends in a 100 mM tris/100 mM tricine, pH 8.1 
buffer.  A negative voltage was applied to the outlet electrode and the current was recorded 
for 30 s.  The voltage was tested in 2 kV increments from 0 - 18 kV.  The current as a 
function of voltage was plotted and a line with a slope corresponding to 1/R was generated 
utilizing the data.  The optimum running voltage was determined to be the highest voltage 
that still obeyed a linear relationship between current and voltage. 
2.2.2.3 Limit of Detection 
 In order to determine the limit of detection (LOD) of the CE system, successively 
higher concentrations of a fluorescein reference standard were gravity loaded into the 
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capillary as described above in section 2.2.2.1 and a voltage of -12 kV was applied to the 
outlet.  On the resulting electropherogram, the height of the baseline and the height of the 
corresponding fluorescein peak were measured.  The signal to noise (S/N) ratio was 
determined by dividing the height of the fluorescein reference standard peak by the average 
height of the baseline.  The LOD was chosen as the amount of fluorescein required to 
achieve an S/N value of 3. 
2.2.2.4 Cell Lysis 
 A focused pulse from an Nd:YAG laser was utilized to lyse cells.  Individual cell 
chambers were prepared by using poly(dimethyl siloxane) (PDMS, Sylgard 184) to glue a 
silicon O-ring (McMaster-Carr, Cleveland, OH) to a #1 glass coverslip (Fisher).  The 
location of the laser was determined by visual identification of ink ablation from the surface 
of the coverslip.  Adherent HeLa cells were used to determine the laser energy setting 
appropriate for cell lysis.  A single cell was positioned adjacent to the previously determined 
location of laser position and the laser was fired once.  The cell was visually observed for 
signs of lysis.  Lysis was considered achieved when the plasma membrane of the cell was 
compromised based on visual identification.  The laser energy was chosen based on the 
amount of energy required to lyse >95% of cells with a single pulse.   
2.2.2.5 Buffer Flow System 
 Gravity was utilized to drive the flow of ECB over the cells and vacuum was used to 
remove fluid from the cell chamber.  The temperature in the cell chamber needed to be 
approximately 37 oC, meaning the temperature of the sand bath heating the fluid had to be 
significantly higher.  To determine the required sand temperature, a thermometer was placed 
in the sand and a second thermometer was located in the cell chamber.  Both temperatures 
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were recorded as the sand temperature was increased.  The appropriate sand temperature was 
defined as the temperature required to hold the ECB in the cell chamber between 34 – 37 oC 
while the buffer was flowing. 
 
2.3 Results and Discussion 
2.3.1 Instrument Description 
 The single cell CE instrument possessed the following features or components, which 
are indicated in Figures 2.1 and 2.2.  To load analyte directly into single cells, a 
commercialized microinjection system was installed on the instrument.  To achieve lysis on 
sub-millisecond timescales, a pulsed Nd:YAG laser was incorporated into the system.  
Detection limits in the range of attomoles was desired, so the highly sensitive laser-induced 
fluorescence detection was chosen as the detection method used for this system.  Fiber optic 
cables were utilized in the excitation and emission pathways so that all optical components 
were located on the microscope stage.  Electrophoresis was driven through a fused silica 
capillary positioned over the microscope stage to allow for introduction of a single cell into 
the capillary.  Construction of the instrument is described in the following sections. 
2.3.2 Instrument Construction 
2.3.2.1 Excitation Pathway 
 The primary step in preparing the excitation pathway was to center the laser beam in 
the 3.5 µm-diameter single-mode fiber core by optimizing the power output from the fiber to 
2 mW.  As demonstrated by Peck et al. in a systematic study of optimal laser power for laser-
induced fluorescence detection, there is a maximum output signal reached for each 
fluorophore.54  To obtain the maximum fluorescence signal, the excitation laser power must 
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be high enough for the fluorophores to emit as much as possible, yet not so high that the 
fluorophores photobleach at an unacceptably rapid rate, which would result in lower signal.  
For this system and fluorophore, 2 mW was determined to be the most acceptable power.  
Adjustments were made until a steady output from the fiber of 2.1 mW was achieved. 
 Once the desired power output was attained, the excitation fiber was positioned above 
the capillary.  The most frequent capillary utilized in this system has an inner diameter of 50 
µm, so the excitation fiber was purchased with a pigtail style lens to focus the laser to a spot 
size of 40 µm at a working distance of 3.9 cm.  When properly aligned, the excitation laser 
spot fills the majority of the inner diameter of the capillary while minimizing light scatter 
from the curved fused silica walls.  The x,y, z translational stage holding the excitation fiber 
was mounted to the CE-LIF base which was mounted directly to the microscope stage 
(Figure 2.3) and the emitting end of the excitation fiber was fixed to a z position 3.9 cm 
above the capillary detection window.  The y position was determined by monitoring the 
diffraction pattern produced on the opposite side of the fluid-filled capillary.  In the desired 
position where the 40 µm laser spot was centered in the capillary lumen, the diffraction 
pattern was symmetrical.  The x position of the capillary was determined in conjunction with 
alignment of the emission pathway (described in section 2.3.2.2). 
2.3.2.2 Emission Pathway 
 A 40X objective lens with a numerical aperture (NA) of 0.75 was positioned at a right 
angle from the excitation laser and was fit into the custom-made CE-LIF Detector Housing 
attached to an x, y, z translation stage using the custom-modified plate adapter (Figure 2.4).  
The focal length of this objective was just long enough to reach the center of the capillary 
lumen, where the location of maximum fluorescence was located.  Positioning of the 
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objective to the precise focal length of the lens permitted maximum fluorescence signal 
collection by the objective lens.55  A larger collection lens was attached to the opposite side 
of the Detector Housing to focus the emission light from the objective lens into the 200 µm 
core of the multimode emission fiber.  The multimode emission fiber is capable of 
transmitting both infrared and visible light, a range containing the 520 nm wavelength of 
fluorescein emission.  A collimator was placed at the terminus of the emission fiber to reduce 
the spread of emission light directed into the PMT entrance.  The collimator was directly 
attached to the custom-designed PMT Housing.  Prior to passing into the PMT entrance slit, 
the emission light was filtered through two spectral filters to reduce detection of emission not 
due to the fluorophore.  An ultrasteep long-pass edge filter at 488 nm was utilized to 
eliminate wavelengths below 488 nm, including any radiation from the excitation laser.  A 
single band bandpass filter centered at 525 nm (± 25 nm) was used to collect emission from 
the fluorophore and attenuate all wavelengths below and above the range of the bandpass 
filter.  A custom-designed shutter was inserted to protect the PMT when data collection was 
not in process.  Incident light entering the PMT strikes the first photocathode, which 
generates electrons.  These electrons are steered to additional dynodes within the PMT, 
releasing a cascade of electrons at each dynode and generating a current at the anode of the 
PMT.  Thus, the PMT converts photons into a current.  The PMT was connected to a pre-
amplifier utilized to amplify the current from the PMT, convert it to a positive voltage, and 
step the voltage to a range readable by the DAQ board.  The pre-amplifier was positioned as 
closely as possible to the PMT to minimize the amount of noise introduced into the signal 
prior to amplification. 
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 The x, y and z position of the Detector Housing, and therefore the position of the 
microscope objective, was determined by filling the capillary with a 10 µM solution of 
fluorescein reference standard in water and monitoring fluorescence as the x, y and z 
positions of the Detector Housing were adjusted.  Additionally, the x position of the 
excitation laser was also adjusted as needed.  These four positions were altered until a 
maximum signal was observed.  Optimal positioning of the Detector Housing is key for 
obtaining the desired detection limit because as much emission light as possible needs to 
enter the PMT to maximize the amount of signal recorded.  When the maximum signal was 
seen after adjustments to the four positions, each position was locked into place. 
2.3.2.3 Laser-Based Cell Lysis 
 The Nd:YAG laser used for achieving cell lysis was steered at a right angle and 
elevated to the appropriate height with 2 mirrors adjusted with thumbscrews to direct the 
beam into the microscope.  The pulsed laser beam alignment was adjusted until it filled the 
entire back aperture of the microscope objective.  Filling the back aperture of the objective 
lens maximized the radiant flux focused at the focal point of the lens, delivering the 
maximum amount of energy.  When the beam was properly aligned, the laser light was 
focused with the microscope objective to a location at the interface of the cell chamber 
surface and fluid, determined as described above (Section 2.2.2.4).  Laser energy was 
adjusted and measured with an energy meter at the location of the cell chamber, with the 
microscope objective removed to protect the energy meter, as focusing of the beam by the 
objective results in energies higher than the upper limit of detection of the energy meter.  The 
pulse was focused by the objective to a point just below the interface of the coverslip and the 
fluid in the cell chamber.  Upon firing at this location, the pulse generated a plasma which 
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created a cavitation bubble.  Collapse of the cavitation bubble generated a shock wave 
originating from the bubble and propagating outward.56, 57  This cavitation bubble was 
responsible for disruption of the plasma membrane of the cells, with higher energies resulting 
in more complete disruption.  On some occasions, the coverslip was cracked and a small 
bubble generated in the fluid above this location.  This was an indication of sub-optimal 
focusing and was an indication of the laser being focused in the coverslip rather than at the 
interface between the coverslip and the fluid.  All of these results are similar to what has been 
previously described for Nd:YAG laser-based lysis.41, 57  To determine the energy required to 
reproducibly lyse cells, a cell was positioned approximately 10 µm laterally from the laser 
pulse location and was visually inspected for lysis after a single pulse from the laser.  A laser 
energy of 30 µJ was found to lyse more than 95% of cells with a single pulse and was 
selected as the working energy. 
2.3.2.4 Temperature Controlled Buffer Flow System 
 The main reservoir of ECB was located approximately 1 m above the CE system to 
provide gravity flow to bathe cells in the culture dish in a continuous stream of buffer.  
Continuous buffer flow allowed for maintenance of culture temperature at 37oC, solution pH, 
and a means to remove excess analyte from the cell chamber prior to analysis.  1/4 inch 
diameter tubing was connected to a 3-way valve, with one end connected to a Luer-lock 30 
mL syringe and the other end to a 1/16 inch inner diameter tubing that was wound around a 
metal rod and immersed in sand in a dry bath incubator.  As this smaller tubing exited the 
sand, it was insulated with weather stripping and directed to the cell chamber to minimize 
heat loss from the solution.  Effluent ECB was removed from the cell chamber via vacuum.  
The vacuum line was positioned slightly above the influent line so that approximately 500 µL 
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of fluid remained in the cell chamber at all times.  A sand temperature between 70 – 75 oC 
provided an ECB temperature between 34 – 37 oC in the cell chamber with an approximate 
flow rate of 3 mL min-1.  This resulted in a fluid velocity of 0.2 mm s-1 experienced by the 
cells.  This velocity is approximately 10X less than a previously reported velocity utilized for 
calculating shear stress experienced by cells in a microfluidic device, which was determined 
to be well below the acceptable limits for mammalian cells.10, 58  Based on these 
measurements and comparisons to past calculations of shear stress, it was determined that the 
flow rate experienced by the cells in the chamber did not adversely affect the cells. 
2.3.2.5 Capillary Electrophoresis 
 The voltage was supplied by a Spellman High Voltage Power Supply connected to a 
platinum electrode at the outlet end of the capillary (Figure 2.5).  This high voltage outlet 
electrode was encased in a custom-made chamber as a safety precaution to protect the user 
from exposure to the electrode.  The ground electrode was located on the microscope stage.  
For additional safety reasons, the entire optical table was grounded to prevent excess charge 
buildup around the system.  The capillary inlet was mounted to a custom-made capillary 
holder with 3 cm movement in the z direction.  The x and y position of the capillary inlet in 
this system was fixed over the location of cell lysis, determined as described in Section 
2.2.2.4.  Movement in the z direction allowed the capillary to be raised and lowered into the 
cell chamber or inlet buffer reservoir as needed.  Gravity injections were performed with the 
capillary at the highest position relative to the microscope stage and outlet buffer reservoir, a 
3-cm height difference that initiated hydrodynamic fluid flow into the capillary inlet. 
 The capillary was threaded through a custom-designed capillary holder that 
positioned the capillary window in front of the objective through which emission light was 
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collected.  The holder cell was anchored to the CE-LIF Base to hold the capillary in a fixed 
position relative to the emission objective lens to provide maximum collection stability.  The 
holder cell was designed with a V-groove for precise capillary positioning so that when a 
new capillary was installed, the detection window remained in the same location each time, 
reducing the likelihood of having to realign the emission pathway with each new capillary 
installment.  The outlet of the capillary was inserted into the chamber containing the high 
voltage electrode.  In addition to providing a barrier between the user and the high voltage 
electrode, this chamber was also designed to be completely sealed when a fluid-filled glass 
vial (03-338A, Fisher) was screwed into position.  To wash the capillary, a nitrogen line at 20 
psi was attached to the chamber with a simple on/off value to pressurize the chamber and 
force fluid from the vial through the capillary.  An inlet reservoir was created by inverting 
the cap of a 15 mL centrifuge tube and the microscope stage was positioned with this inlet 
buffer reservoir below the capillary.  When the capillary inlet and ground electrode were 
immersed in the buffer, electrophoresis could commence by application of a voltage to the 
outlet electrode.  Voltage and data acquisition were controlled through the software described 
in Section 2.3.2.6. 
2.3.2.6 Software and Hardware Interfacing 
 There were four components linked to the DAQ card through modified BNC cables.  
The pulsed Nd:YAG laser and the CE power supply were connected to the digital to analog 
(D/A) converter in the DAQ card and were controlled by user-input values.  A 100 ms digital 
pulse was utilized to trigger the laser when indicated by the user.  A sustained voltage 
specified by the user was applied to the CE power supply to drive electrophoresis.  Analog 
data was converted to digital input by the analog to digital (A/D) converter in the DAQ card.  
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The analog voltage from the pre-amplifier was converted to a 32 bit digital signal by the A/D 
converter and recorded by the computer.  Additionally, the current readout from the CE 
power supply across the electrodes was digitized by the A/D converter and recorded by the 
personal computer. 
 All hardware control, software data acquisition, and software filtering was performed 
with a custom-made program in LabVIEW.  The code to initialize all hardware was adapted 
from a program constructed by Alexandra J. Dickinson.  A copy of the front panel and select 
portions of the block diagram can be found in Appendix B.  The program utilizes event-based 
programming to permit the program to remain idle while not in use, allowing the program to 
remain on and the hardware to remain initialized for immediate use when needed, yet does 
not slow the computer by running continuously in the background.  When a task is requested, 
the task executes exactly once and then returns the program to idle mode.  Tasks included in 
this event code are: voltage control for an electrokinetic injection of a specified voltage and 
duration; control of the lysis laser; sequential firing of the laser and an electrokinetic 
injection; starting a CE run with a specified voltage; and stopping a CE run. 
 The code executed when the “Start CE” case is called is shown in the block diagram 
in Appendix B.  This code controls the voltage on the HV power supply, initializes the PMT, 
power supply and DAQ card for sample acquisition, generates a unique file for writing data 
and collects and displays the data.  The user can specify a name or the program will auto-
increment a number to identify each separate file.  The DAQ collects data from the PMT at 
12 kHz and averages this data so that 3,000 data points are averaged for a single output value 
every 0.25 s.  Signal averaging was chosen to reduce the baseline noise and increase the S/N 
ratio for the system.  Signal averaging works by assuming that noise is random with a mean 
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centered around an average and is not related to signal, while the signal is assumed to be a 
non-random, positive value.  Signal averaging reduces the noise by averaging these random 
noise values, resulting in a value closer to the average.  Because the signal is non-random and 
positive in value, signal averaging only partially attenuates the signal.  The combination of 
reduced noise and minimal decrease of signal increases the S/N ratio.  The S/N ratio 
increases in proportion to the square root of the number of measurements, so the more 
measurements taken yields a better S/N ratio, which is directly correlated to the LOD for the 
system.  This unfiltered, averaged data is written directly to an ASCII file where a user can 
further filter with software if desired.  Additionally, to further reduce the noise and enhance 
the S/N ratio, the collected data is filtered through a 2nd order Butterworth filter (with a 
frequency of 10 Hz and a low cutoff frequency of 0.5 Hz) and is displayed in real-time on the 
front panel while also being saved in a separate ASCII file.  All data presented in this 
dissertation utilizing this system was the data filtered through the Butterworth filter, unless 
specified otherwise. 
2.3.3 Instrument Validation 
2.3.3.1 CE Optimal Electrophoretic Voltage 
 Prior to using any new CE system or a new CE buffer, the working voltage ranges 
must be determined.  The van Deemter equation for the open tubular column utilized in CE 
reduces down to Equation 2.2, indicating that a higher voltage results in smaller plate 
heights, giving a higher plate count and a better theoretical sensitivity. 
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Equation 2.2:59 
 
        H = theoretical plate height 
        B = longitudinal diffusion 
        u = linear velocity 
 
 However, in each capillary-buffer system, there is an upper limit to the voltage that 
can be applied.  This upper limit is defined as the voltage at which Joule heat can no longer 
be effectively dissipated from the solution in the capillary and depends on the size of the 
capillary, the amount of current-carrying species in the buffer, and the ability to dissipate any 
heat generated.59-61  The limit should be determined for each capillary-buffer system utilized 
as running too far below this limit means the system is not as efficient as it could be and 
running above this limit causes thermal band-broadening, unstable current and irreproducible 
results. 
 In order to determine the optimum running voltage for a 50-µm ID capillary on this 
system, a 100 mM tris/100 mM tricine, pH 8.1 buffer was loaded into the capillary and the 
inlet and outlet reservoirs.  Varying voltages were applied across the capillary and the 
resulting current was measured.  The current was plotted as a function of voltage (Figure 2.6) 
and deviation from linearity began just above 12 kV.  Above this voltage, the current 
increased more than theory predicted, indicating Joule heating and ineffective heat 
dissipation.  Based on these results, a run voltage of 12 kV was selected for this particular 
capillary-buffer system. 
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2.3.3.2 CE Limit of Detection 
 Determination of the LOD for this system was important to ensure that the system 
was aligned properly and achieved an LOD sufficient to detect analytes from single cells.  It 
was also important to establish the LOD measurement as a benchmark for future comparison 
– a dramatically different LOD would result in sub-optimal performance and indicate system 
misalignment or capillary compromise.  To determine the limit of detection, a known amount 
of successively higher concentrations of a fluorescein reference standard were 
electrophoresed and detected with laser-induced fluorescence.  The resulting 
electropherogram was inspected and two values obtained: the height of the baseline noise (an 
average of three measurements) and the height of the signal peak.  The signal to noise ratio 
was calculated by dividing the signal height by the average height of the noise and the LOD 
was defined as the amount of fluorescein reference standard required to give a signal to noise 
ratio of 3.  The buffer utilized in this determination was 100 mM tris and 100 mM tricine, pH 
8.1 with a voltage of -12 kV applied to the outlet reservoir.  A 100 pM solution of fluorescein 
reference standard was gravity injected at the capillary inlet (0.6 nL, calculated with Eq 2.1) 
prior to initiation of electrophoresis.  The resulting electropherogram and sample 
measurements can be found in Figure 2.7.  The LOD for this system was determined to be 3 
x 10-20 moles, approximately 10 times higher than the best detection limits of previous 
systems in this lab, but acceptable for most experiments.  The robustness of this system has 
been tested several times throughout its lifetime, and the LOD remains the same from month 
to month, indicating acceptable instrument performance. 
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2.4 Conclusions 
 The design and construction of a CE-LIF instrument for single cell analysis was 
presented.  The instrument has an excellent limit of detection, as measured using a 
fluorescent reference standard and compared to similar instrument designs.  This instrument 
converted both the excitation and emission pathways to fiber optics, extending on previous 
single-cell CE instruments in this lab by eliminating ambient light from the detection 
pathway and reducing instrument footprint.  Cells in custom made chambers can be 
incubated in warm extracellular buffer, which serves to keep the cells from becoming 
hypertonic as the solution evaporates.  Additionally, this system was constructed to run 
entirely with LabVIEW software and was utilized for all single cell work presented in this 
dissertation. 
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2.5 Figures 
 
Figure 2.1:  The single cell CE-LIF instrument described in this chapter.  (A) The laser head 
for the Nd:YAG laser utilized for cell lysis; (B) the two mirrors used to steer the beam into 
the back of the microscope; (C) dry bath incubator to keep the ECB flow at approximately 37 
oC; (D) arc lamp; (E) CE system, described in detail in Figure 2.2; (F) Zeiss Axiovert 135 
microscope; and (G) CMOS camera connected to computer monitor. 
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Figure 2.2: The CE portion of the CE-LIF instrument.  (A) Microinjector connection; (B) cell 
chamber and ECB buffer flow inlet and outlet; (C) capillary holder and ground electrode; (D) 
x, y, and z translation knobs for capillary positioning; (E) collection lens for emission light; 
(F) microscope objective to collect fluorescence emission at the capillary window; (G) 
excitation fiber optic holder; (H) capillary holder cell; (I) outlet reservoir, the pink wire is the 
high voltage line from the CE power supply and the clear tubing is the nitrogen line for 
pressure driven capillary washing. 
 61 
 
 
Figure 2.3: Schematic of the excitation pathway for the CE-LIF system.  The fiber optic 
focusing lens is positioned 3.9 cm from the middle of the capillary detection window. 
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Figure 2.4: Schematic of the emission pathway for the CE-LIF system.  The x, y, and z 
translation stages are adjusted to bring the microscope objective to the correct location for 
maximum collection of fluorescence emission. 
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Figure 2.5: Schematic of the capillary electrophoresis portion of the CE-LIF system. 
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Figure 2.6: An Ohm’s plot generated for a 100 mM tris and 100 mM tricine, pH 8.1 buffer on 
the single cell CE-LIF instrument.  The data points are an average of three replicates and the 
error bars (shown in red) are the standard deviation of three replicates.  The line represents 
theoretical current and voltage relationship. 
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Figure 2.7: Limit of detection calculations for the CE-LIF system.  (A) Electropherogram of 
100 pM fluorescein reference standard.  (B) The red bars show three locations for measuring 
the height of the noise and the green bar shows the measurement of the signal height. 
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CHAPTER 3 
 
METABOLISM OF PEPTIDE REPORTERS IN CELL 
LYSATES AND SINGLE CELLS 
 
3.1 Introduction 
3.1.1 Synthetic Peptides as Kinase Substrates and Inhibitors 
 Synthetic peptides have found widespread use in biomedical research particularly as 
substrates and inhibitors of kinases and peptidases.  The chemistry of solid-phase peptide 
synthesis is well-defined, permitting relatively straightforward construction of large 
quantities of peptides comprised of native and non-native amino acids.  Peptides have a long 
shelf life and are readily derivatized with labels such as fluorophores and targeting elements 
(e.g. biotin).  Peptides are an attractive alternative to proteins in a variety of applications (e.g. 
enzyme assays) due to their chemical simplicity and ease of handling.  Furthermore, the 
substrate preference of many protein kinases is largely determined by the amino acid 
sequence surrounding the phosphoryl-accepting residue. Consequently, consensus peptide 
sequences have been defined for large numbers of these enzymes.1-4  In many cases, these 
short peptide sequences mimic the kinetic properties of the native protein substrates for the 
enzyme.  For kinases, replacement of the residue that undergoes phosphorylation (serine, 
threonine, or tyrosine) with a non-phosphorylatable analogue (alanine or phenylalanine) 
often yields a peptide with excellent inhibitory properties for the targeted kinase.5, 6  
Modifications of a peptide substrate with non-
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inhibitors when the inhibitor peptide binds tightly to the substrate binding domain of the 
kinase and prevents docking of the target substrate.5, 7  For these reasons, a wide array of 
substrate and inhibitor peptides are commercially available to manipulate or monitor a 
plethora of kinase activities in in vitro systems. 
3.1.2 Peptides as Reporters in Cell Lysates and Single Cells 
 In addition to their use in assays with purified kinases, peptides are often used to 
assay kinase activity in cell lysates and also increasingly in intact cells.8-15  Cell lysates offer 
a native enzyme in an environment which retains many of the co-factors and other regulatory 
elements of the cell.  Cell lysates can be prepared in large volumes to meet the sensitivity 
needs of almost any detection strategy.  Manipulation of the reaction environment by 
addition or removal of modifiers or inhibitors is also relatively trivial in a cell lysate 
compared to intact cells.  However, lysates do not recapitulate the environment of an intact 
cell in a variety of ways.  For example, the contents of a cell lysate are diluted and intermixed 
when intracellular compartments are fragmented during lysis, resulting in a loss of protein 
compartmentalization as well as normal spatial relationships found in intact cells.  
Additionally, the heterogeneity of single cell populations has been well documented16, 17 and 
cell lysates eliminate this heterogeneity when samples are pooled.  For these reasons, intact 
cells are also used as an assay format in which peptides act as inhibitors or substrates for 
enzymes.18-20  The low molecular weight of peptides offers the advantage of efficient loading 
into cells relative to intact proteins.21  The loading of substrate peptides into cells followed by 
lysis and separation of substrate and product by electrophoresis has been performed to track a 
variety of enzymatic reactions including those of kinases, acyl transferases, and proteases.22-
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24  This strategy offers direct quantification of the substrate and product quantities as well as 
the identification of the products of competing reactions with zeptomole detection limits. 
3.1.3 Limitations of Peptide Reporters 
 Despite their benefits as substrates and inhibitors in biomedical research, the use of 
peptides in the presence of cellular constituents is plagued by unwanted and rapid 
proteolysis.  Exo- and endo-peptidases are an integral part of the protein recycling and 
antigen processing machinery of cells and ensure that most peptides are rapidly hydrolyzed 
to their amino acid constituents.25  While peptidase inhibitors can be used to slow these 
reactions, they are generally insufficient to eliminate peptide hydrolysis, are often not 
specific to a single protease, and have significant other off-target effects.  Furthermore, many 
peptidase inhibitors are poorly soluble in aqueous solutions necessitating the use of organic 
solvents that may interfere with cellular reactions.  To prevent peptide bond hydrolysis, a 
number of alternative strategies have been utilized to impart stability to peptides.  Peptide 
cyclization reduces degradation by creating a fixed secondary structure preventing protease 
access to the peptide bond.26-29  Although circularized peptides are excellent at resisting 
peptidase actions, peptide cyclization can be difficult and is often of low yield due to 
competing intermolecular reactions.  More importantly, cyclization often reduces or 
eliminates the ability of kinases to phosphorylate the peptide.  Another method frequently 
utilized to impart stability to peptides is the addition of a polyethylene glycol moiety 
(PEGylation); shorter PEG chains (average molecular weight of approximately 6,000 Da) 
attached to peptides show better affinity for the targeted enzyme yet less ability to resist 
degradation than PEGylated peptides with average molecular weights near 25,000 Da.30-32  
The addition of a PEG group greatly increases substrate molecular weight and diminishes the 
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chemical differences of the substrate and product, making detection and quantification of the 
substrate and product challenging.  The polydispersity of molecular weights in PEG 
formulations also yields unacceptably broad electrophoretic peaks.  Introduction of non-
native residues into peptides, which can be achieved with standard solid phase synthesis 
strategies, has been shown to block unwanted proteolytic reactions.  This strategy has been 
particularly successful in stabilizing inhibitor peptides.30, 33-38  Extensive libraries of non-
native amino acids provide numerous possibilities for the construction of selective inhibitors 
or substrates, as demonstrated by Lee et al. in 2004.14  However, design of peptides that act 
as substrates for specific enzymes yet are peptidase resistant has been challenging. 
3.1.4 Reporter Peptide Design and Evaluation 
 A strategy was developed to rationally design a kinase-substrate peptide with 
increased stability in cell lysates and intact cells.  A consensus substrate sequence was 
selected for Abl kinase and used as the starting point for the design modifications.  Abl 
kinase was chosen because of its role in chronic myelogenous leukemia (CML), where a 
constitutively active Abl enzyme results from the fusion of the Bcr to Abl protein in a 
majority of patients with CML.39  The average rate and locations of lysate-induced cleavage 
sites in an Abl peptide substrate were identified by capillary electrophoresis.  The starting 
peptide was then modified by replacement of residues adjacent to the identified cleavage site 
with non-native amino acids and then re-evaluated for peptidase resistance in the cell lysate.  
The modified peptides were also evaluated for Abl substrate suitability.  Multiple cycles of 
peptide modification and assessment of protease resistance and kinase substrate efficacy 
generated a final modified peptide that was characterized in a cell lysate.  The substrate was 
also assessed for phosphorylation by Abl relative to the starting sequence.  Proteolytic 
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sensitivity of both the starting peptide sequence as well as the final modified peptide was also 
assessed in intact single cells. 
3.2 Experimental Design 
3.2.1 Chemicals 
 Peptide synthesis reagents were purchased from Aldrich or Fisher except for the 
following:  2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate (HCTU), 1-(Mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT), 9-
Fluorenylmethoxycarbonyl (Fmoc) amino acids, 5-carboxyfluorescien (5-FAM) and resins 
were received from ChemPep or NovaBiochem; N-Hydroxybenzotriazole (HOBt) was 
obtained from AnaSpec; and Fmoc-3-(2-Naphthyl)-L-Alanine was purchased from Peptides 
International.  All other chemicals used in the assays were procured from Fisher or Sigma 
except for the following: Active Abl-1 enzyme was purchased from Invitrogen; bovine serum 
albumin (BSA) was received from Calbiochem; Roswell Park Memorial Institute Media 
(RPMI-1640) and Dulbecco’s Modified Eagle’s Medium (DMEM) were obtained from 
Cellgro; Penicillin/streptomycin was procured from Gibco; and fetal bovine serum (FBS) 
was purchased from Atlanta Biologicals. 
3.2.2 Peptide Synthesis and Preparation 
3.2.2.1 Synthesis of Full-Length Peptides Amidated on the C-Terminus 
 All peptides were synthesized by collaborator Dr. Qunzhao Wang in the Lawrence 
Lab unless specified otherwise.  A detailed table of all peptides prepared and utilized in this 
dissertation can be found in Appendix C.  Full-length substrate peptides with an amidated C 
terminus were synthesized via standard Fmoc peptide synthesis (Prelude Peptide Synthesizer, 
Protein Technologies, Tucson, AZ) utilizing TGR resin.  Coupling was performed with two 5 
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min incubations in dimethylformamide (DMF) with 5 equivalents (eq) amino acid, 5 eq 
HCTU, and 10 eq N,N-Diisopropylethylamine (DIPEA).  Fmoc deprotection was achieved 
with two 2.5 min incubations with 20% piperidine in DMF.  The free N-terminus was reacted 
with 5 eq 5-FAM, 5 eq diisopropylcarbodiimide (DIC), and 5 eq HOBt in DMF overnight, 
then treated with 30% piperidine in DMF for 30 min.  The peptide was cleaved with 
trifluoroacetic acid:water:triisopropylsilane (TFA:H2O:TIS) in a ratio of 95:2.5:2.5, 
precipitated with ether, and dried in air.  Peptide purity was assessed with HPLC-MS and 
further purification via HPLC was performed if needed.  Peptides were dissolved in Tris 
buffer, pH 7.5, aliquoted, and stored at -80 oC.   
3.2.2.2 Alternative Coupling for Difficult Amino Acids  
 In some instances, amino acids were coupled overnight in N-Methyl-2-pyrrolidone 
(NMP) with 5 eq amino acid, 5 eq bromo-tris-pyrrolidino phosphonium hexafluorophosphate 
(PyBrop), and 10 eq DIPEA.  Capping with acetic anhydride was performed if necessary 
based on a ninhydrin test.  Remaining amino acids were coupled as described in section 
3.2.2.1.  Product formation was assessed using HPLC-MS. 
3.2.2.3 Synthesis of Peptide Fragment Standards 
 Peptide fragment standards with a free carboxylic acid at the peptide C terminus were 
synthesized using either a Wang or 2-Chlorotrityl resin.  When using the Wang resin, 10 eq 
of the first Fmoc amino acid in CH2Cl2 was reacted with 7.5 eq 1-methylimidazole and 10 eq 
MSNT for 15 minutes in a dry glass vial on a shaker.  The reaction mixture was transferred 
to another dry glass vial containing the Wang resin and incubated for 1 h.  For the 2-
Chlorotrityl resin, 1 eq of the first Fmoc amino acid and 4 eq DIPEA in dry CH2Cl2 was 
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reacted with the 2-Chlorotrityl resin for 2 h in a dry glass vial on a shaker.  The remaining 
amino acids were attached as described in section 3.2.2.1 or 3.2.2.2. 
3.2.3 Cell Culture 
 Baf/BCR-ABL cells are a mouse B-cell lymphoma line that was stably transfected 
with and overexpress Bcr-Abl.40  HeLa cells were obtained from the American Type Culture 
Collection.  Baf/BCR-ABL cells were cultured in RPMI-1640 medium supplemented with 
10% FBS, penicillin (100 units/mL) and streptomycin (100 µg/mL).  HeLa cells were 
cultured in DMEM medium supplemented with 10% FBS, penicillin (100 units/mL) and 
streptomycin (100 µg/mL).  All cells were maintained in a humidified atmosphere of 37 oC in 
5% CO2 and passaged into fresh media every 2 – 3 days.  HeLa cells used for single cell-CE 
experiments were plated the day before onto custom chambers, prepared by using 
poly(dimethyl siloxane) (PDMS, Sylgard 184) to glue a silicon O-ring (McMaster-Carr) to a 
#1 glass coverslip (Fisher).  A dilute cell suspension was added to 500 µL of DMEM media 
in the chamber and the chambers were placed in the humidified incubator until use in the 
experiments. 
3.2.4 Measurement of Peptide Degradation in a Cell Lysate 
 Baf/BCR-ABL cells were collected from two confluent 75 cm2 flasks and were 
washed with and resuspended in phosphate buffered saline (PBS; 137 mM NaCl, 10 mM 
Na2HPO4, 27 mM KCl, 1.75 mM KH2PO4, pH 7.4).  The cells were submerged in liquid 
nitrogen for 1 min and rapidly thawed at 37 oC for a total of three cycles.  The mixture was 
centrifuged at 14,000 x g for 5 min at 4 oC.  The supernatant was transferred to a clean 
centrifuge tube and maintained on ice until use in the assay.  Total protein concentration in 
the supernatant was measured using fluorescamine.41  Briefly, fluorescamine (10 µL, 3 
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mg/mL in acetone) was added to a cell lysate (30 µL) and incubated for 5 min at 25 oC.  
Fluorescence was measured with a fluorescence plate reader (SpectraMax M5, Molecular 
Devices, Sunnyvale, CA) with an excitation of 390 nm (bandwidth of 9 nm) and emission of 
475 nm (bandwidth of 15 nm). 
 Assay of peptide degradation was performed by mixing peptide (1 µM) with the 
Baf/BCR-ABL cell lysate (3 mg/mL total cell protein) and incubating at 37 oC for 1 h.  
Aliquots were removed from the reaction mixture at various time intervals.  The reactions 
were stopped by adding HCl to a final concentration of 100 mM.  A 0 min timepoint was 
prepared by adding the HCl to the lysate prior to addition of the substrate peptide.  Reaction 
mixtures were then separated by capillary electrophoresis and detected by LIF.    Peptide 
fragments were identified by adding standards (250 nM) to the HCl-terminated aliquots and 
comparing the electropherograms with and without the added standard.  The average initial 
degradation and fragmentation rates were calculated using the first two time points by 
monitoring the change in peptide amount divided by the change in time per amount cytosolic 
protein.  The units are defined as zmol of peptide per pg of cytosolic protein per s, or zmol 
pg-1 s-1. 
3.2.5 in vitro Kinase Assay 
 Protein kinase assays were performed at 30 oC in assay buffer [50 mM Tris (pH 7.4), 
5 mM MgCl2, 1 mM MnCl2, 2 mM DTT, 1 mM ATP] with Abl-1 kinase (12 nM) and 
substrate (29 µM).  Aliquots were then removed from the reaction mixture at varying times.  
The reactions were stopped by heating at 90 oC for 4 min.  Additionally, a negative control 
with no ATP was simultaneously assayed and sampled.  The amount of peptide 
phosphorylation was measured using capillary electrophoresis coupled with laser-induced 
 79 
fluorescence to separate the substrates and products and quantify peak areas.  The samples 
with and without ATP were compared to identify the phosphorylated product and the non-
phosphorylated precursor (Figure 3.1). 
3.2.6 Measurement of Kinetic Parameters 
 Protein kinase assays were performed as described in section 3.2.5 with the following 
exceptions: substrate concentration ranged from 10 to 100 µM; Abl-1 (Invitrogen, Carlsbad, 
CA) enzyme concentration was 12 nM for QW-III-67B and 6 nM for QW-V-48B.  The 
immobilized metal ion affinity-based fluorescent polarization (IMAP) assay (Molecular 
Devices Corp., Sunnyvale, CA) was used to measure the amount of phosphorylated peptide 
in reaction mixtures (http://www.moleculardevices.com/pages/reagents/imap.html).  A 
calibration curve was constructed by measuring the anisotropy of solutions with known ratios 
of phosphorylated to non-phosphorylated peptide.  The standard with 100% phosphorylated 
peptide was prepared using Abl-1 kinase and the percentage phosphorylation was verified 
with capillary electrophoresis.  Anisotropy was measured using a fluorescence plate reader 
(SpectraMax M5, Molecular Devices, Sunnyvale, CA) with an excitation of 485 nm 
(bandwidth of 9 nm) and emission of 525 nm (bandwidth of 15 nm).  Samples were diluted to 
the working concentration of 100 nM for the IMAP assay with a buffer containing 10 mM 
Tris-HCl (pH 7.2), 10 mM MgCl2, and 0.01% Tween-20. 
3.2.7 Capillary Electrophoresis 
 Laser-induced fluorescence (LIF, 488 nm) was used for peptide detection during 
capillary electrophoresis (ProteomeLab PA800, Beckman Coulter, Fullerton, CA).  Fused-
silica capillaries [50 µm inner diameter, 360 µm outer diameter, (Polymicro Technologies, 
Phoenix, AZ)] had a total length of 30 cm with an effective length of 20 cm.  Capillaries 
 80 
were conditioned prior to use with 0.1 M NaOH for 12 h, H2O for 1 h, 0.1 M HCl for 6 h, 
and H2O again for 12 h.  After each sample, the capillary was sequentially rinsed with 1 M 
NaOH, H2O, and buffer for 2 min by applying a pressure of 20 psi to the capillary inlet.  A 
sample plug was hydrodynamically loaded into the capillary by applying 0.5 psi to the inlet 
for 5 s.  Electrophoresis was initiated by application of a negative voltage to the outlet.  For 
the assays employing a cell lysate, the electrophoretic buffer was 100 mM Tris and 100 mM 
Tricine, pH 8.1 and the field strength was 500 V/cm.  For the in vitro kinase assay samples, 
the electrophoretic buffer was 100 mM Tris, 100 mM Tricine and 5 mM SDS, pH 8.1 and 
field strength was 600 V/cm.  The data was analyzed using commercial software (32 Karat, 
version 8.0, Beckman Coulter, Fullerton, CA). 
3.2.8 Single Cell Capillary Electrophoresis 
 Single cell capillary electrophoresis was performed using the custom-made CE 
system with LIF detection as described in detail in Chapter 2 of this dissertation.  Fused-
silica capillaries [30 µm inner diameter, 360 µm outer diameter, (Polymicro Technologies, 
Phoenix, AZ)] with a total length of 38 cm and an effective length of 21.5 cm were 
conditioned as described above.  A negative voltage of 14 kV was applied to the outlet 
reservoir while the inlet reservoir was held at ground.  The electrophoretic buffer was 100 
mM Tris and 100 mM Tricine, pH 8.1.  Cells were perfused with extracellular buffer (ECB; 
135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 10 mM HEPES, pH 7.4, 25 oC) 
during experiments, with the flow turned off immediately prior to cell lysis and loading into 
the capillary.  Laser-based cell lysis was achieved with a focused Nd:YAG laser as 
previously described in Chapter 2.  To identify peptide fragments formed in cells, standards 
of peptide fragments (100 nM) were hydrodynamically loaded into the capillary immediately 
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following loading of a single HeLa cell into the capillary.  The HeLa cell was not loaded with 
peptide prior to loading into the capillary.  The lysed HeLa cell provided a milieu for the 
subsequently loaded standards similar to that for peptide obtained from a lysed cell.  To 
calibrate the amount of peptide on the electropherograms, a known concentration of a 
standard of each intact peptide was hydrodynamically loaded into the capillary, 
electrophoresed, and the area under the peak calculated.  Poiseuille’s equation (Equation 2.1) 
was utilized to estimate the amount of peptide injected, as demonstrated by Meredith et al.22  
Data was collected with the custom software described in Chapter 2 (LabVIEW 9.0.1, 
National Instruments, Austin, TX) and analyzed utilizing Origin software (version 7.5, 
OriginLab Corporation, Northampton, MA). 
 
3.3 Results and Discussion 
3.3.1 Selection of the Starting Peptide 
 The starting peptide QW-III-67B (5FAM-GGAYAAPFKKKA) is based on a related 
sequence obtained from an oriented peptide library by Songyang et al. directed at 
determining tyrosine kinase specificity.42  The Songyang substrate was phosphorylated with 
good efficiency by Abl and was minimally phosphorylated by Src, a close relative of Abl that 
shares a similar consensus sequence.  Another similar sequence has been shown to have good 
efficiency for both Abl and Bcr-Abl.43  Based on these favorable properties and the good 
specificity for Abl kinase, peptide QW-III-67B was chosen as the starting peptide for this 
work. 
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3.3.2 Characterization of Peptide QW-III-67B Degradation in Cytosolic 
Lysates 
 
 To determine whether the peptide QW-III-67B is degraded by cytosolic peptidases, 
the peptide was incubated in a Baf/BCR-ABL cell lysate.  After varying times, aliquots were 
removed and separated by electrophoresis followed by detection of all fluorescent peptides 
(Figure 3.2A-3.2C).  At time zero, a single peak with a migration time identical to that of the 
standard intact peptide QW-III-67B was present.  Within one minute, three peaks were seen, 
the intact peptide and two peaks with longer migration times.  Under these conditions, the 
starting peptide possessed a half-life of 1.3 ± 0.4 min in the cytosolic lysate.  The average 
rate of peptide breakdown in the cell lysate over 5 min was 1.7 ± 0.3 zmol pg-1 s-1 and 
approximately 6.2 ± 2.7 % of the intact peptide remained after 5 min.  After 30 min, the 
initial peak was no longer identified and five additional peaks had formed, all with migration 
times slower than the intact peptide.  Given the presence of peptidases in a cytosolic lysate, it 
was likely that these peaks were proteolytic fragments of the intact starting substrate.  In 
order to determine the temporal pattern of fragment formation, the percentage of each 
fragment with respect to total peptide was plotted as a function of time (Figure 3.2D).  The 
initial fragment was generated nearly as fast as the intact peptide was degraded, with an 
average initial rate of 1.2 ± 0.1 zmol pg-1 s-1.  It is possible that the later appearing fragments 
were formed as a consequence of further peptidase action on the first fragment.  
Phosphorylated product was not observed since neither ATP nor phosphatase inhibitors were 
present in the assay. 
 To compare the breakdown of QW-III-67B in lysates generated with different cells, 
the peptide was incubated in a HeLa cell lysate.  During various times, aliquots were 
removed and separated by capillary electrophoresis.  A peptide-fragment pattern similar to 
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that observed in the Baf/BCR-ABL lysate was present (Figure 3.2E).  The initial rate of 
breakdown in the HeLa cell lysate was 1.3 zmol pg-1 s-1, similar to that in the Baf/BCR-ABL 
lysate.  Additionally, the major fragment that formed over time possessed a migration time 
identical to the major peak formed in the Baf/BCR-ABL lysate.  This product formed at a 
rate of 1 zmol pg-1 s-1, nearly identical to the result in the Baf/BCR-ABL lysate.  Two 
additional peaks formed on slower time scales and the migration times of these peaks 
matched the two secondary peaks formed in the Baf/BCR-ABL lysate.  The pattern and rate 
of breakdown in HeLa and Baf/BCR-ABL lysates was very similar despite the difference in 
species and tumor type.  For this reason, subsequent lysate experiments utilized only the 
Baf/BCR-ABL cells.   
3.3.3 Characterization of Peptides Following Lysine Replacement 
 Since trypsin-like proteases are common in cells and favor positively charged 
residues, the initial cleavage site was thought to be at one of the lysine residues near the 
carboxy terminus of the peptide.44  Ornithine, a lysine analog, possesses a positively charged 
side chain but with one less carbon (Figure 3.3).  Replacement of lysine with ornithine has 
been shown to limit the ability of trypsin to act on lysine-containing substrates.45  Peptides 
with ornithine inserted into the peptide in place of one, two, or all three lysine residues 
(peptides QW-III-90A through QW-III-90G in Table 3.1) were synthesized, purified, and 
then incubated in the Baf/BCR-ABL cytosolic lysate for varying times.  Aliquots were 
removed and electrophoresed to assess the formation of fluorescent fragments.  The resulting 
traces were very similar to that of the control peptide, with the initial timepoint for each 
peptide showing a single peak that migrated at the same time as the intact parent.  
Subsequent time points demonstrated the disappearance of the initial peak and the 
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appearance of multiple peaks with slower migration times, presumably fragment peptides of 
the lysine-substituted peptides.  To determine the pattern of fragment formation, the fraction 
of peptide present as each fragment was plotted as a function of time, with results for each of 
the seven modified peptides appearing very similar to that of the starting peptide QW-III-67B 
(Figure 3.4).  Irrespective of the number or location, ornithine-for-lysine substitution 
provided only a modest enhancement in stability relative to that of the starting peptide, with 
the peptide half-lives (t1/2) in the lysate ranging from 4.3 to 6.0 min compared to the 1.3 min 
for the starting peptide (Table 3.1). 
 To determine whether the ornithine-for-lysine-substituted peptides retain the ability to 
be phosphorylated by Abl kinase, each modified peptide was incubated with Abl kinase in 
vitro and aliquots were removed over time and separated.  The relative peak areas of the 
phosphorylated and non-phosphorylated peptides were used as a measure of the Abl substrate 
efficacy.  Half of the ornithine-containing peptides were phosphorylated at a faster rate than 
that of the QW-III-67B peptide.  When the time for 50% peptide phosphorylation (t50%P) was 
measured, three of the double-ornithine peptides and one of the single-ornithine peptides 
achieved a 1.7-6X shorter t50%P than that of QW-III-67B.  The remaining single and triple-
ornithine peptides were phosphorylated more slowly than QW-III-67B with a 3-4X greater 
t50%P.  While peptidase resistance was slightly improved and kinase substrate suitability was 
acceptable, the ornithine-containing peptides did not possess dramatically improved 
proteolytic resistance relative to the starting peptide, suggesting that the lysine residues might 
not be the initial site of cleavage. 
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3.3.4 Identification of the Peptide Fragments 
 To identify the primary site of peptide-bond hydrolysis, standards consisting of all 
possible fluorescent peptide fragments formed from QW-III-67B were synthesized and 
characterized by electrophoresis.  Under the electrophoretic conditions used, each peptide 
fragment migrated at a unique time and was present as a single major peak.  Thus, the 
fragments formed and peptide cleavage sites targeted by the cytosolic lysate should be 
readily identifiable.  The starting peptide, QW-III-67B, was incubated in a cell lysate and 
after the reaction was stopped, each of the possible fluorescent peptide standards was 
sequentially added to the lysate mixture to identify the lysate peaks.  Each peak present in the 
cytosolic lysate matched to a fragment peak suggesting that the additional peaks on the 
electropherogram were indeed fragments of the original peptide (Figure 3.2).  A 7-residue 
fragment (peptide f) generated by cleavage at the proline-phenylalanine bond formed initially 
and in the greatest quantity.  3, 4, and 5-residue fragments also formed over time but with a 
delay relative to that of the 7-mer.  Since the proline-phenylalanine bond appeared to be the 
site of initial peptide cleavage, these residues were targeted for modification to enhance 
stability. 
3.3.5 Characterization of Peptides with Proline Replacement 
 The proline and phenylalanine in QW-III-67B were replaced with native and non-
native residues (Figure 3.3) and peptide stability assessed.  Proline has a structure unique to 
the native residues in that the backbone nitrogen is linked via a ring to the side chain, 
creating a bend in the peptide backbone.  Three strategies were attempted to replace the 
proline with a goal of diminishing peptidase rather than kinase action: i) an alanine was 
inserted in place of the proline to eliminate the bend in the peptide backbone; ii) native 
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residues with a side chain ring were substituted to maintain a similar side chain character 
while still eliminating the backbone bend; and iii) the non-native residue sarcosine (N-
methylglycine) was used to maintain the backbone kink yet eliminate the closed-ring 
structure.46  Peptides QW-IV-74A to QW-V-74E (Table 3.1) were synthesized, purified, 
incubated in a cytosolic lysate and then separated by CE to determine whether fluorescent 
fragments were formed.  In each case, approximately eight fluorescent fragments were seen 
within 5 min of incubation in the lysate.  Although these fragment peaks grew larger over 
time, additional peaks were not observed.  To compare the peptidase resistance of these 
peptides to that of the prior peptides, the percentage of peptide fragment over time was 
measured and the t1/2 calculated.  The t1/2 of all of the proline-substituted peptides was 
improved relative to that of the starting peptide QW-III-67B and the ornithine-containing 
peptides (Table 3.1).  The peptide possessing a sarcosine displayed the most dramatic 
increase in stability with a t1/2 of 24.0 min compared to the 1.3 min of the starting peptide 
(Figure 3.5A). 
 To determine whether the proline-substituted peptides also retained the ability to be 
phosphorylated by Abl kinase, each modified peptide was incubated with Abl kinase in vitro 
and phosphorylation measured over time.  Minimal phosphorylation was observed for each 
of the five peptides over the assay period.  Based on the measured phosphorylation rate, t50%P 
for all of these peptides was estimated to be >105 min or >650-times longer than the 150 min 
of the starting peptide (Figure 3.5B).  Despite the increased peptidase resistance, the poor 
substrate efficacy of the proline-substituted peptides rendered these modifications unsuitable 
for the creation of protease-resistant Abl kinase substrates. 
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3.3.6 Characterization of Peptides with Phenylalanine Replacement 
 Phenylalanine possesses a bulky hydrophobic side group, and therefore non-native 
residues with similar features, including β-(2-naphthyl)-L-alanine and 3-nitrotyrosine, were 
substituted in place of phenylalanine (Figure 3.3).  Since both N-methylated and D-amino 
acids have been shown to impart stability to inhibitor peptides, D-phenylalanine and (N-
methyl)phenylalanine were also incorporated as replacements for phenylalanine.27, 35, 36, 38  
Peptides QW-IV-85B through QW-V-23E (Table 3.1) were synthesized, purified, and then 
incubated in the Baf/BCR-ABL cytosolic lysate for varying times.  Aliquots were removed 
and electrophoresed to assess the formation of fluorescent fragments.  Within 1 min, the β-(2-
naphthyl)-L-alanine-substituted peptide showed the appearance of a second peak in the 
electropherogram with a migration time slower than the intact peptide.  This second peak 
grew larger over the course of the assay, and a much smaller, slower migrating peak first 
appeared after 30 min incubation.  The intact peptide disappeared between 15 and 30 min.  A 
similar pattern and time course was also observed for the 3-nitrotyrosine-substituted peptide.  
The electropherogram of the lysate-incubated, D-phenylalanine peptide did not show 
additional peaks until after 5 min of incubation.  Unlike the prior two peptides, 30% of the D-
phenylalanine peptide remained intact at 60 min.  The (N-methyl)phenylalanine-substituted 
peptide showed results similar to that of the D-phenylalanine-substituted peptide but had an 
even slower rate of fragment formation with 70% of the peptide co-migrating with that of the 
starting peptide after 60 min (Figure 3.6).  At this time, 5 additional peaks were present on 
the electropherogram of the (N-methyl)phenylalanine-substituted peptide.  To compare 
cytosolic peptidase resistance among these peptides, the amount of intact peptide was plotted 
as a function of time and t1/2 was calculated.  As expected, the (N-methyl)phenylalanine-
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substituted peptide showed the most dramatic increase in lifetime, with a 40-fold increase 
relative to that of the starting peptide QW-III-67B (Figure 3.5A).  The D-phenylalanine-
substituted peptide was also longer lived with a 30-fold increase in t1/2.  The remaining two 
peptides showed more modest results, with a 4- to 7-fold increase in peptide lifetime (Figure 
3.5A). 
 The ability of each phenylalanine-modified peptide to be phosphorylated in vitro by 
Abl kinase was also assessed as described above.  Two of the peptides, the (N-methyl) 
phenylalanine- and the 3-nitrotyrosine-substituted peptides, showed minimal 
phosphorylation, with t50%P >105 min (Figure 3.5B).  The β-(2-naphthyl)-L-alanine- and the 
D-phenylalanine-substituted peptides were phosphorylated at similar rates to the parent 
peptide with a t50%P of 190 and 82 min, respectively (Figure 3.5B). 
3.3.7 Design and Characterization of an (N-methyl)phenylalanine-
substituted Lead Peptide 
 
 The (N-methyl)phenylalanine-substituted peptide QW-IV-85B was the most 
promising peptide with respect to peptidase resistance but performed poorly as an Abl 
substrate.  Placement of an isoleucine in the position immediately upstream of the 
phosphorylatable tyrosine has been shown to improve Abl phosphorylation efficiency of 
some substrates, but can make the peptide more suitable for phosphorylation by Src.4, 42  To 
improve the substrate behavior of the (N-methyl)phenylalanine-substituted peptide, the 
alanine adjacent to the tyrosine was replaced with an isoleucine.  This new peptide (QW-V-
48B in Table 3.1) was characterized for peptidase resistance as well as Abl- and Src-substrate 
performance.  After a 3 min incubation in the cytosolic lysate, a small peak in addition to 
QW-V-48B appeared.  Over a 5 min time, the average rate of breakdown was 0.20 ± 0.03 
zmol pg-1 s-1 and 79.6 ± 2.5% remained intact in the lysate.   By 10 min, the second peak had 
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increased and was accompanied by two additional peaks.  The t1/2 of this peptide was 19.1 ± 
3.3 min or 15-fold longer than that of the starting peptide yet >2 fold less than that of the 
peptide without isoleucine (Table 3.1, Figure 3.5A).  To determine whether this peptide was 
a substrate for Src, the peptide was incubated with various concentrations of Src kinase and 
the amount of phosphorylation measured.  At all concentrations, no phosphorylation by Src 
was observed (Figure 3.7).  To determine whether the isoleucine improved Abl-substrate 
performance, the QW-V-48B peptide was incubated with Abl kinase and the amount of 
phosphorylation measured.  Incorporation of the isoleucine decreased the t50%P by >2000-fold 
relative to that of the peptide with only the (N-methyl)phenylalanine-substitution (Figure 
3.5B).  The isoleucine peptide also possessed a 3.5X lower t50%P than the original starting 
peptide.  Based on the combined ability of this peptide to resist degradation, resist Src 
phosphorylation yet remain a substrate for Abl, peptide QW-V-48B was chosen for further 
characterization and evaluation.   
3.3.8 Characterization of the Lead Peptide QW-V-48B in a Cytosolic 
Lysate 
 
 Although the lead peptide QW-V-48B possessed a substantially increased lifetime 
relative to that of the starting peptide QW-III-67B, QW-V-48B was still degraded into 
multiple different fragments over time.  In order to understand which residues were the 
preferred sites of cleavage, all possible fluorescent fragments were synthesized and 
characterized by electrophoresis.  Under the electrophoretic conditions used, all of these 
fragment peptides were resolved from each other and from the parent peptide.  The lead 
peptide, QW-V-48B, was incubated in a Baf/BCR-ABL cell lysate and each of the possible 
fluorescent peptide standards were sequentially added to the mixture to identify the unknown 
peaks in the electropherogram.  Each of the peaks present in the cytosolic lysate was matched 
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to a fragment peak (Figure 3.8).  The first fragment formed was a 5-residue peptide cleaved 
at the alanine-alanine bond (peptide t) (Figure 3.8B, E).  The amount of each fragment 
graphed as a function of time (Figure 3.8D) demonstrated that the 5-mer formed at an initial 
average rate of 0.11 ± 0.02 zmol pg-1 s-1 and accounted for approximately 50% of all peptide 
present by 60 min (Figure 3.8D).  Other peptides that formed over time were the 3, 4, and 11-
residue fragments, but they formed on longer time scales relative to that of the 5-mer  (Figure 
3.8C).  Significantly, there was no evidence of the 7-mer fragment that would be generated 
from cleavage between the proline and (N-methyl)phenylalanine.  Thus the substitution of 
(N-methyl)phenylalanine for phenylalanine greatly enhanced resistance to proteolysis.  
 The kinetic parameters of KM and kcat were determined for both peptides in order to 
quantitatively compare the ability of the starting peptide and lead peptide to act as substrates 
for Abl.  Varying concentrations of each peptide were incubated with Abl kinase and the 
initial reaction velocity calculated.  Peptide QW-V-48B had a lower KM than QW-III-67B 
(20 µM compared to 58 µM) and also a higher turnover number, (kcat = 3,000 min-1 compared 
to 2,100 min-1).  The lead peptide QW-V-48B was both a better Abl substrate and possessed 
greater peptidase resistance than the starting peptide QW-III-67B. 
3.3.9 Characterization of Peptides in Single HeLa Cells 
 Although use of cytosolic lysates enables facile optimization of substrate peptide 
properties, most cellular processes are dramatically altered in this homogenous, diluted 
environment.  In particular, peptidases located within organelles are expected to be released 
upon cell lysis.  Thus a peptide in a cell lysate may encounter a different repertoire of 
peptidases relative to a peptide in the cytosol of an intact cell and it is important to 
understand whether the peptide fragments and fragmentation rates from a lysate faithfully 
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mimic that formed in intact cells.  In order to assess and quantify the peptide fragments 
generated in single cells, peptide QW-III-67B was microinjected into a single HeLa cell (24 
± 8 amol, n = 4 cells).  HeLa cells were utilized for single cell studies since they were more 
easily microinjected than non-adherent cells and possessed a similar fragmentation profile to 
that of Baf/BCR-ABL cell lysates (Figure 3.2E).  After a 5 min incubation, cells were lysed 
and loaded into an overlying capillary and the different fluorescent peptides detected and 
quantified.47  The peptide was nearly completely metabolized, with only 10 ± 2 % remaining 
intact (Table 3.2).  Under the conditions used, the average rate of QW-III-67B degradation 
was calculated to be 0.7 ± 0.2 zmol pg-1 s-1 assuming a cellular protein concentration of 100 
mg/mL and a cell volume of 1 pL.48  Nine different peaks were observed on the 
electropherogram (Figure 3.9A), compared to the six peaks seen in the lysate samples (Figure 
3.2C).  The peptide fragment standards were utilized to identify the source of the peaks 
obtained from the single cells and each fragment generated in the single cells co-migrated 
with a standard fragment (Figure 3.9A).  The most abundant fragment generated was the 5-
mer (peptide h) that amounted to 36 ± 6 % of all peptides.  This same 5-mer was also 
generated in the lysate studies but at approximately half the amount observed in single cells 
at 5 min.  The 7-mer fragment (peptide f) that was generated the fastest in the lysate studies 
was present, but to a lesser extent (5 ± 2 %) in the intact cells.  In single cells, the 4, 6, and 
11-residue fragments were also seen at amounts greater than 10% (Table 3.2) while of these, 
only the 4-mer was seen in the lysate studies (Figure 3.2).  The 2-mer seen in small amounts 
in the lysate studies was not seen at all in the intact cell studies.   
 Although the pattern of peptide fragmentation was similar in single cells compared to 
lysates, there were important differences.  While the peptide concentration incubated in the 
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cell lysate was roughly 25-times lower than that loaded into single cells and the lysate protein 
was 30-times more dilute than a single cell, the rate of peptide metabolism in the cell lysate 
still remained significantly greater than that of peptide in an intact cell over the same time 
period.  Thus the peptidase activity in cell lysates was considerably greater than that in the 
cytosol of an intact cell most likely due to the release of sequestered peptidases from 
ruptured organelles in the lysate.  A second significant difference is the predominance of 
peptide h (representing Ala-Ala bond cleavage) in the single cells relative to other peptide 
fragments suggesting that the Ala-Ala bond may be the dominant cleavage site in single cells 
and not the Pro-Phe which dominated in the lysate.  No phosphorylated product was detected 
or expected since HeLa cells do not express Bcr-Abl. 
 The lead peptide QW-V-48B was microinjected into a single HeLa cell, incubated for 
5 min, and then the cellular contents were electrophoretically separated.  On average, 28 ± 6 
amol (n = 4 cells) of QW-V-48B was loaded into the cells.  The peptide was degraded at an 
average rate of 0.6 ± 0.1 zmol pg-1 s-1 with 33 ± 14% remaining intact after 5 min (Table 3.2).  
Thus the average rate of metabolism in single cells was similar for the starting and lead 
peptides.  Five peaks were observed on the electropherogram (Figure 3.9B) and the migration 
time of each of these peaks matched to that of a QW-V-48B fragment standard (Figure 3.9B, 
D).  The 7-residue fragment representing cleavage between the proline and (N-
methyl)phenylalanine was not present in the single cells.  This bond was effectively 
stabilized by replacement with a non-native amino acid.  However, 4, 5, and 11-residue 
peptide fragments were present with the 5-mer (peptide t), representing the Ala-Ala bond 
cleavage, being the most abundant with 22 ± 10 % present after 5 min.  The 2-mer observed 
in cell lysates (Figure 3.8C) was absent from the single cells; however, the single cells 
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possessed a 6-amino acid fragment not observed in the lysates.  As with QW-III-67B, peptide 
metabolism in the single cell was similar to that in a lysate but with some key differences.  
Since the rate of metabolism of QW-V-48B and QW-III-67B in single cells was nearly 
identical, replacement of the Pro-Phe bond did not stabilize the peptide in the single cells.  
The predominance of peptide h and t for both QW-III-67B and QW-V-48B in single cells 
suggests that the Ala-Ala bond is the preferred location for bond cleavage in the intact 
cytosol where disruption of the organelles has not occurred.  No phosphorylated product was 
detected in any single cells. 
 
3.4 Conclusions 
 Identification of the exact cleavage locations within a peptide permitted rational 
peptide redesign by placement of non-native residues at hydrolysis sites, resulting in 
increased peptide lifetimes in a cytosolic lysate.  By contrast, both the starting and lead 
peptides showed similar degradation rates in intact cells suggesting that the cell lysate system 
may not be a good model for estimating intracellular rates and patterns of peptide proteolysis.  
It is likely that different peptidases acted on the substrates in single cells compared to that in 
lysates, leading to differences in primary cleavage sites and rates of proteolysis.  One caveat 
is that only a single time point was sampled for the single cells and formation of the 
fragments over time was not determined.  Assay of single cells loaded with peptide and 
incubated for other times would lead to a more complete picture of peptide fragmentation and 
permit further analysis of substrate lifetime in intact cells.  
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3.5 Figures and Tables 
 
 
 
Figure 3.1: in vitro phosphorylation of the starting peptide (QW-III-67B) by recombinant Abl 
kinase.  (A) – (D) Electropherograms of the peptide after incubation with Abl kinase in the 
presence of ATP for 0 (A), 15 (B), 60 (C) and 120 (D) min.  (E) – (F) Electropherograms of 
the peptide with Abl kinase without ATP present for 0 (E) and 120 (F) min.  The peak eluting 
at ~380 s is the phosphorylated counterpart of the non-phosphorylated peptide migrating at 
~500 s. 
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Figure 3.2: Degradation profile of the starting peptide (QW-III-67B) in a cell lysate.  (A) – 
(C) Electropherograms of the peptide after incubation in the Baf/BCR-ABL lysate for 0 (A), 
1 (B), or 30 (C) min.  (D) Formation of peptide fragments over time in the Baf/BCR-ABL 
lysate.  (E) Formation of peptide fragments over time in a HeLa cell lysate.  Shown on the y-
axis is the percentage of peptide present as a fragment.  The symbols are defined as: filled 
square (peptide a or starting peptide), open square (peptide f), closed triangle (peptide h), 
open circle (peptide i), closed circle (peptide j) and open triangle (peptide k). The symbols 
and error bars represent the average and standard deviation of the data points.  (F) The 
uppercase letters are the single amino acid abbreviations for the starting peptide sequence.  
The lowercase letters indicate the cleavage locations that generate the indicated peptide 
fragments. 
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Figure 3.3: The native residues and the non-native residues that were inserted into the peptide 
to stabilize the peptide against hydrolysis. 
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Figure 3.4: Formation of peptide fragments in the Baf/BCR-ABL lysate over time for the 
ornithine-substituted peptides.  Degradation of peptide QW-III-90A (A), QW-III-90B (B), 
QW-III-90C (C), QW-III-90D (D), QW-III-90E (E), QW-III-90F (F), QW-III-90G (G), and 
QW-III-67B (H).  The symbols are defined as: closed circle (intact parent); open circle 
(fragment migrating at 210 s); closed square (fragment migrating at 240 s); open square 
(fragment migrating at 260 s); closed triangle (fragment migrating at 305 s); and open 
triangle (fragment migrating at 360 s). 
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Figure 3.5: Baf/BCR-ABL cytosolic lysate degradation (A) and in vitro phosphorylation (B) 
of modified peptides.  Filled square (QW-III-67B, starting peptide); open diamond (QW-IV-
74D, sarcosine-substituted peptide); closed circle (QW-IV-85B, (N-methyl)phenylalanine-
substituted peptide); open circle (QW-V-23C, β-(2-naphthyl)-L-alanine-substituted peptide); 
open triangle (QW-V-23E, 3-nitro tyrosine-substituted peptide); and closed triangle (QW-V-
48B, isoleucine and N-methylated phenylalanine-substituted peptide).  The symbols and error 
bars represent the average and standard deviation of the data points. 
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Figure 3.6: Electropherograms of peptide QW-IV-85B incubated in a Baf/BCR-ABL 
cytosolic lysate after 0 (A) and 60 (B) min.  The intact parent peptide is identified as the 
major peak seen in (A) migrating at 100 s. 
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Figure 3.7: Electropherograms of QW-V-48B incubated with recombinant Abl kinase for 60 
min with ATP (A) and without ATP (B) and incubated with recombinant Src kinase for 60 
min with ATP (C) and without ATP (D). 
 101 
 
 
Figure 3.8: Degradation profile of the lead peptide (QW-V-48B) in a Baf/BCR-ABL cell 
lysate.  (A) – (C) Electropherograms of the peptide after incubation in the lysate for 0 (A), 1 
(B), or 30 (C) min.  (D) Formation of peptide fragments over time.  Shown on the y-axis is 
the percentage of peptide present as a fragment.  The symbols are defined as: filled square 
(peptide m), open square (peptide n), closed triangle (peptide t), open circle (peptide u), open 
triangle (peptide w). The symbols and error bars represent the average and standard deviation 
of the data points.  (E) The uppercase letters are the single amino acid abbreviations for the 
lead peptide sequence and MPh represents (N-methyl) phenylalanine.  The lowercase letters 
indicate the cleavage locations that generate the indicated peptide fragments. 
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Figure 3.9: Degradation of peptides in single HeLa cells.  Cells were microinjected with QW-
III-67B (A,C) or the lead peptide QW-V-48B (B,D).  (A,B) Electropherogram of a single cell 
5 min after microinjection.  The lowercase letters label the peptide fragments as defined in 
Figures 3.2F and 3.5E.  (C,D) Identification of fragments formed in single cells.  Single cell 
contents were loaded into a capillary 5 min after starting or lead peptide microinjection into 
the cell.  Immediately after loading the cell contents into the capillary, the fragments of the 
starting peptide QW-III-67B (C) or lead peptide QW-V-48B (D) were loaded into the 
capillary.  A voltage was then applied to the capillary to initiate simultaneous electrophoresis 
of the cellular contents and fragment standards. 
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Table 3.1: Properties of the modified peptides derived from the starting peptide (QW-III-
67B). 
at1/2 is the time at which 50% of the peptide was degraded by the cell lysate.   
bt50% P is the time required for 50% of the peptide to be phosphorylated by Abl-1 kinase under 
the conditions employed.  Abbreviations are the standard single letter amino acids, except for 
the following: O (ornithine), Sarc (sarcosine), MPh [(N-methyl)phenylalanine], DPh (D-
phenylalanine), Nal (β-(2-Naphthyl)-L-alanine), and Tyr(3-NO2) (3-Nitro tyrosine). 
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Table 3.2: Percentage of each fragment formed following a 5 min incubation of the peptides 
in a single cell.  The average and standard deviation are given (n = 4).  The lowercase letters 
represent the peptide fragments defined in Figures 3.2F and 3.5E. 
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CHAPTER 4 
 
DEVELOPMENT OF A PEPTIDASE-RESISTANT 
SUBSTRATE FOR SINGLE-CELL MEASUREMENT OF 
PROTEIN KINASE B ACTIVATION 
 
4.1 Introduction 
4.1.1 Protein Kinase B Activation and Function 
 Protein kinase B (PKB, also known as Akt) is responsible for regulation of many cell 
functions, such as survival under stress, cell proliferation, and apoptosis.1-3  When a cell is 
stimulated, activation of phosphatidylinositol 3-kinase (PI3-K) leads to generation of 
phosphatidylinositol-3,4,5-trisphosphate (PIP3).  PIP3 recruits PKB to the plasma membrane, 
where it is phosphorylated by phosphoinositide-dependent kinase-1 (PDK-1) on a threonine 
residue at position 308.  Phosphorylation at Thr308 by PDK-1 then triggers phosphorylation 
of a serine residue at position 473 by the protein complex mTORC2 (mammalian target of 
rapamycin complex 2), a complex that contains the kinase mTOR and rictor.1-11  PKB is most 
active when it is phosphorylated at both Thr308 and Ser473.2, 10  After activation at the 
plasma membrane, PKB moves throughout the cell to phosphorylate its substrates which go 
on to regulate the functions mentioned above.  Interest in PKB and the PI3-K cascade has 
steadily increased due to their role in enabling cells to survive stressful conditions, namely in 
preventing apoptosis in cells normally targeted for programmed cell death.4  The PI3-K 
cascade and its constituents have been implicated in tumor progression and survival in a wide 
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array of cancers, including pancreatic, breast, and prostate tumors.10, 12  In particular, increase 
PKB activity is often the result of increased upstream activity in the PI3-K pathway, over 
expression of PKB, PKB mutations leading to constitutive activity, and decreased activity of 
the phosphatases dephosphorylating PKB.2-5, 12, 13  Increased PKB of any origin appears to 
enable tumor cells to survive and proliferate in a stressful environment.7, 12, 14  Inhibition of 
the PI3-K pathway and in particular PKB are current targets for drug development for cancer 
therapeutics.  
4.1.2 Methods for Measuring PKB 
 Strategies to monitor PKB activity in tumor cells are needed to identify which 
patients would benefit from inhibitors of the PI3-K pathway as well as in identifying optimal 
therapeutic concentrations.  Analysis of PKB activation can be performed on cell lysates 
using Western blots in which one or both phosphorylated residues are probed with 
phosphospecific antibodies to infer PKB activity.5  A new technology incorporating 
isolelectric focusing within a capillary followed by immunoblotting permits the analysis of 
smaller cell numbers than a Western blot.15  However, neither of these techniques enable 
measurement of PKB activation at the single-cell level.  Alternative methods that use 
phosphospecific antibodies against Thr308/Ser473 to probe PKB activity at the single cell 
level include immunocytochemistry,16 phosphoflow,17-21 and cytometry by time of flight 
(CyTOF).22-24  The latter two methods are designed for non-adherent cells and all require cell 
fixation and permeabilization prior to measurement.  Additionally, immunocytochemistry 
staining of adherent cells identifies the presence of phosphorylated PKB but is generally 
considered to be non-quantitative.25  Indicators employing fluorescent proteins have been 
developed to measure PKB activity at the single-cell level by monitoring fluorescence 
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resonance energy transfer between two fluorescent proteins.26, 27  However, these indicators 
require the transfection of DNA into cells, making their use in primary cells challenging.  
Capillary electrophoresis has also been used to measure PKB activity in single cells; 
however, this strategy requires use of a fluorescently-tagged substrate peptide which can 
have a very short lifetime in cells, substantially limiting the technique’s utility.28-30  
4.1.3 Peptides as Kinase Substrates 
 Peptide substrates have been used extensively in biomedical research to assay kinase 
activity due to the ease of peptide design and synthesis and the ability to construct extensive 
peptide libraries for screening and optimization.  As part of these endeavors, peptides serve 
as assay substrates for kinases obtained in pure form,31, 32 from cell lysates,33-36 and even in 
single cells.37-40  However, peptides often possess limited lifetimes in the cellular milieu due 
to the presence of peptidases which can degrade them.  Multiple strategies have been 
employed to stabilize peptides against degradation, including cyclization, terminus 
modifications, and inclusion of non-native amino acids.  Peptide cyclization yields 
degradation-resistant peptides, but this often results in poor substrate recognition by the 
kinase and these constructs can be synthetically challenging.41-44  Modifications to the C- and 
N-terminus are relatively simple to accomplish and provide protection against amino- and 
carboxy-peptidases, but not endopeptidases.45-47  Terminal modifications can be used in 
combination with non-native residues, including N-methylated and D-amino acids, to impart 
additional stability to peptide bonds.29, 48-51  These non-native residues are readily available 
commercially and are simply incorporated into peptides utilizing standard solid phase peptide 
synthesis.  Peptides with non-native residues generally suffer greatly diminished kinase-
substrate properties and the design of kinase substrates with non-native amino acids remains 
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challenging.51  However, peptidase-resistant substrates should be of wide utility throughout 
biomedical research in assays of kinase activity in the presence of cellular constituents.  
4.1.4 Iterative Strategy for Design of Peptidase-Resistant Kinase Substrates 
 The work described in this chapter develops an iterative strategy to screen rationally 
designed peptides for their suitability to act as a kinase substrate in a cell lysate.  Three 
criteria, time to 50% phosphorylation, half-life within a lysate, and appearance of a dominant 
fragment over time, were utilized to screen small libraries to design a degradation-resistant 
peptide substrate for PKB activity.  Cytosolic lysates and purified kinase assays were utilized 
to rapidly assess synthetic peptides for their peptidase resistance as well as their ability to act 
as a substrate.  Cleavage sites of peptides incubated in a cell lysate were characterized using 
capillary electrophoresis.  Fluorescent peptide fragments were identified by comparison of 
their migration times with those of synthesized standards while the amount of each fragment 
was quantified from its fluorescence.  Identification of cleavage sites permitted iterative 
replacement of amino acids with either non-native residues or more suitable native residues.  
Substitution success was then reassessed using the three criteria above and new substitutions 
incorporated based on these results until a peptidase-resistant PKB substrate was identified.  
This designed substrate was used to assay PKB activity in single prostate cancer cells in the 
presence and absence of a PKB inhibitor.  The heterogeneity of substrate phosphorylation, 
kinase inhibitor performance, and peptidase activity in single cells was also evaluated. 
4.2 Experimental Design 
4.2.1 Chemicals 
 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate 
(HCTU), 1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT), 9-
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fluorenylmethoxycarbonyl (Fmoc) amino acids and resins were obtained from ChemPep or 
Novabiochem and 6-carboxyfluorescein (6FAM), N-Hydroxybenzotriazole (HOBt), Fmoc-
Nα-Me-Arg(Mtr)-OH and were purchased from AnaSpec.  Fmoc-β-HArg(Pbf)-OH was 
received from Aapptec.  Fmoc-α-MeAla-OH, and Fmoc-Phe(F5)-OH were purchased from 
Advanced ChemTech.  All other peptide synthesis reagents were purchased from Aldrich or 
Fisher.   Active PKBα enzyme was purchased from Millipore.  Wortmannin was obtained 
from LC Laboratories.  Bovine serum albumin was procured from Calbiochem.  Roswell 
Park Memorial Institute Media (RPMI-1640) and Dulbecco’s Modified Eagle Medium 
(DMEM) were purchased from Cellgro.  Penicillin/streptomycin was obtained from Gibco 
and fetal bovine serum (FBS) was purchased from Atlanta Biologicals.  All other chemicals 
used in assays were purchased from Fisher or Sigma. 
4.2.2 Peptide Synthesis and Preparation 
4.2.2.1 Synthesis of Full-Length Peptides Amidated on the C-Terminus 
 All peptides were synthesized by collaborator Dr. Qunzhao Wang unless specified 
otherwise.  A complete list of all peptides utilized in this dissertation can be found in 
Appendix C.  Full-length substrate peptides amidated on the C-terminus were synthesized via 
standard Fmoc peptide synthesis (Prelude Peptide Synthesizer, Protein Technologies, 
Tucson, AZ) on TGR resin.  Coupling was achieved with two 5-min incubations in 
dimethylformamide (DMF) with 5 equivalents (eq) Fmoc amino acid, 5 eq HCTU, and 10 eq 
N,N-Diisopropylethylamine (DIPEA).  For couplings of amino acids next to N-methylated 
amino acids, three 60-min incubations in N-Methyl-2-pyrrolidone (NMP) was applied prior 
to capping with acetic anhydride.  Fmoc deprotection was performed with two 2.5-min 
incubations with 20% piperidine in DMF.  The N-terminus of all peptides was reacted with 5 
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eq 6FAM, 5 eq diisopropylcarbodiimide (DIC), and 5 eq HOBt in DMF overnight, then 
treated with 30% piperidine in DMF for 30 min.  Generally, the peptide was cleaved with 
trifluoroacetic acid : water : triisopropylsilane (TFA : H2O : TIS) in a ratio of 95 : 2.5 : 2.5, 
except for N-MeArg containing peptides, where the side chain was protected with Mtr.  In 
these cases, the cleavage occurred overnight in a solution of TFA : Phenol : H2O : TIS in a 
ratio of 88 : 5 : 5 : 2.  All cleaved peptides were precipitated with ether, and dried in air.  
Peptide purity was analyzed with HPLC-MS and further purification via HPLC was 
performed if needed.   
4.2.2.2 Alternative Coupling for Difficult Amino Acids  
 In some cases, amino acids required coupling with 5 eq of Fmoc amino acid, 5 eq 
HCTU, and 10 eq DIPEA in N-methyl-2-pyrrolidone (NMP) for 3 h, repeated for a total of 3 
couplings.  Finally, capping with acetic anhydride was performed and product formation was 
measured using HPLC-MS. Peptides were dissolved in Tris buffer, pH 7.5, aliquoted, and 
stored at – 80 oC. 
4.2.2.3 Synthesis of Peptide Fragment Standards 
 Peptide fragment standards with a free carboxylic acid on the C-terminus were 
synthesized using either a Wang or 2-chlorotrityl resin.  When using the Wang resin, 10 eq of 
the first Fmoc amino acid in CH2Cl2 was reacted with 7.5 eq 1-methyl-imidazole and 10 eq 
MSNT for 15 min in a dry glass vial on a shaker.  The reaction mixture was transferred to 
another dry glass vial containing the Wang resin and incubated for 1 h.  For the 2-chlorotrityl 
resin, 1 eq of the first Fmoc amino acid and 4 eq DIPEA in dry CH2Cl2 was reacted with the 
2-chlorotrityl resin for 2 h in a dry glass vial on a shaker.  The remaining amino acids were 
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attached as described for the amidated peptides above and the N-terminus of all peptides was 
labeled with 6FAM as described above. 
4.2.3 Cell Culture 
 HeLa cells, a human cervical adenocarcinoma cell line, and LNCaP cells, a human 
prostate carcinoma cell line, were obtained from the American Type Culture Collection.  
HeLa cells were cultured in DMEM medium supplemented with 10% FBS, penicillin (100 
units/mL) and streptomycin (100 µg/mL).  LNCaP cells were cultured in RPMI medium 
supplemented with 10% FBS, penicillin (100 units/mL) and streptomycin (100 µg/mL).  All 
cells were maintained in a humidified atmosphere of 37 oC in 5% CO2 and passaged into 
fresh media every 2 – 3 days.  LNCaP cells used for single-cell CE experiments were plated 
the day before onto custom chambers prepared by gluing a silicon O-ring (McMaster-Carr) to 
a #1 glass coverslip (Fisher) using poly(dimethyl siloxane) (PDMS, Sylgard 184).  A dilute 
cell suspension was added to 500 µL of RPMI-1640 media in the chamber and the chambers 
were placed in the humidified incubator until use in the experiments.  Cells treated with 
inhibitor were incubated with 500 nM Wortmannin in RPMI-1640 for 10 min prior to 
experiments. 
4.2.4 Measurement of Peptide Degradation in a Cell Lysate 
 A HeLa or LNCaP cell pellet was washed with and resuspended in phosphate 
buffered saline (PBS; 137 mM NaCl, 10 mM Na2HPO4, 27 mM KCl, 1.75 mM KH2PO4, pH 
7.4).  The cells were submerged in liquid nitrogen for 1 min and thawed at 37 oC for a total of 
three cycles.  The mixture was centrifuged at 14,000 x g for 5 min at 4 oC and the supernatant 
was transferred to a clean centrifuge tube and maintained on ice until use in the assay.  Total 
protein concentration in the supernatant was measured using fluorescamine.52  A standard 
 117 
curve was created utilizing BSA concentrations ranging from 0 – 100 µg mL-1.  Briefly, 
fluorescamine (10 µL, 3 mg/mL in acetone) was added to a cell lysate (30 µL) and incubated 
for 5 min at 25 oC.  Fluorescence was measured with a fluorescence plate reader (SpectraMax 
M5, Molecular Devices, Sunnyvale, CA) with an excitation of 390 nm (bandwidth of 9 nm) 
and emission of 475 nm (bandwidth of 15 nm). 
 Assessment of peptide degradation was performed by mixing peptide substrate (1 
µM) with cell lysate (3 mg mL-1 total cell protein) and incubating at 37 oC.  Aliquots were 
removed and stopped by adding HCl to a final concentration of 100 mM.  A 0 min timepoint 
was prepared by adding the HCl to the lysate prior to the addition of the peptide.  Reaction 
mixtures were then separated and detected with CE-LIF.  Peptide fragments were identified 
by adding standards (250 nM) to the HCl-terminated aliquots and comparing the 
electropherograms with and without the added standard.  The average initial degradation and 
fragmentation rates were calculated using the initial and 5 min time points by monitoring the 
change in peptide quantity divided by the change in time per amount of cytosolic protein.  
The units are defined as zmol of peptide per pg of total cytosolic protein per s (zmol pg-1 s-1).   
4.2.5 in vitro Kinase Assay 
 Protein kinase assays were performed at 30 oC in assay buffer [8 mM MOPS (3-(N-
morpholino)propanesulfonic acid), pH 7.0, 0.2 mM EDTA, 4 mM MgCl2, 1 mM ATP] with 
PKBα kinase (6 nM) and substrate (25 µM).  Aliquots were removed from the reaction 
mixture at various times and the reaction was halted by heating at 90 oC for 4 min. The 
amount of peptide phosphorylation was measured using capillary electrophoresis coupled 
with laser-induced fluorescence detection (CE-LIF). 
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4.2.6 Measurement of Kinetic Parameters 
 Protein kinase assays were performed as described in the in vitro kinase assay section 
with the following exceptions: substrate concentrations ranged from 0.5 to 30 µM; and PKBα 
enzyme concentration was 1 nM for peptide I and 6 nM for peptide VI-B.  The immobilized 
metal ion affinity-based fluorescent polarization (IMAP) assay (Molecular Devices 
Corporation, Sunnyvale, CA) was used to measure the amount of phosphorylated peptide in 
reaction mixtures.  A calibration curve was constructed by measuring the anisotropy of 
solutions with known ratios of phosphorylated to non-phosphorylated peptide.  The standard 
with 100% phosphorylated peptide was prepared using purified PKB and the percentage 
phosphorylation was verified with capillary electrophoresis.  Anisotropy was measured using 
a fluorescence plate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) with an 
excitation of 485 nm (bandwidth of 9 nm) and emission of 525 nm (bandwidth of 15 nm).  
Samples were diluted to the working concentration of 100 nM for the IMAP assay with a 
buffer containing 10 mM Tris-HCl (pH 7.2), 10 mM MgCl2, and 0.01% Tween-20. 
4.2.7 Capillary Electrophoresis 
 Laser-induced fluorescence (excitation of 488 nm and emission at 525 nm) was used 
for peptide detection during capillary electrophoresis (ProteomeLab PA800, Beckman 
Coulter, Fullerton, CA).  Fused silica capillaries [50 µm inner diameter, 360 µm outer 
diameter (Polymicro Technologies, Phoenix, AZ)] had a total length of 30 cm with an 
effective length of 20 cm.  Capillaries were conditioned prior to use with 0.1 M NaOH for 12 
h, H2O for 1 h, 0.1 M HCl for 6 h, and H2O again for 12 h.  After each sample, the capillary 
was sequentially rinsed with 1 M NaOH, H2O, and buffer for 2 min by applying a pressure of 
20 psi to the capillary inlet.  A sample plug was hydrodynamically loaded into the capillary 
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by applying 0.5 psi to the inlet for 5 s.  Electrophoresis was initiated by application of a 
negative voltage to the outlet.  For most peptides, the electrophoretic buffer was 100 mM 
borate and 100 mM SDS, pH 7.7, with a field strength of 400 V cm-1.  For the remaining 
peptides, the electrophoretic buffer was 100 mM borate and 7 mM SDS, pH 9.5, with a field 
strength of 333 V cm-1. 
4.2.8 Single-Cell Capillary Electrophoresis  
 Single-cell CE was performed using a custom made CE system with LIF detection, as 
described previously.29  Fused silica capillaries [30 µm inner diameter, 360 µm outer 
diameter, (Polymicro Technologies, Phoenix, AZ)] with a total length of 38 cm and an 
effective length of 21.5 cm were conditioned as described above.  For peptide I, the 
electrophoretic buffer was 100 mM borate and 100 mM SDS, pH 7.7 and a field strength of 
315 V cm-1 was applied.  For peptide VI-B, the electrophoretic buffer was either 300 mM 
borate, pH 7.5 or 100 mM borate and 7 mM SDS, pH 7.7, with a field strength of 260 V cm-1.  
In all instances, electrophoresis was initiated by application of a negative voltage to the outlet 
while the inlet reservoir was held at ground.  Cells were perfused with extracellular buffer 
(ECB; 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 10 mM HEPES, pH 7.4, 
37 oC) during experiments, with the flow turned off immediately prior to lysis and loading 
into the capillary.  Laser-based lysis was achieved with a focused Nd:YAG laser as 
previously described53 and the cell contents were electrokinetically loaded into the capillary 
by applying -3 kV to the capillary outlet while holding the inlet at ground. To identify the 
peptide fragments formed in a cell, standards of peptide fragments (100 nM) were 
hydrodynamically loaded into the capillary following the contents of a cell previously 
microinjected with the full-length peptide.  A voltage was then applied across the capillary to 
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initiate electrophoretic separation.  These electropherograms were compared to 
electropherograms with no standard co-injected to determine if that peptide fragment was 
formed.  To calibrate the amount of peptide on the electropherograms, a known concentration 
of standard of each intact peptide was hydrodynamically loaded into the capillary, 
electrophoresed, and the area under the peak calculated.  Poiseuille’s equation was utilized to 
estimate the amount of peptide injected.37 
 
4.3 Results and Discussion 
4.3.1 Selection of the Starting Peptide and Screening Lysates 
 The starting peptide I (6FAM-GRPRAATFAEG) was based on the consensus 
sequence RPRAATF, determined in a library screen to be phosphorylated by PKB, but not 
phosphorylated by two other closely-related kinases, p70 S6 Kinase and MAP kinase 
activated protein kinase-1, the only peptide screened in the library with these properties.54  
Furthermore, in a large multiplexed assay to analyze substrate specificity of 26 kinases, 
peptide I was found to be relatively selective for PKB.55  Peptide I was efficiently 
phosphorylated by purified PKB in vitro (Figure 4.1).  Two cell types with upregulated PKB 
activity were chosen for this proof-of-principle work.  LNCaP cells, a line derived from a 
human metastatic prostate adenocarcinoma, have decreased PTEN (phosphatase and tensin 
homolog) activity resulting in elevated PKB activity.56  PTEN is a phosphatase that 
dephosphorylates the lipid messenger PIP3, leading to a decrease in the association of PKB to 
the membrane and a decrease in additional PKB activation2, 5, 57  HeLa cells, a line derived 
from a human cervical adenocarcinoma, overexpress PI3-K, also resulting in increased PKB 
activity.58 
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 In order to identify the initial peptide bond hydrolyzed in a cellular environment, 
peptide I was incubated in a HeLa or LNCaP cell lysate.  Aliquots were removed over time 
and CE-LIF was utilized to quantify the peak area of fluorescent species over time.  At time 
zero in both the HeLa and LNCaP cytosolic lysates, a single peak with a migration time 
identical to that of the intact substrate was seen (Figure 4.2A).  However as the incubation 
time was increased, peptide I was rapidly metabolized with a lifetime of 20 ± 2 and 6 ± 0.9 
min in the HeLa and LNCaP lysate, respectively (Figure 4.2-4.4).  Under these conditions 
and when normalized for total cytosolic protein, peptide I was broken down at an average 
initial rate of 0.12 ± 0.01 and 0.4 ± 0.06 zmol pg-1 s-1 in the HeLa and LNCaP lysates, 
respectively.  In both the HeLa and LNCaP lysate, multiple additional peaks formed over 
time with similar initial rates.  This suggested that in these lysates, several different peptide 
bonds could be utilized as the initial site of hydrolysis.  By 60 min, six peaks other than that 
due to the starting peptide were present in the lysate and the original peptide had decreased to 
approximately 10% and 0% of all species present in the HeLa and LNCaP lysate, 
respectively.  Since the cytosolic lysates did not possess peptidase or phosphatase inhibitors 
or added ATP, it was likely that the six additional peaks were proteolytic fragments of the 
starting peptides.  The significantly shorter lifetime of the peptide in the LNCaP lysate 
relative to the HeLa lysate was most likely due to the large amounts of proteases synthesized 
by cells of the prostate lineage.59    
 To identify which peptide fragments were formed in the cell lysates, standards of all 
possible fluorescent fragments of peptide I were synthesized and the migration time of each 
standard compared to that resulting from the cell lysates.  Under the electrophoretic 
conditions utilized, all fragment standards were present as a single major peak and each 
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migrated at a unique time.  Each of the peaks generated in the HeLa and LNCaP lysates 
matched to a single standard fragment (Figure 4.2B, C, F).  After incubation in the HeLa 
lysate for 60 min, two peptide fragments (peptides k and i, Figure 4.2F) each totaled 
approximately 20% of all species present, while the remaining four peptide fragments 
(peptides h, g, f, and e) each comprised less than 10% of all species present.  After 60 min in 
the LNCaP lysate, the same 6 peptide fragments were present although in different amounts 
and peptide k was present as the dominant species.  From these data, no clear initial bond 
was identified as a primary site of hydrolysis in either cell lysate. 
4.3.2 Strategy for Design of a Peptidase-Resistant PKB Substrate 
 Since there was no clear initial peptidase cleavage site on peptide I for either cell 
lysate, a strategy to repeatedly generate a small library incorporating altered peptide residues 
followed by screening was utilized.  Each library targeted a single residue for modification 
and was screened for the time for 50% phosphorylation by PKB (t50%P) as well as for the 
peptide lifetime (t1/2) and the appearance of a dominant fragment in a HeLa cell lysate 
(Figure 4.5).  The appearance of a dominant hydrolysis site narrowed the choice of residues 
for targeted modifications and offered a rational next step in peptide modification.  After 
identification of the optimal peptide sequence in the library, all possible fluorescent 
fragments were synthesized to identify cleavage sites to target for subsequent alterations.  A 
second small library was generated followed by rescreening for t50%P and t1/2 and dominant 
fragment formation.  Successive iterations of this process led to identification of multiple 
cleavage locations that were stabilized to yield a longer-lived substrate for PKB.   
4.3.3 Characterization of Peptides Following Replacement of the Amino-
Terminal Alanine 
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 The alanine residue on the amino-terminal side of the alanine-alanine bond was 
selected at random for initial residue modification.  Cleavage of this peptide bond yielded 
peptide g, a five-residue fragment.  Peptide I was synthesized with the amino-terminal 
alanine replaced by one of the alanine derivatives: β-, N-methylated, or D-alanine (Figure 
4.6) all of which have been demonstrated to impart resistance to peptidase activity in peptide 
substrates.49-51  t50%P and t1/2 for peptides II-A through II-C (Table 4.1) were measured.  None 
of the peptides showed an increased resistance to degradation when compared to peptide I, 
with t1/2 values equal to or much less than peptide I (20, 11, and 3 min compared to 20 min).  
No phosphorylation was detected for any of these peptides either.  As none of these peptide 
modifications resulted in a substrate peptide with any improved properties, these peptides 
were not pursued further. 
4.3.4 Characterization of Peptides Following Arginine Replacement 
 The next site targeted for modification was the arginine carboxy-terminal to the 
proline since cleavage at this site yielded peptide i, a three-residue peptide and the most 
abundant fragment formed in the HeLa lysate after 45 min of incubation with peptide I.  
Mono- and di-methyl-substituted, β-, and D-arginine are readily available derivatives that can 
impart stability against proteolysis.50  These modified arginine residues were utilized to 
synthesize peptides III-A through III-D (Table 4.1) and t1/2 and t50% P were measured for each 
peptide.  These peptides showed no improvement in t1/2 over peptide I, with values ranging 
from 2 to 17 min.  Three of the four peptides showed no evidence of phosphorylation, while 
the N-methylated arginine-substituted peptide (III-B) possessed a t50% P of 1013 min, more 
than 50X longer than peptide I.  When the fragment standards of peptide III-B were 
generated and utilized to identify the fragments formed in the lysate, the cleavage at the 3-
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mer site or Arg-Pro bond was eliminated.  After 60 min, the 4- and 5-mer fragments 
accounted for a small percentage of the total peptide, while the 6-residue fragment generated 
by hydrolysis of the alanine-threonine bond was the dominant fragment, comprising 92% of 
all peptide present within 15 min.  Although III-B possessed poorer properties than the 
starting substrate, it did yield a dominant fragment upon incubation with a cell lysate and a 
single preferred hydrolysis site that could be targeted for modification.  For this reason, 
peptide III-B was used as the template in all subsequent optimization rounds.  
4.3.5 Characterization of Peptides Following the Replacement of the 
Carboxy-Terminal Alanine 
 
 The alanine residue located at the alanine-threonine cleavage site of III-B was 
targeted for modification since hydrolysis of this peptide bond yielded the dominant fragment 
when III-B was incubated in a HeLa cell lysate.  Non-native derivatives of alanine, β- and D-
alanine, were substituted for the alanine (peptides IV-A and IV-B, Table 4.1).  Furthermore, 
since the active site of PKB possesses a hydrophobic pocket near the phosphorylatable 
threonine and is adjacent to a localized region of positive potential,60 two hydrophobic 
residues (peptides IV-D and IV-E) and a glutamic acid (peptides IV-F) were also inserted in 
place of the alanine (Table 4.1).  The t1/2 and t50% P were measured for each of the peptides 
IV-A through IV-E.  Peptide IV-E showed no resistance to degradation ( t1/2 of 2 min).  Two 
peptides, IV-A and IV-D, displayed a t1/2 of 14 min, 7X longer than peptide III-B.  Peptides 
IV-B and IV-C exhibited even longer t1/2 values, 32 and 37 min, respectively.  Three 
peptides, IV-A, IV-B and IV-C, possessed a t50% P more than 30X greater than the starting 
peptide I.  Peptide IV-E demonstrated a t50% P of 125 min, 7X longer than peptide I, but 8X 
better than that of peptide III-B.  The final peptide, IV-D, demonstrated a t50% P of 30 min, on 
the same order of magnitude as that for peptide I and over 30X faster than that of peptide III-
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B.  Additionally, when the fragments of peptide IV-D were analyzed, the dominant initial 
fragment in the HeLa lysate was the 8-residue fragment generated when the phenylalanine-
alanine bond was hydrolyzed.  Thus peptide IV-D was selected as the next lead peptide. 
4.3.6 Characterization of Peptides Following Phenylalanine or Alanine 
Replacement 
 
 The next residues targeted for modification were the two amino acids flanking the 
cleavage site of the most abundant fragment of peptide IV-D.  Pentafluorophenylalanine 
(Figure 4.6) was substituted in place of the phenylalanine to impart additional hydrophobicity 
to the position (peptide V-A).61  In addition, the non-native derivatives D-alanine and 
sarcosine (Figure 4.6) were inserted in place of the alanine to investigate substrate suitability 
(peptides V-B and V-C).  Peptides V-A and V-C possessed t1/2 values 5X greater than that of 
peptide IV-D.  However, peptide V-B displayed the greatest resistance to proteolysis, with a 
t1/2 of nearly 900 min, over 60X greater than that of IV-D.  Although V-A and V-B were 
phosphorylated more slowly than peptide IV-D (t50% P values more than 6X larger than that of 
IV-D), peptide V-C was phosphorylated at a rate (t50% P of 21 min) similar to that of IV-D.  
Furthermore, V-C displayed upon lysate incubation a single fragment which formed over 
time, the 9-mer peptide generated by hydrolysis of the sarcosine-glutamic acid bond (40% of 
the total peptide present after 60 min).  Based on this single hydrolysis position, peptide V-C 
was selected for further modifications. 
4.3.7 Characterization of Peptides Following Truncation of the Substrate 
 As illustrated by the consensus sequence, RPRAATF (where T is the site of 
phosphorylation), the amino terminal sites play the predominant role in PKB substrate 
recognition.  Thus removal of the two carboxy-terminal residues from the lead peptide V-C 
might not significantly alter the suitability of the substrate for PKB.  Since the only fragment 
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formed when peptide V-C was incubated in the cytosolic lysate was the 9-residue fragment, 
this truncated peptide (peptide VI-A) was assessed for its stability over time in a HeLa cell 
lysate.  Additionally t1/2 and t50% P for a methyl-alanine substituted 9-mer (peptide VI-B) was 
also measured.  The t1/2 of peptide VI-A was 13 min, indicating that this peptide was 
significantly less stable than the parent peptide V-C.  However, peptide VI-B possessed a t1/2 
of 92 ± 7 min, similar to that of peptide V-C.  When the peptides were incubated with PKBα, 
t50% P for both VI-A and VI-B was similar to that of peptide V-C.  Based on these combined 
properties, peptide VI-B was selected for further characterization. 
4.3.8 Characterization of Lead Peptide VI-B in Cytosolic Lysates 
 Although the lead peptide VI-B was more stable than peptide I in a HeLa cell lysate, 
it was still hydrolyzed into four fragments.  The latter were identified by synthesizing all 
possible fluorescent fragments.  Under the electrophoretic conditions employed, all of the 
fragments were present as individual non-co-migrating peaks that also did not co-migrate 
with the intact non-phosphorylated or phosphorylated parent peptides (Figure 4.7).  Each 
peak in the lysate mixture co-migrated with a single standard peak (Figure 4.8B).  Peptide p, 
which was the fragment present in the highest amount, comprised 20% of all species after 60 
min, and formed at an average initial rate of 0.02 ± 0.002 zmol pg-1 s-1 (Figure 4.8D).  Three 
additional peaks also formed in the HeLa lysate, but on much slower timescales than peptide 
p (Figure 4.8D).  The parent peptide was degraded at an average initial rate of 0.03 ± 0.004 
zmol pg-1 s-1, and approximately 60% remained after 60 min. 
 Peptide VI-B was also incubated in a LNCaP cytosolic lysate, a more aggressive 
proteolytic environment, and fragment formation over time was assessed (Figure 4.8E and 
4.9).  Only three fragments were seen in addition to the intact parent peptide, with peptide p 
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making up 90% of all peptide present after 60 min.  The rate of breakdown of the intact 
parent in the LNCaP lysate was 0.16 ± 0.03 zmol pg-1 s-1, over 5X faster than breakdown in 
the HeLa lysate.  Peptide p formed at a rate essentially as fast as the parent was degraded, at 
0.14 ± 0.02 zmol pg-1 s-1.  Two additional fragments, peptides o and n, formed at a much 
slower rate, similar to the result obtained in the HeLa lysate.  As expected in the cell line 
with a more aggressive proteolytic environment, peptide bond hydrolysis proved to be much 
faster, although the primary cleavage location remained the same. 
 The kinetic parameters KM and kcat were determined for peptide I and the lead peptide 
VI-B in order to compare the substrate efficiency of these peptides.  Varying concentrations 
of each peptide were incubated with PKB and the initial reaction velocity was calculated for 
each substrate concentration.  Peptide I exhibited a better KM than peptide VI-B (3 µM 
compared to 23 µM) but a poorer kcat (3,400 min-1) relative to that of VI-B (5,800 min-1) 
leading to a 4.5-fold better efficiency for VI-B over peptide I. 
4.3.9 Characterization of Peptide Degradation in Single LNCaP Cells 
 In order to assess the fate of the peptides when loaded into single cells, peptide I or 
VI-B was microinjected into a single LNCaP cell.  Individual single cells were washed, 
briefly incubated, lysed with a single pulse from an Nd:YAG laser, and the cell contents 
separated and detected by CE-LIF.  Eight peaks were observed on the electropherogram upon 
incubation of peptide I for 90 s in a single cell (n = 7 cells; Figure 4.10A).  Fragment 
identification was achieved by injecting the fluorescent fragment standards immediately after 
the contents of a microinjected cell and electropherograms of samples with and without 
standards were compared.  Under the electrophoretic conditions employed, all fragment 
standards were present as non-co-migrating individual single peaks, making positive 
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identification of all fragments possible.  In addition, the phosphorylated peptide was detected 
and comprised between 0 – 22% of the total peptide in a cell (9 ± 8%).  Finally, the intact 
peptide I constituted between 4 – 25% of all peptide present (11 ± 7%).  Fragment peptides i 
(3-mer) and f, (6-mer), were present at the highest amounts, up to 26% and 27%, 
respectively, and a smaller amount of 1-, 4-, 5-, and 7-mer fragments were present.  In short, 
peptide I was degraded too rapidly for use in intact LNCaP cells.  By contrast, the lead 
peptide VI-B comprised 56 ± 13% (n = 30 cells) of all peptide species present and 
phosphorylated substrate 10 ± 9% (with a range from 0 – 37%; Figure 4.10B).  Only two 
other species were observed, namely fragments corresponding to peptides m (8-mer) and p 
(5-mer). 
 Based on these preliminary results, peptide VI-B was selected for further study in 
single LNCaP cells.  To quantify the amount of peptide degradation and phosphorylation 
over a longer time scale, peptide VI-B was microinjected into single LNCaP cells (n = 19) 
and incubated for 5 min prior to cell lysis and CE-LIF.    Four peaks were observed, with 
intact, non-phosphoryated, parent peptide accounting for 15 ± 5% of all species present.  The 
parent peptide was degraded into one of two fragment peaks (peptides m or p) or converted 
to phosphorylated product (Figure 4.11A).  In addition, the major peptide fragment identified 
in single cells was peptide m (40% of total peptide present), the 8-residue fragment seen only 
in small amounts in the LNCaP lysate studies (Figure 4.8E).  The major fragment seen in the 
LNCaP lysate studies, peptide p, was present only as a minor species in the single cells. 
Assuming a cell volume of 1 pL and a total protein concentration of 100 mg mL-1,62 the intact 
peptide was eliminated at an average rate of 0.1 ± 0.2 zmol pg-1 s-1, similar to the breakdown 
rate measured in LNCaP cytosolic lysates.  The rate of degradation of the intact parent 
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peptide was linearly dependent on the peptide concentration (4 ± 8 µM) in the cell (Figure 
4.11C), with a linear regression analysis yielding an R2 value of 0.9899. 
4.3.10 Phosphorylation of Peptide VI-B in Single LNCaP Cells 
 Five min after introduction of VI-B into single cells, the percentage of intact peptide 
that was phosphorylated ranged from 0 – 80% (58 ± 26%).  The amount of phosphorylated 
peptide present varied linearly with respect to the amount of peptide microinjected into the 
cell (Figure 4.11D).  A linear regression analysis of the rate of phosphorylation yielded an R2 
value of 0.9401, indicating greater cell-to-cell variability in amount of peptide 
phosphorylated relative to that degraded in cells even after correction for the amount of 
peptide loaded into cells.  This may be due to a greater variation in the concentration of 
active kinase present in single cells relative to that of the peptidases.  Flow cytometry-based 
measurements suggest that the numbers of protein molecules per cell for enzymes involved 
in proteolytic degradation are tightly regulated and thus have relatively little cell-to cell 
variation. 63  By contrast, the copy number for molecules acting as components of signaling 
cascades responsive to environmental stimuli generally have significant noise or much 
greater variation in the cell-to-cell copy numbers. 
4.3.11 Inhibition of PKB Activity in Single Cells 
 Wortmannin is a selective inhibitor of PI3-K when used in nanomolar 
concentrations.64  The decreased formation of PIP3 resulting from wortamnnin-exposure 
leads to decreased PKB activation.  LNCaP cells were pre-incubated with 500 nM 
wortmannin (10 min) and then loaded with VI-B (n = 10).  After 5 min, cells were 
individually lysed and their contents separately electrophoresed.  Four peaks (intact parent, 
phosphorylated substrate, and fragments m and p) were identified in these cells as with the 
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cells without wortmannin (Figure 4.11B).  There was no statistical difference in the amount 
of degradation observed when compared to cells with no pre-treatment (p-value of 0.77) 
(Figure 4.11C). Formation of phosphorylated product was substantially decreased (13% ± 
12%) compared that for cells not pretreated with wortmannin (p-value of 1.1 x 10-6 ).  
Wortmannin also inhibits mTOR, myosin light chain kinase (MLCK), and 
phosphatidylinositol 4-kinase (PI4K) but at micromolar concentrations.64  Thus, inhibition of 
phosphorylation by these low concentrations of wortmannin suggests that the peptide was 
predominantly acting as a substrate for PKB. 
 
4.4 Conclusions 
 An iterative design and screening process was used to identify and stabilize locations 
susceptible to proteolysis in a kinase substrate peptide.  Each round of redesign yielded a 
substrate with more favorable properties until a peptide resistant to lysate peptidases, yet 
suitable as a PKB substrate, was obtained.  The optimized peptide displayed similar 
fragmentation patterns in lysates from cervical (HeLa) vs prostate (LNCaP) cancer cell lines, 
but the rates of hydrolysis were dramatically different.  The relatively high proteolytic rates 
observed in the prostate-derived cells was likely due to the fact that normal prostate produce 
an abundance of proteases.  The rate of proteolysis in the LNCaP lysate was similar to that 
seen in the single LNCaP cells.  Remarkably, the primary cleavage locations differed 
between lysates and single cells, suggesting that different peptidases may access the peptide 
in these two conditions, thereby indicating that lysates do not always provide an accurate 
mimic of the intact cell.  Although substantial variability existed in the percentage of peptide 
degraded in single cells, this variability was a consequence of the variation in the amount of 
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peptide loaded into cells i.e. the final intracellular peptide concentration.  With regard to 
phosphorylation, substantial variability existed between single cells, indicating differing 
amounts of kinase activity in cells within the same population.  These measurements are 
consistent with other measures of single cell variability, such as that seen in flow cytometry 
and microscopy.18, 65-68 
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4.5 Figures and Tables 
 
Figure 4.1:  in vitro phosphorylation of starting peptide I over time.  (A) – (C) 
Electropherograms of the reaction mixture with PKB after 0 (A), 15 (B), and 120 (C) min of 
incubation.  The * represents phosphorylated product.  (D) – (E) Electropherograms of 
peptide product after 0 (D) and 120 (E) min incubation with the reaction mixture with PKB 
but without ATP.  (F) Peptide phosphorylation as a function of time. 
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Figure 4.2:  Degradation of the starting peptide I in cytosolic lysates.  (A) - (C) 
Electropherograms of peptide I after incubation in a HeLa or LNCaP lysate for 0 min (A) for 
30 min in HeLa (B) or for 30 min in LNCaP (C) cytosolic lysate.  (D) Formation of peptide 
fragments over time in HeLa lysate.  (E) Formation of peptide fragments over time in LNCaP 
lysate.  The symbols are defined as: closed circle (peptide a or starting peptide); open circle 
(peptide i); closed square (peptide k); open square (peptide h); closed triangle (peptide g); 
open triangle (peptide f); and closed diamond (peptide e).  (F) The uppercase letters are the 
single amino acid abbreviations for the starting peptide sequence.  The lowercase letters 
represent cleavage locations that form the indicated fluorescent peptide fragments. 
 134 
 
 
Figure 4.3:  Electropherograms of the starting peptide I when incubated in HeLa cytosolic 
lysate for 0 (A), 1.5 (B), 3 (C), 30 (D), 45 (E), and 60 (F) min.  The lowercase letters 
represent the intact peptide or fragment peptides as defined in Figure 4.2F. 
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Figure 4.4:  Electropherograms of the starting peptide I when incubated in LNCaP cytosolic 
lysate for 0 (A), 1.5 (B), 3 (C), 30 (D), 45 (E), and 60 (F) min.  The lowercase letters 
represent the intact peptide or fragment peptides as defined in Figure 4.2F. 
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Figure 4.5:  Schematic of rational peptide substrate design.  (A) Synthesize starting peptide.  
The different geometrical shapes represent different amino acids.  (B) Synthesize all possible 
peptide fragments of starting peptide (B1) and incubate starting peptide with active enzyme 
and ATP (B2).  (C) Use CE-LIF to analyze degradation and identify peptide fragments 
formed (C1) and to assess phosphorylation over time (C2).  (D) Determine the half-life of the 
peptide in the lysate (D1) and the time required for the peptide to reach 50% phosphorylation 
(D2).  (E) Of the peptides showing favorable t1/2 and t50% P values, identify whether a 
preferred cleavage site exists in the peptide.  (F) Synthesize a library of new peptide 
substrates with non-native amino acids adjacent to the most susceptible bond in the lead 
peptide.  (G) Reiterate through steps (B) - (F) until a suitable, long-lived substrate is 
obtained. 
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Figure 4.6: Line bond structures of native and non-native amino acids utilized in peptide 
construction. 
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Figure 4.7: Electropherograms of the lead peptide VI-B when incubated in HeLa cytosolic 
lysate for 0 (A), 1.5 (B), 3 (C), 30 (D), 45 (E), and 60 (F) min.  The lowercase letters 
represent the intact peptide or fragment peptides as defined in Figure 4.8F. 
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Figure 4.8:  Degradation of the lead peptide VI-B in cytosolic lysates.  (A) - (C) 
Electropherograms of peptide I after incubation in a HeLa or LNCaP lysate for 0 min (A) for 
30 min in HeLa (B) or for 30 min in LNCaP (C) cytosolic lysate.  (D) Formation of peptide 
fragments over time in HeLa cell lysate.  (E) Formation of peptide fragments over time in 
LNCaP cell lysate.  The symbols are defined as: closed circle (peptide l); open circle (peptide 
p); closed square (peptide o); open square (peptide n); and closed triangle (peptide m).  (F) 
The uppercase letters are the single amino acid abbreviations for the lead peptide sequence, 
MeArg is N-methylated arginine, and MeAla is N-methylated alanine.  The lowercase letters 
represent cleavage locations that form the indicated fluorescent peptide fragments. 
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Figure 4.9:  Electropherograms of the lead peptide VI-B when incubated in LNCaP cytosolic 
lysate for 0 (A), 1.5 (B), 3 (C), 30 (D), 45 (E), and 60 (F) min.  The lowercase letters 
represent the intact peptide or fragment peptides as defined in Figure 4.8F. 
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Figure 4.10:  Electropherograms of single LNCaP cells 90 s after microinjection of the 
starting peptide I (A) or lead peptide VI-B (B).  The lowercase letters represent the intact 
peptide or peptide fragments identified in Figures 4.2F and 4.8F and the * represents 
phosphorylated peptide product. 
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Figure 4.11:  Electropherograms of single LNCaP cells 5 min after microinjecting the lead 
peptide QW-VII-48F without (A) or with pre-treatment with wortmannin (B).  The lowercase 
letters mark the peaks due to the intact peptide or peptide fragments identified in Figure 4.8F 
and the * labels the peak due to the phosphorylated peptide product. Two representative cells 
are shown for (A) and for (B).  (C) Rate of degradation of parent peptide as a function of 
amount microinjected in single cells with (open squares, n = 19) and without (closed circles, 
n = 10) pre-treatment with wortmannin.  (D) Rate of phosphorylation as a function of amount 
microinjected in single cells. 
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Table 4.1: Properties of the modified peptides derived from starting peptide I. 
 
 
 
at50% P is the time required for 50% of the peptide to be phosphorylated and bt1/2 is the half-life 
of the intact peptide in a cytosolic lysate.  NP = no phosphorylation.  ND = not determined.  
The amino acids are represented by their standard one letter code except for the following, 
which are defined as: βAla (Beta-alanine), MeAla (N-methylated alanine), DAla (D-alanine), 
βArg (Beta-arginine), MeArg (N-methylated arginine), Arg(Me2) (N-ω,ω-dimethyl-L-
arginine(symmetrical)), MePhe (N-methylated phenylalanine), Phe(F5) 
(pentafluorophenylalanine), and Sarc (sarcosine, or N-methyl glycine). 
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CHAPTER 5 
 
MEASUREMENT OF PKB ACTIVITY IN SINGLE 
PANCREATIC CANCER CELLS 
 
5.1 Introduction 
5.1.1 Pancreatic Ductal Adenocarcinoma 
 Pancreatic ductal adenocarcinoma (PDA) accounts for greater than 90% of all types 
of pancreatic cancer and it is the 4th most common cause of cancer-related deaths in the 
United States.1-4  PDA generally develops in adults over 60 in and around the pancreatic duct 
and can lead to a blockage of the pancreatic or bile ducts.  PDA tumors can invade deep into 
the pancreas and into nearby organs and can also metastasize to the lymph nodes or other 
regions of the body often prior to diagnosis.5, 6  The American Cancer Society estimates there 
will be approximately 44,000 new cases of PDA and 38,000 deaths from PDA in 2012, with 
equal mortality rates between men and women.5  The 1-year survival rate after diagnosis with 
PDA is only 26%, with a 5-year survival rate around 6%.  The facts are even more grim for 
individuals diagnosed with late-stage PDA, where the 5-year survival rate is only 2%.5  As 
there are little to no early symptoms of PDA, greater than 50% of individuals are not 
diagnosed until the late stages, once the cancer has already metastasized, giving a median 
survival rate of 6 months.  Treatment for patients with PDA can include surgical removal of 
the cancer as well as radiation therapy and chemotherapy, though these measures usually  
only relieve symptoms and may briefly extend survival, and rarely do they end in a cure.5 
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Two chemotherapeutic drugs often used are gemcitabine and erlotinib (Tarceva) and many 
new compounds are in clinical trials with hopes of identification of new and useful 
treatments for PDA.5, 7  
5.1.2 Protein Kinase B and PDA 
 The PI3-K pathway, and specifically PKB, is responsible for multiple cellular 
functions such as transcription, proliferation, stress response, and apoptosis (section 1.1.2).  
The PI3-K/PKB pathway has been found to be mutated or overactive in greater than 50% of 
all human cancers, meaning this pathway is of intense interest to cancer researchers and 
clinicians working to understand and eliminate cancer.8-10  PKB has been found to be 
constitutively active in PDA, both in tissue-cultured cell lines and human tumor samples, 
though actual activity varies between cell type.2, 9, 11-15  No gene mutations of PKB have been 
found, meaning alterations to the pathway are likely occurring at the mRNA or protein levels 
through mechanisms not yet fully elucidated.16 
 Activation of PKB in tumors can occur by modulation of the upstream components of 
the PI3-K pathway.  Expression of the phosphatase responsible for dephosphorylation of PIP3 
(PTEN) is often found to be low or missing in PDA cell lines and tumor specimens, with 
PTEN activity undetected in 5 of 8 cells lines and in 12 of 17 tumor specimens interrogated.2  
When PTEN expression and activity is low, PIP3 remains phosphorylated with sustained 
recruitment of PKB to the membrane (section 1.1.2), resulting in sustained PKB activity.  
Furthermore, activation of PKB can be an indicator of the aggressiveness of the pancreatic 
cancer, with higher levels of PKB associated with decreased patient survival as PKB helps to 
prevent apoptosis and promote angiogenesis within the bulk PDA tumor.9, 14, 15, 17, 18  In 
studies where PI3-K and PKB activity were inhibited with wortmannin or LY294002 (a 
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reversible PI3-K inhibitor), cells became sensitive to anti-cancer treatment, further 
demonstrating the role of the PI3-K/PKB pathway in cancer survival and progression.1, 9, 12  
As PKB gene copy number and protein levels do not always correlate with a measurable 
increase in PKB activity, a technique that can directly measure PKB activity would be of 
high utility in determination of PKB kinase activity in single PDA cells. 
5.1.3 Xenografts of Human Cancer 
 A technique widely used in pharmaceutical testing of anticancer therapeutic 
compounds involves the transplantation of human cell lines into nude mice.  Although these 
cell lines have been sustained in tissue culture for prolonged times, the cell lines retain the 
ability to form tumors in vivo.  These tumors are known as xenografts and have long been 
used as a model of various human cancers such as breast, lung, ovarian, and pancreatic 
cancers.19, 20  The mice are treated with therapeutics and the tumor response is characterized, 
with the hopes that the murine model will predict behavior of the corresponding tumor type 
in humans.  However, in most cases, therapeutics that appear to work in the mouse tumors 
derived from tissue-cultured cell lines do not often work in the human form of the cancer.19  
However, first reported in the 1970s was the use of a direct-transfer xenograft (also known as 
a tumorgraft), where a section of a tumor removed from a human patient is directly 
transferred into a mouse model and allowed to grow.  These types of xenografts show 
proliferation within the mouse, retain the heterogeneity and behaviors of the human tumor, 
and provide a model for drug discovery, therapy, or histological analysis of the human 
tumor.7, 19, 20  A recent paper by Hidalgo et al. outlines the use of direct-transfer xenografts 
from 14 different cancer patients to determine likely therapeutic drugs for successful 
treatment of their respective cancers.7  The authors reported likely treatment options for 12 of 
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the 14 patients, and showed treatment success in all but one of those patients (who died prior 
to treatment), demonstrating a potential use for direct-transfer xenografts.  In the context of 
the work described in this chapter, these direct-transfer xenografts provide a means of 
obtaining primary human pancreatic cancer cells for analysis of PKB activity.  Collaborator 
Dr. Jen Jen Yeh, of the UNC-CH Department of Pharmacology and UNC Hospitals Division 
of Surgical Oncology, provided all xenograft cells utilized in this work. 
5.1.4 Single-cell Analysis of PKB Activity in Pancreatic Cancer Cells 
 The peptidase-resistant peptide substrate reporter developed in Chapter 4 was used to 
assay PKB activity in single tissue-cultured pancreatic cancer cells and in primary human 
pancreatic cancer cells derived from direct-transfer xenografts into mice.  The immortalized 
tissue cultured cells were used to assess PKB activity in cell lines with varying amounts of 
PKB activity to demonstrate the feasibility of the technique, the heterogeneity of cells within 
a population, and to characterize the substrate breakdown and phosphorylation in single cells.  
Finally, this substrate was characterized in single primary pancreatic cells obtained from the 
direct-transfer xenografts and utilized to measure PKB activity in these cells 
 
5.2 Materials and Methods 
5.2.1 Chemicals 
 Peptide synthesis reagents were purchased as indicated in sections 3.2.1 and 4.2.1 of 
this dissertation.  Dulbecco’s Modified Eagle Medium (DMEM), was procured from Cellgro; 
Iscove’s Modified Dulbecco’s Medium (IMDM), Minimal Essential Medium (MEM), 0.25% 
trypsin, and penicillin/streptomycin were obtained from Gibco; fetal bovine serum (FBS) was 
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purchased from Atlanta Biologicals; and wortmannin was obtained from LC Laboratories.  
All other chemicals used in the assays were purchased from Sigma for Fisher. 
5.2.2 Peptide Synthesis and Preparation 
 All peptides were synthesized by collaborator Dr. Qunzhao Wang in the Lawrence 
Lab unless specified otherwise.  A detailed table of all peptides prepared and utilized in this 
dissertation can be found in Appendix C.  Synthesis of the peptide used in this chapter is 
fully described in section 4.2.2. 
5.2.3 Cell Culture 
5.2.3.1 Immortalized Cell Lines 
 HPAF-II (human pancreatic adenocarcinoma), CFPAC-1 (human metastatic ductal 
pancreatic adenocarcinoma), and PANC-1 (human pancreatic carcinoma) were obtained from 
the American Type Culture Collection.21-23  HPAF-II cells were cultured in MEM 
supplemented with 10% FBS, penicillin (100 units/mL), and streptomycin (100 µg/mL).  
CFPAC-1 cells were cultured in IMDM supplemented with 10% FBS, penicillin (100 
units/mL), and streptomycin (100 µg/mL).  PANC-1 cells were cultured in DMEM 
supplemented with 10% FBS, penicillin (100 units/mL), and streptomycin (100 µg/mL).  All 
cells were maintained in a humidified atmosphere of 37oC in 5% CO2 and passaged into fresh 
media every 2-3 days.  Cells used for single-cell CE experiments were plated the day before 
onto custom chambers, prepared by using poly(dimethyl siloxane) (PDMS, Sylguard 184) to 
glue a silicon O-ring (McMaster-Carr) to a #1 glass coverslip (Fisher).  A dilute cell 
suspension was added to 500 µL of the appropriate media in the chamber.  Chambers were 
placed in the humidified incubator until use in the experiments. 
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5.2.3.2 Xenograft Cells 
 In the Yeh lab, tumors were removed from each mouse, washed with PBS solution, 
and dissected into small fragments.  Tumors were disaggregated by incubating at 37oC for 20 
min in 40 mg mL-1 collagenase D and Dispase II.  After incubation, the mixture was 
centrifuged at 1,500 x g for 2 min prior to resuspension in fresh media.  These direct-transfer 
xenograft cell solutions procured from the Yeh lab were immediately placed in standard 
tissue culture flasks or single cell chambers and were cultured in DMEM supplemented with 
10% FBS, penicillin (100 units/mL), and streptomycin (100 µg/mL) and maintained in a 
humidified atmosphere of 37oC in 5% CO2.  The chambers for single cell experiments were 
prepared by using PDMS to glue a silicon O-ring to a 22 mm2 cellulose acetate coverslip.  
Chambers were plasma treated and either plated immediately with a dilute suspension of 
cells or were coated with a 0.1% gelatin solution prior to addition of cells. 
5.2.4 Single Cell Analysis of PKB Activity 
 Chambers plated with cells the day before the experiment were placed on the 
microscope stage and rinsed with ECB at 37 oC to remove all traces of media.  Cell volume 
was estimated by measuring the length and width of each cell and assuming a height of 3 µm.  
A single cell was microinjected with peptide VI-B and incubated for 5 min in ECB flowing at 
3 mL min-1 at 37 oC.  The cell was lysed with the Nd:YAG laser, loaded electrokinetically 
into the capillary, and the capillary was transferred to electrophoretic buffer prior to initiation 
of electrophoresis.   
Cells pre-treated with the inhibitor wortmannin were treated as follows: prior to 
experiment start, the media was removed from the cell chamber and replaced with 500 µL of 
500 nM wortmannin in the appropriate cell media.  The cells were incubated for 10 min in a 
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37 oC humidified incubator.  After this step, the cells were treated the same as the untreated 
cells described above.   
5.2.5 Single-Cell Capillary Electrophoresis 
 Single-cell CE was performed using the custom built CE system with LIF detection 
described in Chapter 2 of this dissertation.  Fused silica capillaries [30-µm inner diameter, 
360-µm outer diameter, (Polymicro Technologies, Phoenix, AZ)] with a total length of 38 cm 
and an effective length of 21.5 cm were conditioned as described in section 3.2.7.  A negative 
voltage of 10 kV was applied to the outlet reservoir while the inlet reservoir was held at 
ground.  The electrophoretic buffer was 300 mM borate, pH 7.5.  Cells were perfused with 
ECB during experiments, with the flow turned off immediately prior to cell lysis and loading 
into the capillary.  Laser-based cell lysis was achieved with a focused Nd:YAG laser as 
previously described in Chapter 2.   
 To identify peptide fragments formed in cells, standards of peptide fragments (100 
nM) were hydrodynamically loaded into the capillary immediately following loading of a 
single cell into the capillary.  The cell was not loaded with peptide prior to loading into the 
capillary, it just provided a milieu for the subsequently loaded standards similar to that 
obtained from a lysed cell.  To calibrate the amount of peptide on the electropherograms, a 
known concentration of standard of each intact peptide was hydrodynamically loaded into the 
capillary, electrophoresed, and the area under the peak calculated.  Poiseuille’s equation 
(Equation 2.1) was utilized to estimate the amount of peptide injected, as demonstrated by 
Meredith et al.24  Data was collected with the custom software described in Chapter 2 
(LabVIEW 9.0.1, National Instruments, Austin, TX) and analyzed using Origin Software 
(version 7.5, OriginLab Corporation, Northampton, MA). 
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5.3 Results and Discussion 
5.3.1 Selection of the Substrate Peptide and Cell Lines 
 Peptide VI-B (6FAM-GRP-MeArg-AFTF-MeAla-NH2) was selected as the peptide 
substrate for several reasons and the development of peptide VI-B is thoroughly discussed in 
Chapter 4.  In brief, peptide VI-B was more resistant to peptidase degradation than a peptide 
substrate composed entirely of native amino acids when incubated in single cells.  Peptide 
VI-B was also efficiently phosphorylated by purified PKB enzyme in vitro (KM of 23 µM and 
kcat of 5,800 min-1), and was phosphorylated in single prostate cancer cells, most likely by 
PKB (Chapter 4). 
 Three representative pancreatic cancer cell lines were selected based on their 
variability in PKB activity, as determined by members of collaborator Dr. Jen Jen Yeh’s lab, 
where PKB activity was determined by utilizing Western blot analysis to measure the amount 
of phosphorylated serine at position 473 with anti-Ser473 antibody.25  Pancreatic cancer was 
chosen as the model for the reasons discussed in the introduction of this chapter (section 5.1).  
HPAF-II cells were derived from a human pancreatic carcinoma isolated from the peritoneal 
ascitic fluid of a 44-year old Caucasian male with primary pancreatic adenocarcinoma and 
metastases to the liver, diaphragm, and lymph nodes.21  HPAF-II cells displayed very low 
amounts of active PKB as determined by the Western blot analysis in the Yeh lab.  CFPAC-1 
cells were derived from the liver of a 26-year old Caucasian male with cystic fibrosis and 
pancreatic cancer22 and showed moderate amounts of active PKB in the Western blots 
performed by the Yeh lab.  PANC-1 cells were derived from a 56-year old Caucasian male 
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with pancreatic cancer23 and showed the highest amount of active PKB in the Yeh lab 
Western blot analysis. 
5.3.2 Characterization of Peptide Degradation in Single Tissue-Cultured 
Cells 
 
 To assess the degradation of peptide VI-B in intact pancreatic cancer cell lines, the 
peptide was microinjected into a cell and incubated for 5 min prior to lysis and 
electrophoresis.  Peaks corresponding to fragment peptides were identified based on co-
migration with fragment standards, as described in Chapters 3 and 4.  When peptide VI-B 
was incubated in HPAF-II cells (n = 10) for 5 min, four peaks were present in the 
electropherogram, corresponding to intact parent peptide, phosphorylated parent, and two 
fragment peptides (Figure 5.1A).  The fragment peptides were the same fragments seen when 
peptide VI-B was incubated in LNCaP cells (Chapter 4), the 5- and 8-residue fragments.  The 
8-mer fragment formed in the highest amounts, comprising 41 ± 4% of all peptide present 
after 5 min.  The 5-mer was less prevalent, making up only 10 ± 2% of total peptide.  45 ± 
2% of the parent peptide was detected in the HPAF-II cells after 5 min.  When the total 
amount of protein in each cell was assumed to be 100 pg,26 the rate of degradation of the 
parent peptide was estimated as 0.3 ± 0.3 zmol pg-1 s-1, with a range from 0.02 – 0.7 zmol pg-
1 s-1.  Initial substrate concentration in each cell was determined by dividing the calculated 
number of moles microinjected into each cell (section 5.2.5) by the estimated cell volume 
(section 5.2.4).  When the rate of degradation of intact VI-B was plotted as a function of 
initial substrate concentration, the rate increased linearly as the substrate concentration was 
increased (Figure 5.2A).  This was the same trend that was seen in the prostate cancer cell 
line (LNCaP) described in Chapter 4. 
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 When peptide VI-B was microinjected into CFPAC-1 cells (n = 11) and incubated for 
5 min, the same four peaks were seen in the electropherograms as were seen in the HPAF-II 
cells, only at slightly different amounts (Figure 5.1B).  The parent peptide was present in the 
highest amounts, accounting for 39 ± 13% of all peptide present after 5 min.  The 8-mer 
fragment peptide was the next most abundant, at 36 ± 17% of all peptide.  The 5-residue 
fragment was present as 9 ± 5% of all peptide after 5 min.  When assuming a total protein 
concentration of 100 pg per cell, the rate of degradation of the parent peptide was 0.1 ± 0.2 
zmol pg-1 s-1, with a range of values similar to that seen in the HPAF-II cells, from 0.01 to 
0.6 zmol pg-1 s-1, indicating that there was no difference in the amount of degradation 
between CFPAC-1 and HPAF-II cells (p-value of 0.053).  The same trend was also observed 
when degradation rate of intact VI-B was plotted as a function of initial substrate 
concentration, with the rate increasing linearly with an increase in concentration (Figure 
5.2B). 
 When peptide VI-B was incubated in PANC-1 cells (n = 11) for 5 min, the same four 
peaks were seen as has been previously described for the HPAF-II and CFPAC-1 cells, just at 
varying amounts (Figure 5.1C).  The 8-residue fragment was formed in the highest amounts 
after 5 min, accounting for 38 ± 10% of all peptide present after 5 min.  The intact parent 
peptide was present as 23 ± 10% of all peptide after 5 min, and the 5-residue fragment 
comprised 12 ± 3% of all peptide.  When the cells were assumed to contain 100 pg of total 
protein, the rate of degradation was found to be 0.08 ± 0.2 zmol pg-1 s-1, with a range from 
0.01 to 0.5 zmol pg-1 s-1, not statistically different from that seen in CFPAC-1 cells (p-value 
of 0.24) or in HPAF-II cells (p-value of 0.81).  The same linear trend of increased rate as the 
substrate concentration was increased was also observed in PANC-1 cells when degradation 
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rate of intact peptide VI-B was plotted as a function of initial substrate concentration (Figure 
5.2C). 
 
5.3.3 Phosphorylation of Peptide VI-B in Single Tissue-Cultured Cells 
 In addition to the two fragment peaks observed in single cells, phosphorylation of 
peptide VI-B was also seen in all 3 cell types.  After a 5 min incubation of peptide VI-B in 
HPAF-II cells, 7 ± 6% of undegraded peptide was present as the phosphorylated product and 
ranged from 0 to 15% (Figure 5.3).  When the total protein in each cell was taken to be 100 
pg, the rate of phosphorylation was 0.01 ± 0.01 zmol pg-1 s-1, with a range from 0 to 0.05 
zmol pg-1 s-1.  The rate of phosphorylation was plotted as a function of initial substrate 
concentration (Figure 5.4A) and it was determined that the rate of phosphorylation increased 
linearly as substrate concentration was increased. 
 When peptide VI-B was incubated for 5 min in CFPAC-1 cells, phosphorylated 
substrate accounted for 29 ± 18% of undegraded peptide present in the electropherograms 
(Figure 5.3), ranging from a low of 8% to a high of 59% phosphorylation.  It was also noted 
that the distribution of phosphorylated product appeared to be bimodal, with a cluster of 6 
cells showing lower amounts of phosphorylation (8 – 20%) and a cluster of 5 cells showing 
higher amounts of phosphorylation (41 – 60%).  A t-test analysis of these two groups of cells 
reveals that they are statistically different from each other (p-value of 3.6 x 10-5).  The 
percent phosphorylation plotted as a function of time was utilized to determine if a bimodal 
variation of concentration injected into the cells would explain the bimodal distribution of 
phosphorylation.  However, no such relationship was observed, as there appeared to be no 
correlation between initial substrate concentration and percent phosphorylation.  Perhaps 
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PKB is activated in an on/off fashion, though many more cells would need to be sampled 
prior to drawing this conclusion.  When a cell was assumed to contain 100 pg total protein, 
the rate of phosphorylation of CFPAC-1 cells was found to be 0.03 ± 0.03 zmol pg-1 s-1, with 
a range from 0.003 to 0.09 zmol pg-1 s-1.  When the rate of phosphorylation was plotted as a 
function of initial substrate concentration, the same linear trend as was seen in HPAF-II cells 
was also observed: as the concentration increased, the rate of phosphorylation also increased 
(Figure 5.4B). 
 When peptide VI-B was incubated for 5 min in PANC-1 cells, the amount of 
phosphorylated substrate ranged from 0 to 76% of undegraded peptide, with an average of 51 
± 25% (Figure 5.3).  The amount of phosphorylation was skewed to the high end, with 7 cells 
showing greater than 50% phosphorylation, and only 4 cells with phosphorylation amounts 
more than 10% below the average.  Once again, when substrate phosphorylation was plotted 
as a function of initial substrate concentration, there was no correlation between these two 
parameters and these populations were also statistically different when analyzed with a t-test 
(p-value of 0.01).  This also caused the rate of phosphorylation rates to vary widely, from 0 
to 0.09 zmol pg-1 s-1, with an average of 0.02 ± 0.03 zmol pg-1 s-1, if each cell was assumed to 
contain 100 pg of total protein.  As was seen with both the HPAF-II and CFPAC-1 cells, the 
rate of phosphorylation increased linearly as a function of initial substrate concentration 
(Figure 5.4C). 
 Single cell analysis of substrate phosphorylation by PKB in HPAF-II, CFPAC-1, and 
PANC-1 cells revealed the difference in the PKB activity amongst the 3 lines.  HPAF-II cells 
showed the lowest amount of substrate phosphorylation, CFPAC-1 cells demonstrated a 
moderate amount of substrate phosphorylation, and PANC-1 cells possessed the highest 
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amount of substrate phosphorylation (Figure 5.3), suggesting low, moderate, and high levels 
of active PKB in the cells, respectively.  A non-parametric statistical analysis of variance of 
these three populations demonstrated a statistically significant difference between the 
populations (p-value of 4.4 x 10-4).  This was the same trend observed in the Western Blot 
analysis performed by the Yeh lab, where PKB activity was determined by measurement of 
the amount of phosphorylated serine at position 473 with anti-Ser473 antibody.25  However, 
the single-cell work presented here offers information on cell-to-cell heterogeneity that is not 
available via Western blot.  While HPAF-II cells demonstrated the lowest amount of 
substrate phosphorylation, a range of nearly 20% was observed.  As discussed briefly above, 
the CFPAC-1 cells appeared to be bi-modally distributed about the mean, while the PANC-1 
cells appeared skewed, with a higher number of cells demonstrating phosphorylation greater 
than the mean, and tailing off toward lower amounts, with one cell even demonstrating no 
phosphorylation.  None of these results are resolvable in Western blot analyses. 
 Western blot analysis required hundreds of thousands of cells and can only reveal the 
average of a population, while single cell interrogation can give a wider understanding of 
what is happening on an individual basis and in the population as a whole.  However, the 
measurement technique utilized in this work is low throughput, with only 7 – 10 cells 
successfully analyzed in a single day, much too slow for analysis of statistically significant 
numbers of cells.  While tentative conclusions can be drawn about variability within and 
between each cell population from these results, there is not enough data to draw over-
reaching conclusions.  Ideally, hundreds to thousands of cells need to be analyzed to further 
demonstrate the heterogeneity within and among cell populations.  However, even with these 
small sample numbers, differences between cells in the same population did exist.  These 
 163 
differences could have arisen from the cells being at different stages in the cell cycle, where 
PKB and regulatory enzyme activity could vary dramatically.  As was determined by Hu et 
al., protein expression varied in a cell cycle-dependent manner, though PKB was not one of 
the proteins analyzed.27  It is possible that PKB could vary depending on cell cycle, 
accounting for the differences seen among cells of the same type.  In each case, while the rate 
of phosphorylation varied linearly with respect to initial substrate concentration, it did not 
appear as if there was a correlation between phosphorylation percent and the initial substrate 
concentration. 
 Another indication of the variability in these cells is when the rates of 
phosphorylation were plotted as a function of initial substrate concentration (Figure 5.4).  In 
all 3 cells lines, these plots were linear, with the rate increasing as the concentration was 
increased.  However, there was a large variability in these plots, more than what was seen 
when rate of degradation of the parent peptide was calculated (Figure 5.2).  This same trend 
was also observed in the LNCaP cells (Chapter 4).  Perhaps the kinases and phosphatases are 
tightly regulated, but are active during some parts of the cell cycle and inactive during other 
parts.27  Cells sampled at different stages of the cell cycle could yield large differences in 
PKB activity.  It could also indicate that the peptidases are simply more tightly regulated than 
the kinase and phosphatases are.  Protein degradation is a destructive process that can 
irreparably damage cell function when not tightly controlled, while regulations on the 
variability of kinase and phosphatase activity can be less stringent.  This was demonstrated 
by Newman et al. in S. cerevisiae, where potentially destructive processes varied less than 
expected while other processes not inherently destructive to the cell varied more than 
expected.28  As was postulated by Newman et al., variability in kinase function imparts 
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phenotypic differences in a population that provide the variations in function that can lead a 
population to survive selective pressures by ensuring that some, if not all, of the population 
can survive under various stresses.  But the evolutionary cost versus benefit is too high for 
potentially destructive processes, and so more energy likely goes into regulation of the 
potentially detrimental functions such as peptide degradation.28 
5.3.4 Inhibition of PKB Activity in Single Tissue-Cultured Cells 
 Wortmannin, an irreversible inhibitor of PI3-K at nanomolar levels, can also inhibit 
mTOR, myosin light chain kinaes, and PI4K when used in micromolar concentrations.29  
Wortmannin prevents the phosphorylation of PIP2 to PIP3, which is needed for PKB 
recruitment to, and activation at, the cell membrane.  To provide evidence that PKB was at 
least partially responsible for phosphorylation of peptide VI-B in the single cells, HPAF-II (n 
= 10), CFPAC-1 (n = 11), and PANC-1 (n = 11) cells were pre-treated with 500 nM 
wortmannin prior to microinjection of VI-B into single cells.  In all three cell lines, pre-
treatment with wortmannin essentially eliminated any phosphorylation seen in the single 
cells, with phosphorylation averaging 0.4 ± 0.7% in HPAF-II cells, 0.1 ± 0.3% in CFPAC-1 
cells, and 1 ± 3% in PANC-1 cells (Figure 5.3).  In all cases, there was a statistical difference 
in the amount of phosphorylation seen in treated and non-treated cells (p-values of 0.0033, 
2.8 x 10-6, and 4.8 x 10-5, respectively).  Inhibition of phosphorylation by these low 
concentrations of wortmannin suggests that the peptide was predominantly acting as a 
substrate for PKB, as the concentration of wortmannin was an order of magnitude less than 
that reported for efficient inhibition of MLCK, the next kinase most susceptible to 
wortmannin.  Degradation of peptide VI-B was also observed in all wortmannin-treated cells, 
and evidence of both the 8- and 5-residue fragments were observed in most of the 
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wortmannin-treated cells (Figure 5.5).  When the rate of degradation of the parent peptide 
was plotted as a function of initial substrate concentration (Figure 5.2), a linear correlation 
with a positive slope was observed, no different than that seen in untreated cells (p-values of 
0.27, 0.078, and 0.26 for HPAF-II, CFPAC-1, and PANC-1 cells, respectively).  
5.3.5 Characterization of VI-B in Pancreatic Tumor Xenografts 
 Behavior of peptide VI-B in single cells obtained from primary human pancreatic 
cancer xenografts was assessed next.  Peptide VI-B was microinjected into a single xenograft 
cell and incubated for 90 s or 5 min prior to electrophoresis and detection of fluorescent 
products.  When the peptide was incubated for 90 s (n = 2), intact parent peptide and the 8-
mer fragment were detected (Figure 5.6A-B).  When the amount of protein in the cell was 
taken to be 100 pg, the parent peptide was degraded at a rate of 0.003 and 0.1 zmol pg-1 s-1 in 
the two cells.  No phosphorylated product was detected in these two cells.  This could be due 
to the very short incubation time or could be because these cells were stromal cells and not 
epithelial cells.  At this point, there have not been been efforts to distinguish between the 
fibroblast and epithelial cells in these xenograft samples, though this will be done in the 
future.  When the peptide was incubated for 5 min (n = 1), four products were detected: intact 
parent peptide, the 8-mer and 5-mer fragments, and phosphorylated product (Figure 5.6C).  
The parent peptide was degraded at a rate of 0.04 zmol pg-1 s-1, in the same range as the 
degradation rate for the shorter incubation time.  The phosphorylated product accounted for 
31% of intact peptide after 5 min, and formed at a rate of 0.006 zmol pg-1 s-1.  This result 
indicates that phosphorylation of peptide VI-B can be accomplished in primary samples and 
demonstrates the feasibility of using this peptide for analysis of PKB activity in single 
primary cells.  However, many more cells would need to be analyzed prior to drawing 
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conclusions regarding the amount of PKB activity in these cells.  This work is currently 
underway. 
5.4 Conclusions 
 Single cell analysis of PKB activity in three different cell lines showed differences 
between cells of different lineage, with some possessing greater amounts of PKB, such as 
PANC-1, when compared to others, such as HPAF-II.  The variability of PKB activity in 
cells from the same population points to potential differences in cell cycle as well as to 
kinase variability due to biological noise.  The variability in kinase and phosphatase activity 
could provide the phenotypic variety to enable these cell lines to survive certain selective 
pressures.  Peptide VI-B was also phosphorylated in a single primary cell obtained from a 
human pancreatic cancer xenograft, demonstrating the feasibility of this method for primary 
cells.  Future work includes extended characterization of peptide degradation and 
phosphorylation in mouse xenograft cells derived from human pancreatic cancer tumors as 
well as in primary cells from human tumors.  Further stabilization of peptide substrate VI-B 
is also underway, using the iterative design strategy described in Chapter 4 to render the 
peptide more proteolytically stable in single cells.  Analysis of substrate specificity for PKB 
is also desired in order to ensure proper interpretation of enzyme activity in single tissue-
cultured and primary cells. 
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5.5 Figures 
 
 
 
Figure 5.1: Select electropherograms from HPAF-II (A), CFPAC-1 (B), and PANC-1 (C) 
cells with no inhibitor treatment.  Two representative cells are shown for each cell line.  Peak 
1 is the intact parent peptide; peak 2 is the 8-residue fragment; peak 3 is the 5-residue 
fragment; and peak 4 is phosphorylated product. 
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Figure 5.2: The rate of degradation of intact peptide VI-B as a function of initial substrate 
concentration in HPAF-II (A), CFPAC-1 (B), and PANC-1 (C) cells with no treatment (open 
squares) or pre-treatment with wortmannin (closed circles). 
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Figure 5.3: Percent phosphorylation in HPAF-II (open squares), CFPAC-1 (open triangles), 
and PANC-1 (open circles) cells with and without pre-treatment with wortmannin.  Percent 
phosphorylated peptide is calculated for undegraded peptide only.  The average and standard 
deviation are indicated for each untreated cell line. 
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Figure 5.4:  The rate of phosphorylation of intact peptide VI-B as a function of initial 
substrate concentration in HPAF-II (A), CFPAC-1 (B), and PANC-1 (C) cells. 
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Figure 5.5: Select electropherograms from HPAF-II (A), CFPAC-1 (B), and PANC-1 (C) 
cells pre-incubated with wortmannin.  Two representative cells are shown for each cell line.  
Peak 1 is the intact parent peptide; peak 2 is the 8-residue fragment; peak 3 is the 5-residue 
fragment; and peak 4 is phosphorylated product. 
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Figure 5.6: Electropherograms from incubation of peptide 48F in human pancreatic cancer 
xenograft cells for 90 s (A and B) and 5 min (C).  Two representative cells are shown for the 
90 s incubation time.  Peak 1 is the intact parent peptide; peak 2 is the 8-residue fragment; 
peak 3 is the 5-residue fragment; and peak 4 is phosphorylated product. 
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CHAPTER 6 
 
FURTHER STABILIZATION OF A BCR-ABL KINASE 
SUBSTRATE REPORTER 
 
6.1 Introduction 
 As was discussed in Chapter 3, the lead peptide developed as a substrate for Abl 
kinase was QW-V-48B (5FAM-GGIYAAP-MePh-KKKA), derived from the native amino 
acid substrate QW-III-67B (5FAM-GGAYAAPFKKKA).1  Peptide QW-V-48B was more 
stable than QW-III-67B in a cytosolic lysate, but the two peptides were degraded at nearly 
identical rates in single HeLa cells.  Also determined in Chapter 3, the major cleavage 
location of QW-V-48B in single cells was between the two alanine residues, leaving a 5-
residue fragment in single cells.  In order to render the peptide even more resistant to 
peptidase degradation, the strategy outlined in Chapter 4 was applied to peptide QW-V-48B, 
where this susceptible cleavage location between the alanine residues was targeted for 
stabilization.  This was accomplished by inserting non-native amino acids into the positions 
adjacent to the susceptible bond and re-evaluating each resulting peptide for resistance to 
degradation and suitability as a Bcr-Abl substrate. 
6.2 Experimental Design 
6.2.1 Chemicals 
 Peptide synthesis reagents were purchased from Aldrich or Fisher except for the 
following:  2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
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hexafluorophosphate (HCTU), 1-(Mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT), 9-
Fluorenylmethoxycarbonyl (Fmoc) amino acids, 5-carboxyfluorescien (5-FAM) and resins 
were received from ChemPep or NovaBiochem; N-Hydroxybenzotriazole (HOBt) was 
obtained from AnaSpec.  All other chemicals used in the assays were procured from Fisher or 
Sigma except for the following: Active Abl-1 enzyme was purchased from Invitrogen; 
bovine serum albumin (BSA) was received from Calbiochem; Roswell Park Memorial 
Institute Media (RPMI-1640) was obtained from Cellgro; Penicillin/streptomycin was 
procured from Gibco; and fetal bovine serum (FBS) was purchased from Atlanta Biologicals. 
6.2.2 Peptide Synthesis and Preparation 
6.2.2.1 Synthesis of Full-Length Peptides Amidated on the C-Terminus 
 All peptides were synthesized by collaborator Dr. Qunzhao Wang in the Lawrence 
Lab unless specified otherwise.  A detailed table of all peptides prepared and utilized in this 
dissertation can be found in Appendix C.  Full-length substrate peptides with an amidated C 
terminus were synthesized via standard Fmoc peptide synthesis (Prelude Peptide Synthesizer, 
Protein Technologies, Tucson, AZ) utilizing TGR resin.  Coupling was performed with two 5 
min incubations in dimethylformamide (DMF) with 5 equivalents (eq) amino acid, 5 eq 
HCTU, and 10 eq N,N-Diisopropylethylamine (DIPEA).  Fmoc deprotection was achieved 
with two 2.5 min incubations with 20% piperidine in DMF.  The free N-terminus was reacted 
with 5 eq 5-FAM, 5 eq diisopropylcarbodiimide (DIC), and 5 eq HOBt in DMF overnight, 
then treated with 30% piperidine in DMF for 30 min.  The peptide was cleaved with 
trifluoroacetic acid:water:triisopropylsilane (TFA:H2O:TIS) in a ratio of 95:2.5:2.5, 
precipitated with ether, and dried in air.  Peptide purity was assessed with HPLC-MS and 
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further purification via HPLC was performed if needed.  Peptides were dissolved in Tris 
buffer, pH 7.5, aliquoted, and stored at -80 oC.   
6.2.2.2 Alternative Coupling for Difficult Amino Acids  
 In some instances, amino acids were coupled overnight in N-Methyl-2-pyrrolidone 
(NMP) with 5 eq amino acid, 5 eq bromo-tris-pyrrolidino phosphonium hexafluorophosphate 
(PyBrop), and 10 eq DIPEA.  Capping with acetic anhydride was performed if necessary 
based on a ninhydrin test.  Remaining amino acids were coupled as described in section 
6.2.2.1.  Product formation was assessed using HPLC-MS. 
6.2.2.3 Synthesis of Peptide Fragment Standards 
 Peptide fragment standards with a free carboxylic acid at the peptide C terminus were 
synthesized using a 2-Chlorotrityl chloride resin.  To couple the first amino acid, 1 eq of the 
first Fmoc amino acid and 4 eq DIPEA in dry CH2Cl2 was reacted with the 2-Chlorotrityl 
chloride resin for 2 h in a dry glass vial on a shaker.  The remaining amino acids were 
attached as described in section 6.2.2.1 or 6.2.2.2. 
6.2.3 Cell Culture 
 Baf/BCR-ABL cells were cultured in RPMI-1640 medium supplemented with 10% 
FBS, penicillin (100 units/mL) and streptomycin (100 µg/mL) and were maintained in a 
humidified atmosphere of 37 oC in 5% CO2.  Cells were passaged into fresh media every 2 – 
3 days.   
6.2.4 Measurement of Peptide Degradation in a Cell Lysate 
 Baf/BCR-ABL cells were collected from two confluent 75 cm2 flasks and were 
washed with and resuspended in phosphate buffered saline (PBS; 137 mM NaCl, 10 mM 
Na2HPO4, 27 mM KCl, 1.75 mM KH2PO4, pH 7.4).  The cells were submerged in liquid 
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nitrogen for 1 min and rapidly thawed at 37 oC for a total of three cycles.  The mixture was 
centrifuged at 14,000 x g for 5 min at 4 oC.  The supernatant was transferred to a clean 
centrifuge tube and maintained on ice until use in the assay.  Total protein concentration in 
the supernatant was measured using fluorescamine.2  Briefly, fluorescamine (10 µL, 3 
mg/mL in acetone) was added to a cell lysate (30 µL) and incubated for 5 min at 25 oC.  
Fluorescence was measured with a fluorescence plate reader (SpectraMax M5, Molecular 
Devices, Sunnyvale, CA) with an excitation of 390 nm (bandwidth of 9 nm) and emission of 
475 nm (bandwidth of 15 nm). 
 Assay of peptide degradation was performed by mixing peptide (1 µM) with the 
Baf/BCR-ABL cell lysate (3 mg/mL total cell protein) and incubating at 37 oC for 1 h.  
Aliquots were removed from the reaction mixture at various time intervals.  The reactions 
were stopped by adding HCl to a final concentration of 100 mM.  A 0 min timepoint was 
prepared by adding the HCl to the lysate prior to addition of the substrate peptide.  Reaction 
mixtures were then separated by capillary electrophoresis and detected by LIF.    Peptide 
fragments were identified by adding standards (250 nM) to the HCl-terminated aliquots and 
comparing the electropherograms with and without the added standard.  The average initial 
degradation and fragmentation rates were calculated using the 0 and 5 min time points by 
monitoring the change in peptide amount divided by the change in time per amount cytosolic 
protein.  The units are defined as zmol of peptide per pg of cytosolic protein per s, or zmol 
pg-1 s-1. 
6.2.5 in vitro Kinase Assay 
 Protein kinase assays were performed at 30 oC in assay buffer [50 mM Tris (pH 7.4), 
5 mM MgCl2, 1 mM MnCl2, 2 mM DTT, 1 mM ATP] with Abl-1 kinase (12 nM) and 
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substrate (29 µM).  Aliquots were then removed from the reaction mixture at varying times.  
The reactions were stopped by heating at 90 oC for 4 min.  Additionally, a negative control 
with no ATP was simultaneously assayed and sampled.  The amount of peptide 
phosphorylation was measured using capillary electrophoresis coupled with laser-induced 
fluorescence to separate the substrates and products and quantify peak areas.  The samples 
with and without ATP were compared to identify the phosphorylated product and the non-
phosphorylated precursor. 
6.2.6 Capillary Electrophoresis 
 Laser-induced fluorescence (488 nm) was used for peptide detection during capillary 
electrophoresis (ProteomeLab PA800, Beckman Coulter, Fullerton, CA).  Fused-silica 
capillaries [50 µm inner diameter, 360 µm outer diameter, (Polymicro Technologies, 
Phoenix, AZ)] had a total length of 30 cm with an effective length of 20 cm.  Capillaries 
were conditioned prior to use with 0.1 M NaOH for 12 h, H2O for 1 h, 0.1 M HCl for 6 h, 
and H2O again for 12 h.  After each sample, the capillary was sequentially rinsed with 1 M 
NaOH, H2O, and buffer for 2 min by applying a pressure of 20 psi to the capillary inlet.  A 
sample plug was hydrodynamically loaded into the capillary by applying 0.5 psi to the inlet 
for 5 s.  Electrophoresis was initiated by application of a negative voltage to the outlet.  For 
the assays employing a cell lysate, the electrophoretic buffer was 100 mM Tris and 100 mM 
Tricine, pH 8.1 and the field strength was 500 V/cm.  For the in vitro kinase assay samples, 
the electrophoretic buffer was 100 mM Tris, 100 mM Tricine and 5 mM SDS, pH 8.1 and 
field strength was 600 V/cm.  The data was analyzed using commercial software (32 Karat, 
version 8.0, Beckman Coulter, Fullerton, CA). 
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6.3 Results and Discussion 
6.3.1 Characterization of Peptides Following Replacement of the N-
Terminal Alanine 
 
 To determine if substitution on the N-terminal side of the cleaved bond resulted in 
greater peptide stability, the alanine residue in this position was replaced by (N-
methyl)alanine, sarcosine, or D-alanine (Figure 6.1).  All of these residues have been known 
to impart stability to peptides when incorporated into sequences.3-5  Peptides VII-A through 
VII-C (Table 6.1) were synthesized, purified, incubated in a Baf/BCR-ABL cytosolic lysate 
and then separated by CE to determine if fluorescent fragments were formed.  Over the 
course of 60 min, peptides VII-A, VII-B, and VII-C were degraded into 3, 3, and 4 fragment 
peptides, respectively (Figure 6.2).  In order to compare degradation resistance of each 
peptide, the percentage of intact parent peptide was plotted as a function of time and the half-
life (t1/2) was calculated (Figure 6.3A, Table 6.1).  Peptide VII-A possessed a t1/2 of 1.6 min, 
12X less than that for QW-V-48B.  Peptide VII-B had a t1/2 of 5.5 min, 3.5X less than that for 
QW-V-48B, while peptide VII-C showed the greatest resistance to degradation with a t1/2 of 
17.9 min, approximately the same as that for QW-V-48B. 
 To determine whether these substituted peptides retained the ability to be 
phosphorylated by Abl kinase, each peptide was incubated with purified Abl kinase in vitro 
and phosphorylation was measured over time.  In all cases, none of the modified peptides 
showed evidence of phosphorylation over the 120 min incubation, while both QW-III-67B 
and QW-48B demonstrated t50% P (time to attain 50% phosphorylation) values of 190 and 400 
min, respectively (Figure 6.3B).  The poor substrate efficacy of these substituted peptides 
rendered these modifications unsuitable for follow up. 
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6.3.2 Characterization of Peptides Following Replacement of the C-
Terminal Alanine 
 
 The next round of modifications involved replacement of the alanine on the C-
terminal side of the susceptible bond with sarcosine, D-alanine, or (N-methyl)alanine (Figure 
6.1) in an attempt to render the bond more peptidase-resistant.  Peptides VIII-A through VIII-
C (Table 6.1) were synthesized and assessed for stability in a Baf/BCR-ABL cytosolic lysate.  
After 60 min in the cytosolic lysate, peptides VIII-A and VIII-C were each metabolized into 
5 fragment peptides and VIII-B was metabolized into 4 fragment peptides (Figure 6.4).  
Peptides VIII-A and VIII-B were more stable than previous peptides tested, with 22 ± 8% 
and 43 ± 10% of each parent peptide remaining after 60 min, respectively.  When the t1/2 
values were calculated (Figure 6.5A) and used to compare peptide resistance to degradation, 
peptide VIII-C was found to have a t1/2 of 5.1 min, approximately 4X less than that of QW-V-
48B.  Peptides VIII-A and VIII-B had t1/2 values of 25.8 and 48.7 min, respectively, 
corresponding to a 1.3- and 2.5-fold increase over that of QW-V-48B. 
 The ability of each modified peptide to be phosphorylated in vitro by Abl kinase was 
also assessed and t50% P was calculated (Figure 6.5B).  Peptide VIII-C showed minimal 
phosphorylation, with a t50% P greater than 105 min.  Peptide VIII-A possessed a t50% P of 68 
min, approximately 6X faster than QW-V-48B, while VIII-B demonstrated a t50% P of 650 
min, approximately 1.5X slower than that of QW-V-48B.  Based on the t1/2 and t50% P values 
calculated, it was determined that both peptides VIII-A and VIII-B were suitable candidates 
for further evaluation.  And though it appeared to be a poorer substrate for Abl kinase, 
peptide VIII-B was selected for further evaluation based on its increased ability to resist 
degradation by peptidases, with the thought that a longer-lived substrate would be more 
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beneficial than a shorter-lived substrate with more favorable kinetic properties, if the longer-
lived substrate could still act as a kinase substrate. 
6.3.3 Characterization of VIII-B in a Baf/BCR-ABL Cytosolic Lysate 
 Although the sarcosine-containing VIII-B peptide possessed a much longer lifetime in 
the cytosolic lysate than QW-V-48B, it was still broken down into four additional fragments 
over time.  To determine which locations were the preferred sites of cleavage, all possible 
fluorescent fragments were synthesized and characterized by electrophoresis, as described in 
Chapters 3 and 4.  Under the electrophoretic conditions utilized, all of the fragment peptides 
were resolved from each other and from the parent peptide.  Peptide VIII-B was incubated in 
a Baf/BCR-ABL lysate and each of the possible fluorescent peptide standards were 
sequentially added to the mixture to identify the unknown peaks in the electropherogram.  
Each of the peaks present in the cytosolic lysate was matched to a fragment peak (Figure 
6.6).  Percentage of peptide was plotted as a function of time to calculate the degradation and 
formation of each peptide over time (Figure 6.6D).  The first fragment formed, and the one 
that formed in the highest abundance over time, was peptide a, the longest possible fragment.  
Peptide a formed at a rate nearly equal to that of the degradation of the parent peptide, or 
0.04 zmol pg-1 s-1.  The remaining 3 fragments, 2-, 5-, and 9-residue peptides, formed at very 
low amounts compared to peptide a.  While the replacement of the alanine with a sarcosine 
did not eliminate cleavage at the 5-mer bond, it did reduce bond hydrolysis significantly, 
with this 5-mer representing approximately 2% of all peptide present after 60 min (Figure 
6.6C). 
 184 
6.3.4 Characterization of Peptide Following Truncation of the Substrate 
 As the consensus sequence of many kinases usually involves those residues nearest to 
the phosphorylatable residue, removal of a single residue at the carboxy-terminus might not 
eliminate kinase suitability, but might impart stability to the substrate by eliminating the 
cleavage site.  The most abundant fragment of peptide VIII-B was formed when the last 
residue was cleaved, so an alternate substrate was synthesized without this residue and the 
resistance to degradation and suitability as a substrate was assessed.  Peptide IX-A (Table 
6.1) was slowly degraded over time, and 4 small peaks in addition to the parent peptide were 
seen on the electropherogram (Figure 6.7A-C).  After 60 min in the Baf/BCR-ABL cytosolic 
lysate, the parent peptide was 68% of all peptide present.  One fragment peptide accounted 
for 18% of all peptide, with the remaining 3 fragments making up the remainder of peptides 
(Figure 6.7).  The t1/2 of peptide IX-A was 365 min, over 19X better than QW-V-48B and 7X 
better than precursor peptide VIII-B (Figure 6.8A).  The identification of the fragment 
peptides was accomplished with the fragment standards (Figure 6.7).  Remarkably,  the data 
suggest that the fragment formed in largest amounts was peptide a (Figure 6.7E), which was 
formed by removing only the amidated terminus from the last amino acid.  This type of 
cleavage has not been previously observed in any peptides examined and its formation was 
surprising.  However, this bond is still a pseudo-peptide bond, meaning that it can 
theoretically be cleaved by peptidases.  More investigations, including mass spectrometric 
analysis, need to be performed in order to confirm this result.  Furthermore, two of the three 
additional fragments that formed were different from those formed when the precursor VIII-
B peptide was incubated in the lysate, as a 3- and 6-mer fragment were seen in addition to the 
5-mer seen previously. 
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 Additionally, the substrate efficacy of peptide IX-A for purified Abl kinase was also 
examined.  When incubated with purified kinase, the substrate was phosphorylated at a rate 
similar to that of the precursor peptide (Figure 6.8B), with a t50% P of 610 min, compared to 
650 min for the predecessor peptide VIII-B (Table 6.1).  This t50% P value is approximately 
3X slower than that for the control peptide QW-III-67B.  Further work needs to be performed 
to determine if peptide IX-A is a suitable substrate for Bcr-Abl in vitro and in intact cells. 
 
6.4 Conclusions 
 Identification of susceptible cleavage locations in peptide QW-V-48B led to further 
stabilization by replacement of native amino acids with non-native residues.  The location 
targeted was the most abundant fragment formed in single cells, the 5-residue peptide 
generated when QW-V-48B was incubated in single HeLa cells.  The iterative design 
strategy demonstrated in Chapter 4 for a PKB substrate peptide was successfully utilized to 
render this Bcr-Abl substrate peptide more peptidase-resistant in cytosolic lysates.  While not 
yet evaluated in single cells, peptide IX-A was much more stable in a cytosolic lysate than 
previous peptides tested, showing an increase in stability over 280X that of the original, 
unmodified peptide QW-III-67B.  Future work includes extensive characterization of peptide 
stability and evaluation of substrate suitability of IX-A in single cells.  Future work for all 
peptides evaluated in this dissertation also includes higher-throughput analyses of single cells 
as well as analysis of PKB and Bcr-Abl kinase activity in single primary cells obtained 
directly from human patients. 
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6.5 Figures and Tables 
 
 
 
 
Figure 6.1: The non-native amino acids utilized in the construction of alternative peptides. 
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Figure 6.2: Select electropherograms of peptide VII-A (A), VII-B (B), and VII-C (C) 
incubated for 60 min in a Baf/BCR-ABL cytosolic lysate.  Peak 1 in each case corresponds to 
the intact parent peptide or the location of migration of the intact parent peptide.  The other 
numbers correspond to fragments of each peptide.
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Figure 6.3: Baf/BCR-ABL cytosolic lysate degradation (A) and in vitro phosphorylation (B) 
of the series VII peptides.  Open square (QW-III-67B), closed square (QW-V-48B), closed 
circle (VII-A), open triangle (VII-B), and open diamond (VII-C). 
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Figure 6.4: Select electropherograms of peptide VIII-A (A), VIII-B (B), and VIII-C (C) 
incubated for 60 min in a Baf/BCR-ABL cytosolic lysate.  Peak 1 in each case corresponds to 
the intact parent peptide or the location of migration of the intact parent peptide.  The other 
numbers correspond to fragments of each peptide.
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Figure 6.5: Baf/BCR-ABL cytosolic lysate degradation (A) and in vitro phosphorylation (B) 
of the series VIII peptides.  Open square (QW-III-67B), closed square (QW-V-48B), closed 
triangle (VIII-A), open circle (VIII-B), and closed diamond (VIII-C). 
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Figure 6.6: Degradation profile of peptide VIII-B in a Baf/BCR-ABL cell lysate.  (A) – (C) 
Electropherograms of the peptide after incubation in the lysate for 0 (A), 30 (B), or 60 (C) 
min.  (D) Formation of peptide fragments over time.  Shown on the y-axis is the percentage 
of peptide present as a fragment.  The symbols are defined as: closed square (peptide a), open 
circle (peptide b), closed triangle (peptide d), open triangle (peptide h), closed circle (peptide 
k).  (E) The uppercase letters are the single amino acid abbreviations for the lead peptide 
sequence, Sarc represents sarcosine and MPh represents (N-methyl) phenylalanine.  The 
lowercase letters indicate the cleavage locations that generate the indicated peptide 
fragments. 
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Figure 6.7: Degradation profile of peptide IX-A in a Baf/BCR-ABL cell lysate.  (A) – (C) 
Electropherograms of the peptide after incubation in the lysate for 0 (A), 30 (B), or 60 (C) 
min.  (D) Formation of peptide fragments over time.  Shown on the y-axis is the percentage 
of peptide present as a fragment.  The symbols are defined as: filled square (peptide m), open 
circle (peptide b), closed triangle (peptide g), open triangle (peptide h), closed circle (peptide 
j).  (E) The uppercase letters are the single amino acid abbreviations for the lead peptide 
sequence, Sarc represents sarcosine and MPh represents (N-methyl) phenylalanine.  The 
lowercase letters indicate the cleavage locations that generate the indicated peptide 
fragments. 
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Figure 6.8: Baf/BCR-ABL cytosolic lysate degradation (A) and in vitro phosphorylation (B) 
of peptides.  Open square (QW-III-67B), closed square (QW-V-48B), and open triangle (IX-
A, truncated, sarcosine-containing peptide). 
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Table 6.1: Properties of the modified peptides. 
 
 
 
at1/2 is the time at which 50% of the peptide was degraded by the cell lysate.   
bt50% P is the time required for 50% of the peptide to be phosphorylated by Abl-1 kinase under 
the conditions employed.  Abbreviations are the standard single letter amino acids, except for 
the following: Sarc (sarcosine), MPh [(N-methyl)phenylalanine], MeAla [(N-
methyl)alanine], and DAla (D-alanine). 
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APPENDIX A: SINGLE-CELL CE-LIF INSTRUMENT 
CUSTOM PARTS 
 
 This appendix contains the blueprints for the custom made machined parts for the 
single cell CE-LIF system described in Chapter 2.  These blueprints can also be found on the 
hard drive of the single system CE-LIF computer in the following location: 
Desktop>>Users>>Angie>>Single Cell CE-LIF>>Blueprints.  The blueprints were drafted 
by either Angela Proctor or Freddy Pinero, an employee of the UNC-CH Chemistry Machine 
Shop at the time of drafting.  The parts drafted by Mr. Pinero were originally designed for a 
system built in collaboration between the Allbritton and Weeks labs, which shares similar 
features to the single cell system described here.  Each figure has a brief legend detailing the 
name of the part, who drafted the part, what material should be used for construction and 
how many pieces are required for a single CE-LIF instrument.  Figure A11 is the blueprint 
for the modification of a part purchased commercially from Melles Griot and contains the 
original part and dimensions as well as the modifications required.  For the instrument 
described in Chapter 2 of this dissertation, all parts were machined or modified by the UNC-
CH Physics Machine Shop.  A detailed description of parts required and instrument design 
can be found in Notebook #6, Pages 103-114. 
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Figure A1: Blueprint for the CE-LIF microscope stage adapter, drawn by Angela Proctor.  
Two (2) pieces should be constructed out of aluminum for one CE-LIF system.
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Figure A2: Blueprint for the CE-LIF base, bottom, drawn by Angela Proctor.  One (1) piece 
should be constructed out of aluminum for one CE-LIF system. 
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Figure A3: Blueprint for the CE-LIF base, front, drawn by Freddy Pinero.  One (1) piece 
should be constructed out of aluminum for one CE-LIF system. 
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Figure A4: Blueprint for the CE-LIF base, top, drawn by Freddy Pinero.  One (1) piece 
should be constructed out of aluminum for one CE-LIF system. 
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Figure A5: Blueprint for the CE-LIF detector housing, drawn by Freddy Pinero.  One (1) 
piece should be constructed out of black delrin for one CE-LIF system. 
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Figure A6: Blueprint for the Collection lens holder, drawn by Freddy Pinero.  One (1) piece 
should be constructed out of black delrin for one CE-LIF system. 
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Figure A7: Blueprint for the PMT housing, drawn by Freddy Pinero.  One (1) piece should be 
constructed out of black delrin for one CE-LIF system. 
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Figure A8: Blueprint for the PMT filter drawer, drawn by Freddy Pinero.  One (1) piece 
should be constructed out of black delrin for one CE-LIF system. 
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Figure A9: Blueprint for the PMT shutter plate, drawn by Freddy Pinero.  One (1) piece 
should be constructed out of black delrin for one CE-LIF system. 
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Figure A10: Blueprint for the PMT shutter, drawn by Freddy Pinero.  One (1) piece should 
be constructed out of black delrin for one CE-LIF system. 
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Figure A11: The modifications needed on the two (2) plate adapters (07 RPC521, Melles 
Griot, Albuquerque, NM), drawn by Angela Proctor  (A) A blueprint of the original plate as 
purchased from Melles Griot and (B) the modifications required.  The lip needs to be 
removed from both slots and the indicated screw holes need to be counterbored so the top of 
the plate adapter is flush.  All other dimensions and features are the same as shown in (A). 
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APPENDIX B: SINGLE-CELL CE-LIF INSTRUMENT 
SOFTWARE PROGRAMMING 
  
 This appendix contains select portions of the LabVIEW program created to run the 
single cell CE-LIF system described in Chapter 2 of this dissertation.  The program was 
written by Angela Proctor, with the instrument initialization steps (Figure B2) taken from a 
program written by Alexandra J. Dickinson, a graduate student in the Allbritton lab.  A copy 
of the program can be found on the desktop of the CE-LIF system and a version is also being 
used on another single cell system in the Allbritton lab.  Detailed programming notes can be 
found in Notebook #6, Pages 144-153. 
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Figure B1:  The front panel of the LabVIEW program created for the single cell CE-LIF 
system.  The user specifies a CE running voltage, the voltage and duration for an 
electrokinetic injection and the filename.  The program autoincrements a file number before 
each file, indicates where the data is saved and displays fluorescence and current signals in 
real-time during a CE run. 
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Figure B2:  The first portion of the block diagram of the LabVIEW program created for the 
single cell CE-LIF system.  This portion executes once when the program is started and then 
goes into the event structure (Figure B3) to wait until the user issues a command.  The CE 
case structure (Figures B4-B5) executes only when called by a trigger in the event structure. 
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Figure B3:  The event structure utilized in the block diagram of the LabVIEW program 
created for the single cell CE-LIF system.  The event structure contains six cases, each of 
which executes exactly once when called.  The code shown in this figure is the code that 
executes when the user wants to fire the Nd:YAG laser immediately followed by an 
electrokinetic injection.  Note that the program waits at the event structure indefinitely and 
only exits this while loop when the user presses the “Stop Program” button on the front panel 
(Figure B1).  When this occurs, the instruments are shut down and the program is turned off. 
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Figure B4:  The code contained within the CE case structure which is executed once when 
the user presses the green “Start CE” button on the front panel (Figure B1).  This prepares the 
DAQ for data collection and generates a filename where the data will be saved. 
 213 
 
 
 
Figure B5: The data acquisition portion of the block diagram.  The data is gathered at 12 
kHz, averaged at 4 Hz, and is either passed through a lowpass Butterworth filter and written 
to a text file or directly written to a text file.  This code is contained within the CE case 
structure and executes until the user presses the red “Stop CE” button on the front panel 
(Figure B1). 
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APPENDIX C: PEPTIDE SEQUENCES 
 
 This appendix contains the complete list of peptides utilized in this project, whether 
mentioned previously in this dissertation or not.  Some of the peptides were called by an 
alternate name in papers submitted for publication; both names are listed in the tables below 
to minimize confusion.  Peptides were synthesized by four different individuals and are 
indicated by the initials of the individual.  The initials belong to the following individuals: 
QW is Dr. Qunzhao Wang; AP is Angela Proctor; AK is Ana Kamilaris; and WX is Weichen 
Xu.  Each amino acid is represented by the standard one-letter code for amino acids, except 
when mentioned otherwise and clarified in Table C1. 
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Table C1: The non-standard abbreviations used in the peptide sequences. 
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Table C2: Peptides intended as Abl kinase substrates (Part 1 of 2). 
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Table C3: Peptides intended as Abl kinase substrates (Part 2 of 2). 
 
 
*These are the names used for these peptides when they are mentioned in this dissertation in 
Chapter 6. 
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Table C4: Peptides intended as PKB substrates (Part 1 of 2). 
 
 
*These are the names used for these peptides when they are mentioned in this dissertation as 
well as in the article(s) submitted for publication based on Chapters 4 and 5. 
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Table C5: Peptides intended as PKB substrates (Part 2 of 2). 
 
 
*These are the names used for these peptides when they are mentioned in this dissertation as 
well as in the article(s) submitted for publication based on Chapters 4 and 5. 
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